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D-amino acids are described by D-Xaa in the three-letter code and with the small letter in the one-
letter code. 
 GENERAL INTRODUCTION 
 
 
 
 
 
 
In the past 50 years a wide variety of naturally occurring peptides have been discovered. These 
peptides and their higher relatives proteins play a fundamental role in almost all processes of the living 
cell. As neurotransmitters, immunomodulators, enzyme inhibitors, substrates and hormones peptides 
are responsible for the regulation of biochemical processes such as cell-cell communication and 
control of vital functions like metabolism, immune response, digestion, respiration, sensitivity to pain, 
reproduction, behavior and electrolyte levels. 
Unfortunately, peptides show several limits in their clinical application: 1) being composed of natural 
amino acids, they are readily degraded by specific or non-specific proteases under physiological 
conditions; 2) they tend to be quite conformationally flexible, so that they can bind to more than one 
receptor or receptor subtype, leading to undesired side effects; 3) due to their high molecular mass and 
to the lack of a specific delivery system, they are characterized by poor bioavailability.
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Peptidomimetics are designed to circumvent some of these problems. The essential elements 
(pharmacophores) in a peptdomimetic mimic a natural peptide or protein in 3D space retaining the 
ability to interact with the biological target, producing or blocking the same biological effect. 
The design process begins by developing structure-activity relationships (SAR) that can define a 
minimal active sequence or major pharmacophore elements, and identify the key residues that are 
responsible for the biological effect. Then structural constraints are applied to probe the 3-D 
arrangement(s) of these features. In this process, the peptide complexity is reduced and the basic 
pharmacophore model is defined by its critical structural features in 3D space. As one of the major 
efforts in organic chemistry, a variety of molecules have been designed to mimic the secondary 
structures of peptides, such as -helices, -turns, and -sheets. Peptides composed of naturally 
occurring α-amino acids usually must have a length of at least 12 units in order to adopt a stable 
conformation in solution, while oligopeptides constructed from unnatural amino acids surprisingly 
assume stable secondary structures even in short oligomers of several units. This is a reason why in 
most successful approaches to small molecule mimetics, the chemical modifications involve the 
restriction of conformations performed either by the cyclization of peptides or by the incorporation of 
conformationally restricted building blocks, mostly unnatural amino acids and dipeptide surrogates.  
The other tactic involves replacing a particular peptide bond with its isostere. 
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A variety of methodologies and strategies have been developed and continue to be developed to 
establish systematic tools for transformation of peptides into peptidomimetics or further into small 
drug-like molecules.
2
 
As a result of such endeavors, the advantage of peptidomimetics over the native peptides has been 
demonstrated by: (1) increasing the potency and selectivity; (2) decreasing the side effects; (3) 
improving oral bioavailability, and the half-life of the activity through minimizing enzymatic 
degradation. 
 
1 Peptide secondary structure elements 
Secondary structure is the local conformation of a polypeptide chain or the spatial relationship of 
amino acid residues that are close together in the primary sequence. In globular proteins the three basic 
units of secondary structure are the: -helix, -sheet and turns. 
It is the formation of regular secondary structures into complicated patterns of protein folding that 
ultimately leads to the characteristic functional properties of proteins and peptides. 
 
1.1 -helix 
-helix  (Figure 1) is the most common repetitive feature of peptide secondary structure. It can be 
visualized as a poliamide “cylinder” in which the tightly coiled main chain forms the inner part of it, 
while the side chains extend outwards. The -helix is defined as 3.613, 3.6 indicating the number of 
residues per turn and 13 the number of atoms in the ring formed by hydrogen bonds between backbone 
CO and NH in i and i+4 residues, respectively, which stabilize the structure. Because of the right-
handed helicity of an -helix, carbonyls are pointing downward in the direction of the C-terminus, 
while the NHs point upward in the direction of the N-terminus.
3
 
A less common helical secondary structure is the 310 helix. Having three residues per turn, carbonyl on 
residue i is hydrogen-bonded to the amide NH on residue i+3, forming 10-membered repetitive rings.3 
Aminoacids are featured by a peculiar propensity to form helices. Helix propensities accumulate over 
a peptide segment, with Ala being the most helix-stabilizing and Gly the least. 
A number of methods devoted to the stabilization of this kind of secondary structure can be helpful in 
the design of helices-mimics: 
- introduction of Ala residues; 
- design of covalent or non-covalent interactions between residues side chains one turn apart (S-
S bridges, H-bonds, …); 
- addition of nonpeptide templates to initiate helix formation; 
- introduction of charged residues near the N or C termini to electrostatically stabilize the helix; 
- replacement of  one of the main chain intramolecular hydrogen bonds with a covalent  linkage, 
by introduction of an hydrogen-bond surrogate.3 
General Introduction  3 
 
 
Figure 1 – representation of an -helix a) from aside and b) from above. 
 
 
1.2 -strand and  sheet 
The -strand is the second type of periodic secondary structure and is an extended conformation when 
compared with the -helix. 
 
 
Figure 2 – -strands forming a -sheet 
 
A single -strand (Figure 2) is not stable largely because of the limited number of local stabilizing 
interactions. However, the backbone of N–H and C=O groups are oriented approximately 
perpendicular to the direction of the chain and therefore these groups are available for interstrand 
hydrogen bonding. 
 
Consequently, hydrogen bonds can be formed between two or more -strands leading to a stable sheet 
arrangement. These -sheets result in significant increase in the overall stability and in the formation 
of backbone H-bonds between adjacent strands that may involve residues widely separated in the 
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primary sequence. Adjacent strands can align in antiparallel or parallel arrangements with the 
orientation established by determining the direction of the polypeptide from the N- to the C-terminal. 
Antiparallel association of -strands leads to colinear N–H ••• O=C hydrogen bonds and, 
consequently, to a network of 10- and 14-membered H-bonded rings, while a parallel association of 
strands leads to deviation from colinearity and to a network of 12-membered H-bonded rings (Figure 
2). On average -sheets containing antiparallel strands are more common than sheets made up entirely 
of parallel strands. Antiparallel sheets are often formed from just two -strands running in opposite 
directions whilst it is observed that at least four -strands are required to form parallel sheets. 
 
1.3 -  Loops, turns, templates 
Reverse turns constitute one of the most common structural features in globular proteins. Turns have 
the universal role of enabling the polypeptide to change direction and in some cases to reverse back on 
itself. Besides its structural role in the protein fold, turns play also a key role in many of the molecular 
recognition events in biological systems. These events include interactions between peptide hormones 
and their receptors, antibodies and antigens, and regulatory enzymes and their corresponding 
substrates.
4
 
 
Reverse turns comprise the widely distributed -turns, as well as the less prevalent -turns and -turns, 
and may include well-defined loops, such as -loops.5 In current practice, the classification of a turn is 
based on the preferred torsion angles (and of the backbone chain, the position of the stabilizing 
hydrogen bond, and the length of the chain where the turn occurs.
6
 Analysis of the amino acid 
composition of turns reveals that bulky or branched side chains occur at very low frequencies. Instead, 
residues with small side chains such as glycine, aspartate, asparagine, serine, cysteine and proline are 
found preferentially.5
 
 
A -turn (Figure 3) contains three residues and frequently links adjacent strands of antiparallel -
sheets. This kind of turn is characterized by the fact that the middle residue (i+1) does not participate 
in H-bonding whilst the first and third residues can form the final and initial H-bonds of the 
antiparallel -stands, resulting in a 7-membered hydrogen-bonded ring. The change in direction of the 
polypeptide chain caused by a -turn is reflected in the values of  and  for the central residue. As 
result of the size and conformational flexibility, glycine is a favoured residue in this position although 
other amino acids can be found. 
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TURN TYPE i+1 i+1 
CLASSIC -TURN 70º to 85º -60º to -70º 
INVERSE -TURN -70º to -85º 60º to 70º 
Figure 3 - Torsion angles of classic and inverse -turns. 
 
Four residue turns, meaning -turns, are more commonly found in proteins and both linear and cyclic 
peptides. According to the last revaluation of the -turn classification, nine distinct structural types 
were suggested based on the  and  torsion angles in residues i+1 and i+2 (Figure 4).7 -turns, may 
(classical -turn) or may not (open -turn) be stabilized by an intramolecular H-bond formed between 
the C=O of the first residue (i) and the N–H of the fourth residue (i+3) (abbreviated as 4 → 1 H-bond), 
giving rise to a 10-membered H-bonded ring. Two major classes of -turns meet the stereochemical 
criteria, with all peptide bonds  being trans: type I and type II (Figure 4).
8
 These turns differ in the 
orientation of the peptide bond between the i+1 and i+2 residues, and consequently in the preferred 
side chain dispositions in these positions. In a type I turn, both the i+1 and i+2 positions accommodate 
L-residues, however proline preferentially fits in the i+2 position. Type I turns are the most prevalent 
in naturally occurring proteins. In a type II turn, the i+1 position can accommodate an L-residue 
(usually proline) and the i+2 position favours a glycine, small polar L-residues, or a D-residue because 
of steric clash with a side chain in the L-configuration. Proline in the i+1 position is a strong sequence 
determinant for either a type I or II turn because of the restriction on the  angle from the cyclic side 
chain.8 
Other turn geometries are also found. For example, the mirror images of types I and II are known 
respectively as types I’ and II’, and are energetically equivalent if residues of the opposite chirality 
occupy corresponding sequence positions. This means that, for example, a D-Pro residue would be 
favoured in position i+1 of a type I’ turn or in position i+2 of a type II’ turn. On the other hand, the 
intervening peptide bond (between residue i+1 and i+2) can adopt a cis conformation and still allow 
the turn to form an i to i+3 hydrogen bond and link to two -strands. The resulting turn is called a type 
VI turn. 
i+1
i+1
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TURN TYPE i+1 i+1 i+2 i+2 
I -60 -30 -90 0 
I’ 60 30 90 0 
II -60 120 80 0 
II’ 60 -120 -80 0 
IV -61 10 -53 17 
VIa1 -60 120 -90 0 
VIa2 -120 120 -60 0 
VIb -135 135 -75 160 
VIII -60 -30 -120 120 
Figure 4 - Torsion angles of classic -turns. 
 
-hairpins (Figure 5) are the simplest units that can be constructed from -strands and -turns. These 
occur widely in proteins and make up the fundamental building blocks of antiparallel -sheet. They 
are also structures found in many naturally occurring bioactive cyclic peptides such as gramicidin S 
and the peptide hormones oxytocin and vasopressin.8 
 
 
Figure 5 - -hairpin. 
 
-hairpins are stabilized by virtue of turn propensities of amino acid residues as well cross-strand 
interactions between the sequences flanking the turn. Favourable energetic contributions to the 
stability of these structural features have been demonstrate to include cross-strand aromatic-aromatic, 
aromatic-polar, H-bonding and salt-bridge interactions in combination with loop conformational 
propensity and entropy terms dependent on loop length.
9
 
 
type I type II
i+1
i+1
i+2
i+2
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Figure 6 - Minimal -hairpin. 
 
A tetrapeptide can adopt a “minimal -hairpin” conformation (Figure 6) with residues i+1 and i+2 
involved in the -turn. This structure is characterized by the presence of 10- and 14-membered H-
bonded rings. 
 
2 Structural determination 
The knowledge of the three dimensional structure of a peptide is essential to understand its physical, 
chemical and biological properties. Hence, the assessment of the conformational stabilities of peptides 
and their three dimensional structure, which  depends in general on the amino acids it comprises, can 
rely on a wide bouquet of techniques. 
 
Xray diffraction allows structural investigations at atomic resolution. However, not all substances can 
be easily crystallized and, moreover, there might be a huge difference between the conformation in the 
solid state and the one seen in solution. 
 
To gain information about the secondary structure of a peptide in solution, important tools such as 
circular dichroism spectroscopy, 1D and 2D NMR spectroscopy are employed. 
 
NMR Spectroscopy has progressed to become the method for determination of protein structures in 
aqueous solution. Sophisticated NMR methods for protein analysis such as 2D-NMR spectroscopy 
with modern standard measurement options (COSY, TOCSY, HSQC 
13
C/
1
H, HMBC 
13
C/
1
H, NOESY, 
ROESY) and variable temperature 
1
H-NMR contribute to the scope. 
VT-NMR experiments detect amide protons chemical shift variations in function of temperature, thus 
temperature coefficients can be calculated (/T). Evaluating /T values and chemical shifts (, 
much can be said about NH protons tendency to be involved in intramolecular H-bondings. Very low 
absolute values of /T are indicative of a proton involved in a very stable intramolecular H-
bonding, not exposed to solvent. A proton involved in an intramolecular H-bonding is usually 
characterized by a relatively low . The formation of a single H-bonding has a rather deshielding 
effect. When more H-bonds are formed with the solvent, higher  values are generally observed. 
Moreover, high Δδ/ΔT coefficient absolute values are indicative of NH protons involved in an 
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equilibrium between intramolecular H-bonds and H-bonds with the solvent. More than one stable 
conformation can thus be expected. 
COSY, TOCSY (revealing the proton crosspeaks in the same spin system) and NOESY (cross peaks 
due to dipolar coupling resulting from through space interactions) experiments allow the complete 
characterization of the synthesized compounds and assignment of all the proton chemical shifts, thus 
giving information on the primary structure. Medium- and long-range NOE contacts, detected from 
both NOESY and ROESY experiments, are significant in the determination of the preferential 
conformations adopted in solution. 
 
 
Figure 7 – short sequential and medium range 1H-1H distances 
 
For example, some typical sequential and medium range NOEs may be observed in the case of regular 
repeating structures, such as helices (Figure 7). 
Depending on the torsion angles that characterize the secondary structure of a peptide, sequential and 
medium-range 
1
H-
1
H-distances will have different values. For instance the sequential NH-NH and 
CH-NH contacts for a regular -helix are about 2.8 Å and 3.5 Å respectively. The CH-NH contacts, 
since they depend also on the torsion angle on the side chain i, vary between 2.5 and 4.1 Å for a -
helix.
10
 
In the case of peptides, including proline or non proteinogenic amino acids there exists an increased 
possibility of cis-trans isomerization of the peptide bond. The influence of the cis-trans isomerization 
on the sequential 
1
H-
1
H-distances allows closer CH (i)-CH (i+1) and NH (i)-CH (i+1) contacts in 
the cis form whereas shorter CH (i)-CH (i+1) and NH (i)-CH (i+1) contacts are observed for the 
trans form.
10
 
Medium-range distances indicating helical-structures are i→i+2, i→i+3 and i→i+4 contacts. In 
particular i→i+4 contacts are especially useful since they are present in a regular -helix and not in a 
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310-helix. Tight turns have close i→i+2 values. In the case of -structures short medium-range 
distances are not observed, since the polypeptide segments are almost fully extended.
10
 
 
Circular dichroism (CD) is also widely used in the determination of the secondary structure of 
peptidomimetics. UV-CD is based on planar polarized light. Planar polarized light is the sum of the 
left and the right circularly polarized light. When planar polarized light hits an optically active 
substance, the left and the right circularly polarized components are absorbed in a different extent, so 
that polarized light results elliptical. Ellipticity can thus be measured. 
The spectrum does not reflect the absorbance of each individual chromophore, but of a combination of 
the orientated chromophores in the three dimensional arrangement of the polymer. Hence, each type of 
peptide secondary structure gives rise to a unique and distinct CD spectrum.  
CD spectra are recorded in the wavelength region below 300 nm, and a conformer present in the tiniest 
amount or a particular small segment of a macromolecule can make a very large contribution to the 
overall absorption of circularly polarized light. Clues on the presence of regular conformational 
patterns can be obtained observing the CD spectra of molecules of known secondary structure. For 
example, -helix and -sheet structures produce particular patterns in CD spectra. 
Additionally there can be some contributions from aromatic residues (Phe, Tyr, Trp and His) and 
disulfide bonds. If there are a significant number of aromatic residues present in a molecule, the CD 
spectra can be affected in the region of far-UV. The contribution seen in near-UV is smaller. This 
region can be used to investigate changes of tertiary structures, for instance, those caused by ligand 
binding or folding/unfolding processes.
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The NMR data can be finally used as an indirect source of structural information, from which the 
overall 3D structure can be calculated. Hybrid MC/MD simulations are thus performed, starting from 
conformers that possess random torsion angle values and fitting them to the conformational restrains 
derived from the NMR measurements. 
When investigating biologically active compounds, docking studies can also be performed. These 
computational techniques are used to explore the possible binding modes of a substrate to a given 
receptor, enzyme or other binding site, whose crystal structure or analogy model is known. 
 
3 Aim of this work of thesis 
In this thesis we describe our recent efforts on the design of two kinds of peptidomimetics containing a 
bifunctional diketopiperazine (DKP): 
 
I. Cyclic peptidomimetics bearing a bifunctional DKP as a constrained scaffold and either the 
RGD or the iDGR sequence were synthesized and tested as selective ligands for the integrins 
v3 and v5; 
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II. A linear decapeptide was synthesized alternating a bifunctional DKP as a -dipeptide mimic 
and two -amino acids, in order to further evaluate DKP secondary-structure-inducing 
potentials. 
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1 - Introduction 
2,5-Diketopiperazines (DKPs), the smallest cyclic peptides (Figure 1.1), are an important class of 
biologically active compounds
1 
and their research has been fundamental to many aspects of peptide 
chemistry. They were once believed to be only protein artifacts or degradation products, but they have 
regained interest from chemists and pharmacologists thanks to their numerous biological properties
2 
that point to several therapeutic applications, ranging from antibiotics
3,4
 to synthetic vaccines and 
anticancer agents.
5,6 
 
 
Figure 1.1 - General structure of 2,5-diketopiperazines. 
 
2,5-Diketopiperazines have two s-cis secondary amide groups that can hydrogen bond horizontally 
within the ring plane. Due to the rigid cyclic structure bearing amide groups, DKPs are usually poorly 
soluble in organic solvents. In the solid state, most of the N-unsubstituted DKPs adopt a linear tape 
orientation (Figure 1.2a),
7
 while the presence of one N-substituent leads to the formation of one-
dimensional hydrogen bonded tapes through establishment of a non-reciprocal hydrogen-bond 
network (Figure 1.2b) or to hydrogen bonded dimers (Figure 1.2c).
8
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Figure 1.2 - Schematic view of hydrogen bond patterns in solid state structures of 2,5-diketopiperazines. 
 
Due to the structural similarity of 2,5-diketopiperazines to peptides, medicinal chemists have been 
inspired to use DKPs to circumvent the limitations of peptides. Constraining the nitrogen atom of an 
α-amino amide into a DKP ring alters its physical properties, reduces the susceptibility to metabolic 
amide bond cleavage and induces conformational rigidity. These changes in structural and physical 
properties, as well as the presence of groups that can act as donors and acceptors of hydrogen bonds 
enhance favorable interactions with biological targets. Moreover, DKPs are simple heterocyclic 
scaffolds in which diversity can be introduced at up to four positions (N1, N4, C3, C6) and 
stereochemically controlled at two (C3, C6), while they can be prepared from readily available α-
amino acids using conventional synthetic procedures,
9,10
 solid-phase
11,12
 and microwave-assisted 
organic synthesis.
13,14
 
 
Considering all these properties, it is evident why these constrained bifunctional cyclopeptides have 
emerged as privileged structures for the discovery of new lead compounds and represent a useful 
toolset for those pursuing research in the areas of combinatorial biomedical chemistry,
15,16
 de novo 
design of proteins
17
 and functional molecular devices. Furthermore, DKP scaffolds are also interesting 
candidates as organocatalysts and have been used in the asymmetric hydrocyanation of aldehydes
18,19a
 
and imines,
19b
 although in the latter case the results have been questioned.
19c
 
 
Finally, in the last decade a relevant application of DKPs has gained importance: their use as templates 
capable of inducing a defined secondary structure in peptide sequences. In these cases, advantage can 
be taken from the synthesis of symmetrical and unsymmetrical DKPs bearing reactive functionalities 
(e.g., NH2, COOH) in the lateral chains of the amino acids. 
 
2 - Biological Activities 
The peculiar DKP heterocycle, being found alone or as part of larger and more complex molecules in 
several natural products
20,21,22b
 of various origin,
22,23
 constitutes a rich source of new biologically 
Chapter 1  13 
active compounds. The wide spectrum of their biological properties points to various therapeutic 
possibilities.
24
 
The most important biological activities of diketopiperazines are probably the regulation of the P-
glycoprotein (P-gp) activity, the  inhibition of plasminogen activator inhibitor-1 (PAI-1)
25
 and the 
alteration of cardiovascular and blood-clotting functions.
26
 They also act as antitumour,
27,23c 
antiviral,
28
 
antifungal,
29
 antibacterial,
30
 and antihyperglycaemic agents
31
 and affinities for calcium channels and 
opioid,
32
 GABAergic,
33
 serotoninergic 5-HT1A
34
 and oxytocin receptors.
35,36
 
Several examples of DKP-containing natural metabolites showing cytotoxicity (1-4, Figure 
1.3),
22b,r,s,23c
 inhibiting tumor growth (5, Figure 1.3),
22k,l,t
 cell cycle (6-9, Figure 1.3)
22c,h,u
 and cancer 
cell invasion (10, Figure 1.3),
23c
 are reported in the literature. 
 
 
Figure 1.3 -  examples of naturally occurring DKPs, showing cytotoxicity and other cancer related inhibitory activities. 
 
Synthetic cytotoxic DKPs were also designed (Figure 1.4).
 37,38
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Figure 1.4 – Synthetic cytotoxic DKPs 37,38 
 
Some metabolites have shown an interesting activity as HIV-1 replication inhibitors (1-2, Figure 1.3; 
11, Figure 1.5),
22a,b
 some other compounds have proven antibiotic and antibacterial properties(12-17, 
Figure 1.6),
21,22j,m,v,w,23f
 in particular against Mycobacterium tuberculosis (18, Figure 1.6),
23d
 resposible 
for tubercolosis. 
 
 
Figure 1.5 – DKP presenting HIV-1 replication inhibitory activity 
 
 
Figure 1.6 – examples of naturally occurring DKPs, showing antibiotic and antibacterial activities. 
 
 
Gypsetin (21, Figure 1.7) was found to be a competitive ACAT (acyl coenzyme A:cholesterol 
acyltransferase) inhibitor with respect to oleoyl-CoA.
22d
 ACAT enzyme has been identified as the rate-
limiting enzyme in the absorption of cholesterol. Thus, the inhibition of ACAT has received much 
attention due to its potential in moderating the effect of elevated cholesterol level. One of the 
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applications might have been the prevention or the slowdown in the progession of atherosclerosis, 
even though this kind of inhibitors were recentely proven not to be effective for this purpose.
39
 
 
 
Figure 1.7 – ACAT inhibitor gypsetin 
 
P-glycoproteins are part of a larger superfamily of efflux transporters found in the gut, gonads, 
kidneys, biliary system, brain and other organs named the ATP-binding cassette family (ABCs). P-gps 
appear to have developed as a mechanism to protect the body from harmful substances. Using ATP as 
an energy source, they transport certain hydrophobic substances in the following directions: 
 into the gut; 
 out of the brain; 
 into urine; 
 into bile; 
 out of the gonads; 
 out of other organs. 
 
They contribute greatly to the distribution and elimination of many clinically important therapeutic 
substances. Prescription and OTC drugs, foods and substances made by the body may be inhibitors 
and/or inducers of these transporters. 
P-gps (ABCB1) have been implicated as a primary cause of multidrug-resistance in tumors. The 
responsible gene has been found to be MDR1. Many oncological drugs are ABCB1(P-gp) substrates 
and are excluded from the brain at the blood-brain barrier (BBB). In cases of primary or secondary 
brain tumors, finding an ABCB1(P-gp) inhibitor could be found that would block the extrusion of the 
oncological drug from the BBB without causing toxicity, would possibly improve the efficacy of such 
drugs might be improved. Several generations of ABCB (P-gp) inhibitors have been evaluated with 
modest success. A recent study of paclitaxel with elacridar [a third generation ABCB1(P-gp) inhibitor] 
has proved promising. Moreover, the membrane efflux pump P-gp is overexpressed in many multidrug 
resistant cancer cell lines and is an important mechanism whereby cancer cell lines acquire resistance 
to clinically important anticancer agents. Inhibitors of P-gp represent a potential strategy to overcome 
this resistance. 
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A similar targeted strategy for improving drug efficacy could be useful for a wide range of brain 
disorders, from HIV and other infections to mood disorders.
40
 
 
 
Figure 1.8 - noncytotoxic P-gp inhibitor nocardioazine A 
 
Metabolite nocardioazine A (Figure 1.8), isolated form a culture of bacterium Nocardiopsis sp., 
proved to be representative of a new class of noncytotoxic P-gp inhibitors, capable of reversing 
doxorubicin resistance in a P-gp overexpressing drug resistant colon cancer cell line.
23b 
 
Plasminogen activator inhibitor - type 1 (PAI-1), the main physiological inhibitor of the serine 
proteases and primary inhibitor of the tissue-type (tPA) and urokinase-type (uPA) plasminogen 
activators, has been implicated in a wide range of pathological processes, thus becoming an attractive 
target for pharmacologic inhibition. The plasminogen-converting enzymes generate active plasmin, 
which proteolytically degrades fibrin and components of the extracellular matrix. While tPA is an 
essential element in the fibrinolytic system, regulating the formation and degradation of clots, uPA is 
linked to extracellular proteolytic homeostasis and consequently related to detachment and cell 
migration events typical of metastasis, invasion and angiogenesis processes.
25
 
 
When PAI-1 is quantitatively or qualitatively disrupted, a variety of modulated functions are 
implicated in several pathological situations such as thromboembolic disease due to highly active PAI-
1,
25a
 coronary heart disease, atherosclerosis, thrombosis
25b
 and cancer progression
25c
 associated with 
increased levels of circulating PAI-1. The correlation between PAI-1 and cancer has been 
demonstrated in mice: it has been shown that the administration of exogenous PAI-1 leads to an 
increasing number of metastases in animals previously injected with malignant cells, while the 
introduction of monoclonal antibodies to this macromolecular inhibitor reduced the metastatic 
potential. 
 
The inhibitory capacity of PAI-1 depends on the conformation of the reactive centre loop (RCL) and 
on its availability to bind tPA or uPA, so its potential to be explored as a therapeutic macromolecular 
target for the treatment of cardiovascular diseases and cancer emphasises the importance of developing 
drugs as specific inhibitors.
25d 
Diketopiperazines are the most potent PAI-1 inhibitors known,
25b
 they 
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act through a mechanism involving conformational changes, which inactivate PAI-1 
RCLcomplementarity, preventing its binding to the target protein.
25d
 
 
Metabolite 21 isolated from Streptomyces sp., as the first low-molecular-weight PAI-1 inhibitor, was 
the model for designing structural changes in order to obtain more active products (Figure 1.9). Using 
bioisosteric substitutions and combinatorial chemistry approaches, DKP 22 and 23 containing different 
side chains connected by exocyclic double bonds were synthesized and showed both in vivo and in 
vitro PAI-1 inhibitory activity (IC50 3.5 μM and 0.2 μM, respectively).
25a
 Other strategies, such as 
introduction of structural rigidity, were also applied to metabolite 21, leading to compounds like 24 
that also shows an interesting PAI-1 inhibitory activity (IC50 0.3 μM).
25c 
 
 
Figure 1.9 - Diketopiperazines as PAI-1 inhibitors. 
 
Tumour cell pro-coagulant activity has been considered to favour metastatic processes by encasing 
malignant cells in a fibrin coat, which protects them from the host immunological system. Thus, 
components of the blood-clotting system are potential targets for a new class of therapeutic agents 
designed to selectively inhibit tumour growth and prevent metastasis. Haematological studies showed 
that cyclo(L-His-L-Tyr) DKP 25 significantly increases clotting time and prevents platelet adhesion 
and aggregation induced by adenosine diphosphate.
2
 Cyclo(L-His-L-Phe) DKP 26 showed antitumour 
activity by significantly reducing the viability of HeLa, WHCO3 and MCF-7 cells, respectively from, 
cervical, oesophageal and mammary carcinoma.
2 
 
In relation to cardiac effects, compound 25 increased the heart rate in isolated rodent hearts, while 
compound 26 decreased cardiac output and the level of coronary blood flow (Figure 1.10). Much like 
several cyclic dipeptides that display potential activity for the treatment of cardiovascular 
dysfunctions, compounds 25 and 26 could be employed as antiarrhythmic agents, thus reducing 
mortality by ventricular fibrillation in myocardial infarction.
2 
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Figure 1.10 - DKPs which interfere in cardiovascular and blood-coagulation functions. 
 
Figure 1.11 shows a representative set of DKP-based molecules exhibiting other biological 
activities.
28,31,32,33,34,35,36
 
 
Figure 1.11 
 
 
3 - Synthesis of diketopiperazines 
 
3.1 - Mechanism of formation 
The planar backbone amide bonds in polypeptides are known to occur predominantly in the trans 
conformation. Planarity is maintained through a rotational energy barrier because of the partial double 
bond character of the peptide bond. On average, the energy difference between trans and cis peptide 
bond isomers is of the order of 2.5 kcal/mol (Scheme 1.1). 
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Scheme 1.1 
 
Such isomerism is relevant to DKP formation because in a dipeptide derivative the intramolecular 
attack of the amino group on the terminal carboxylic group is possible only from a folded 
conformation containing a cis peptide bond (Scheme 1.2). 
 
 
Scheme 1.2 
 
Cis peptide bonds are not frequent in naturally occurring polypeptides, and this is thought to be due 
mostly to steric conflict between neighbouring C

-substituents in the cis conformation. However, the 
actual frequencies of occurrence of cis peptide bonds in known protein structures do not correlate well 
with residue side-chain bulk. In a similar way, steric interactions between the side chains in the trans 
and cis isomers can not explain sufficiently the relative ease of DKP formation from a number of 
dipeptide derivatives.  Particularly noteworthy in this respect are dipeptides involving -alkyl amino 
acid residues. For such compounds one would predict large energy differences between trans and cis 
isomers on the basis of steric crowding in the cis isomer. Instead such peptides have been observed to 
cyclize quite readily. It is likely that the conformational constrains (on backbone torsional angles) 
introduced into a peptide by for example Aib residues result in amide bond isomerisation/cyclization 
mechanisms with low energy barriers that are favoured. Possibly such factors as overall proximity 
between terminal amino and carbonyl groups, as well as stabilizing intramolecular interactions may be 
involved.
12 
 
3.2 - Conventional synthetic procedures 
The 2,5-DKPs, head-to-tail dipeptide dimers, are a common naturally occurring structural motif and 
consequently most biologically active DKPs are isolated from natural sources. They are also 
frequently generated as unwanted by-products or degradation products in the synthesis of 
oligopeptides. However, due to the relative structural simplicity of its basic nucleus, several synthetic 
methods are also available mainly based on reactions of dipeptides, easily prepared from -amino 
acids by conventional methodology. 
It is possible to prepare symmetrical DKPs simply by heating the free amino acid methyl esters in a 
sealed tube and this method can even be effective for DKPs derived from amino acids with reactive 
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side chains. However, it is generally better to use protected precursors since for example, Dab, Orn, 
and Lys derivatives can give rise do the corresponding pyrrolidone, piperidone and homopiperidone 
by-products. In the case of unsymmetrical DKPs, the oldest synthetic procedure consists in the 
dipeptide ester treatment with methanolic ammonia, but the strongly basic conditions in this procedure 
can lead to epimerization. 
 
 
Scheme 1.3 - Solution-phase synthesis: a) MeOH, reflux, 14 h. 
 
 A method less prone to loss of chiral integrity consists of Boc-dipeptidyl methyl ester N-deprotection 
with formic acid, followed by reflux of the dipeptidyl ester formate salt in 2-butanol/toluene and 
removal of formic acid through azeotropic distillation.
41
 However, for many DKPs, simple reflux of 
dipeptidyl methyl esters in low-boiling solvents, particularly methanol, is normally effective (Scheme 
1.3).
42
 
 
 
Scheme 1.4 - Ugi reaction: a) 1 equiv Et3N, MeOH; b) t-Bu-isonitrile, N-Boc-R-indanylglycine; c) 4 N 
HCl/dioxane, 4 h; d) Et3N. 
 
Another method to obtain diketopiperazines is the Ugi reaction, a synthesis containing a small number 
of multicomponent steps, which allows substitutions on the secondary amino group.
15
 The 
stereospecific synthesis illustrated in Scheme 1.4 was proposed as an alternative in the preparation of 
trisubstituted DKPs. However, it was not possible to control the stereochemistry of the chiral centre 
located in the  carbon of the tertiary amine.43  
 
The problem of stereocontrol might be solved by using a symmetric keton as the starting carbonyl 
compound. As a relevant example in the discovery and synthesis of pharmacologically active 
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compounds involving this kind of Ugi-type reaction approach, aplaviroc is here mentioned (Scheme 
1.5).
36
 Aplaviroc is a CCR5 receptor antagonist and an investigational drug for HIV treatment.
44
 
 
 
Scheme 1.5 – Synthesis of aplaviroc through a Ugi-type 5C-4CR, in solution: a) MeOH, 55°C; b) HClconc. 55%; 
c) AcOH – toluene; d) H2, Pd(OH)2/C, 55°C; e) 4N HCl in EtOAc; f) RCHO, NaBH(OAc)3, AcOH, 
DMF; g) 4N HCl in EtOAc.  
 
As an alternative, the glycine cyclic dipeptide has been used as the starting material for the solution-
phase synthesis of substituted diketopiperazines. The protocol outlined in Scheme 1.6 was used in the 
synthesis of several active compounds.
11
 A similar strategy was employed to generate olefin 
derivatives of N-acetylated diketopiperazines with exocyclic double bonds,
42
 or bis-epoxides, which 
would serve as precursors to more complex DKPs (Scheme 1.7).
45
 
 
 
Scheme 1.6 - Synthesis of substituted diketopiperazines starting from cyclo(Gly-Gly): a) Ac2O, reflux; b) t-BuOH, t-BuOK, 
Ar1CHO, THF, rt; c) Ar2CHO, Cs2CO3, DMF, 80-100ºC. 
 
 
Scheme 1.7 - Synthesis of bis-epoxy diketopiperazines: a) NBS, H2O; b) Et3N. 
 
An innovating strategy employing microwave heating was used to couple peptides intramolecularly, 
resulting in symmetrical dimeric DKP, without epimerisation in the -position of the amino acids. N-
benzoyl-Arg(NO2)-Leu-NH2, a PAR-2 receptor antagonist, was prepared by classical solution-phase 
synthesis. To the C-terminal end of this dipeptide pharmacophore, a glycine residue was introduced 
and activated for auto-condensation, resulting in the DKP cyclo(Gly-Gly) N-substituted by the 
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selected dipeptide. The cyclization reaction is exemplified in Scheme 1.8 and, compared to 
conventional heating, the microwave synthesis furnish the desired compounds in higher yields and 
shorter reaction times.
46
  
 
 
Scheme 1.8 - Dipeptide dimers obtained by microwave heating: a) HBTU/DMAP, DMF, 5 min, 40 ºC, 400 W. 
 
Recently it was also reported a microwave-assisted stereoselective one-pot synthesis of symmetrical 
and unsymmetrical 2,5-DKPs from unprotected amino acids, through a phosphite-promoted one step 
coupling reaction (Scheme 1.9). This method is characterized by overall good yields, scalability, and 
tolerance to several base-stable protecting groups. Simple filtration through a pad of silica provides the 
pure compounds.
47
 
 
 
Scheme 1.9 - PIII-promoted coupling of amino acids: a) MeOPCl2, NEt3, toluene, MW: 84-97%. 
 
Even more recently, an aqueous in situ one-pot N-Boc-deprotection-cyclization of N-Boc-dipeptidyl-
tert-butyl and methyl esters was reported to provide optically pure cis-DKPs in excellent yields under 
microwave irradiation (Scheme 1.10).
48
 
 
 
Scheme 1.10 - N-Boc-deprotection-cyclization of N-Boc-dipeptidylesters to DKPs: a) EDAC, HOBt, DMAP, TEA/CH2Cl2, 
5°C, then overnight at rt; b) H2O (1 mL), MW (250 °C, 250 W and 150 psi) for 10 min. 
 
Phase-transfer catalysis seems to be another reliable method for the one-pot synthesis of symmetric 
1,4-disubstituted-DKPs starting from a suitable amine and chloroacetyl chloride in presence of an 
aqueous base.
49
 
O,N-acyl transfer is receiving greater attention in recent years, as a valuable method for the efficient 
synthesis of difficult peptide sequences and racemization-free segment condensation. This approach 
was also employed for the synthesis of hexa- and pentasubstituted diketopiperazines under mild 
conditions.
50
 An activated ester of the first hindered aminoacid is reacting with the free carboxylic acid 
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of a second fragment forming a mixed anhydride, which is undergoing spontaneous rearrangement and 
procedes to the DKP product (Scheme 1.11). This strategy could also be used to achieve oligomers. 
 
 
Scheme 1.11 – Synthesis of hexasubstituted DKPs via O,N-acyltransfer 
 
DKP can form even when it is not desired. In fact, parallel DKP formation in reactions involving 
amino acids is a quite common side reaction. For example, attempts to perform nucleophilic 
substitutions in substituted pyrimidinic rings, by ethyl glycine chloride in the presence of a strong 
base, DABCO (1,4-diaza-bicyclo[2.2.2]octane), resulted in the glycine DKP produced by predominant 
auto-condensation of ethyl glycine.
51
  
Although solution-phase synthesis presents the advantage of requiring a smaller number of reaction 
steps, solid-phase synthesis has been the most used method to synthesize DKPs, with variations in the 
type of resin, protecting groups and type of cleavage among others. In multistep protocols, a dipeptide 
having the first peptide bond generated in situ is attached to the solid support, and it remains bound 
through the carboxylic extremity up to the cycling step, that is then followed by separation from the 
matrix or release of the N-protective group of the amino acid (cyclative cleavage).
11,52,53 
A generic solid-phase protocol is shown in Scheme 1.12 for obtaining DKPs under mild conditions, 
using the phenacyl ester (O-Pac) bond to attach the carboxylic amino acid terminal to the resin. 
Deprotection of the Boc-amino group and coupling with the next amino acid afforded a dipeptide, 
subsequently deprotected and cyclized by intramolecular aminolysis.
52
 Solid-phase synthesis of 
unsaturated 3-substituted DKP, employing a carbamate bond between the dipeptide N-terminal and the 
resin, was also described.
11
  
 
 
Scheme 1.12 - Solid-phase synthesis: a) BrCH2COBr, AlCl3, nitrobenzene/DCM (1:1); b) Boc-AA’-OH, Et3N, DMF; c) 3.5 
N HCl/AcOH; d) Boc-AA’’-OH, HOBt, DCC, NMM, DMF; e) 10% DIPEA/EtOAc; f) 5% Et3N/THF-H2O 
(8:1). 
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Notwithstanding the successful use of activated ligands such O-Pac, the bond susceptible to 
nucleophilic attack requires amino acid side-chain group protection. This relative lability is generally 
considered responsible for small losses of the elongating peptides. Peptide attachment to the resin by 
the safety-catch technique circumvents this problem, because the stable bond is conveniently activated 
only after ending the peptide synthesis, allowing cleavage and cyclization. The strategy outlined in 
Scheme 1.13 permits the removal of protecting groups before cleavage, facilitating further workup.
15
 
The use of safety-catch ligands allowed the solid-phase generation of bicyclic and tricyclic DKP, 
which show even greater structural diversity. 
 
 
Scheme 1.13 - Solid-phase synthesis by safety-catch approach: a) Boc-AA’-OH, DIC, DIPEA; b) Boc-based solid-phase 
peptide synthesis; c) TFMSA, TFA; d) DIPEA. 
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1 -  Examples in the literature 1 
Having emerged as privileged structures, DKPs were recently used as templates capable of inducing a 
defined secondary structure in peptide sequences. This relevant application, which has gained 
importance in the last decade, inherently takes advantage from the synthesis of symmetrical and 
unsymmetrical DKPs bearing reactive functionalities (e.g., NH2, COOH) in the lateral chains of the 
amino acids. This let them being incorporated into a peptidomimetic moiety. 
These constrained heterocyclic scaffolds were reported to be used in receptors, for the selective 
recognition of small peptides and anions, and in peptidomimetics mimicking topologically relevant 
elements of secondary structure of proteins (e.g., β-turns, β-hairpins, and α-helices). 
 
1.1 -  DKPs as two-armed receptors 
Two-armed receptors consisting of a central scaffold and two, generally symmetrical, lateral modules 
containing several binding sites, have been synthesized (often via a combinatorial approach) and 
reported to bind different kinds of guests (e.g., anions, cations, small molecules, amino acids and short 
peptides). The importance of the central scaffold resides in its ability to: i) create a cleft with an 
adequate size to accommodate the guest, and ii) protrude the two side-arms with the correct geometry 
to wrap the guest with a sufficient number of binding points. Diketopiperazines, with their rather flat 
core and lateral chains of variable size and shape have been proficiently used to this purpose. For 
instance, Wennemers and co-workers have prepared several symmetrical DKP-based two-armed 
receptors, derived from 4-amino-proline where the two amino groups (with a cis disposition) were 
functionalized with two tripeptide side chains (Figure 2.1).
2,3
  
2 DIKETOPIPERAZINES AS TEMPLATES 
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Figure 2.1 - General structure of di-(2S,4R)-4-aminoproline diketopiperazine two-armed receptors. 
 
Five different receptors were prepared. The use of 4-amino-proline imparted the necessary distance 
between the two side arms in order to avoid intramolecular recognition between the two tripeptide 
arms and collapse of the receptor. 
The resulting two-armed receptors were screened towards an encoded
4 
resin-bound tripeptide library 
with the general structure Ac-AA3-AA2-AA1-NH(CH2)6-CONH-PS.  
The screening revealed highly selective binding properties in organic solvents; in particular, each of 
the five structurally similar receptor prototypes selects for different tripeptides within the library. In 
particular, the di-(2S,4R)-4-aminoproline diketopiperazine shows a highly preorganized, turn-like 
conformation which imparts a defined orientation to the tripeptide side arms. 
Water soluble diketopiperazine receptors were also synthesized, containing aspartic acid residues in 
the side arms, and were shown to bind to arginine-rich peptides in aqueous solution.
5
 Interestingly, the 
addition of surfactants to this water-soluble receptor led to the formation of receptor-surfactant 
complexes with thermotropic liquid-crystalline properties.
6
 Later on, the same group reported the 
synthesis of macrocyclic diketopiperazine receptors and demonstrated that the macrocyclization can 
alter the binding properties of the two-armed receptors since macrocyclic receptors bind their peptidic 
substrates with lower binding affinities compared to flexible two-armed receptors. The extent of 
altered binding selectivities depends on the length of the linker used to connect the receptor arms.
7
 
Jolliffe and co-workers have reported another example of symmetrical diketopiperazine-based receptor 
with potential applications as sensor capable of discriminating anions that are ubiquitous in biological 
processes.
8
 The authors designed and synthesized a diketopiperazine-based receptor bearing two 
dipicolylamino (DPA) arms (disposed in a cis configuration), by cyclization of the dipeptide 
Orn(DPA)-Orn(DPA)-OMe. Addition of Zn(OAc)2 to the diketopiperazine-based receptor gave the 
bis[zinc(II)] complex for anion binding studies (Figure 2.2). The receptor showed significant 
selectivity for di- and triphosphate oxoanions over other anions tested (e.g., the sodium salts of nitrate, 
sulfate, bromide, iodide, acetate, (+)-tartrate, citrate, hydrogenphosphate, phosphotyrosine, 
phosphothreonine) in aqueous solution at physiological pH (pH = 7.4). 
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Figure 2.2 - Diketopiperazine-based anion receptor. 
 
 
1.2 -  DKPs as -turn mimics 
 
 
Figure 2.3 - -turn 
 
As already mentioned, a -turn is defined as any tetrapeptide sequence, showing a typical 10-
membered intramolecular H-bonded ring (Figure 2.3).  
Although there has been much discussion in the literature on what constitutes a β-turn mimic and how 
different types of mimics are to be characterized,
9
 these can be roughly classified into three broad 
classes, which are illustrated in Figure 2.4: a) internal β-turn mimics, b) β-hairpin mimics (where a 
rigid scaffold induces reversal of the peptide chain), and c) external β-turn inducers. 
 
 
Figure 2.4 – classification of -turn mimics. 
 
 
1.2.1 -  Internal β-turn mimics 
The first class of β-turn mimics includes scaffolds displaying side chains with trajectories mimicking a 
peptide reverse turn. Several examples of this type of DKP-based scaffolds are reported in the 
literature. Golebiowski and co-workers have developed a solid-supported high-throughput synthesis of 
bicyclic diketopiperazines, starting from racemic piperazine-2-carboxylic acid.
10
 A library of -turn 
mimics was prepared (general structure, Figure 2.5), in which the first two (R
4 
and R
5
) substituents 
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were introduced via the Petasis reaction and subsequent amide bond formation, whereas R
1
 and R
2
 
substituents were originated from an -amino acid and were introduced in the amidation reaction.  
 
 
Figure 2.5 – examples of DKP-based internal -turn mimics. 
 
Later on, the same authors were able to introduce the missing R
3 
substituent by developing a solid-
phase protocol based on the Ugi reaction and using both L- and D-diaminopropionic acid as starting 
material, leading to two (complementary) epimeric series of β-turn mimics 27 (Figure 2.6).11,12 
 
 
 
Figure 2.6 – examples of DKP-based internal -turn mimics. 
 
Simulated annealing calculations were performed on both epimers of structure 27 to determine their 
propensity to adopt a β-turn. The obtained data suggest that both R- and S- epimers of structure 27 fit 
more closely a type I -turn.12 Starting from simple -amino acids, Kahn and co-workers have also 
reported the solution-phase synthesis of a conformationally restricted β-turn mimic 28 based on a 
similar bicyclic diketopiperazine scaffold (Figure 2.6).
13
  
 
 
Figure 2.7 – examples of DKP-based internal -turn mimics. 
 
A cyclopropyl derivative of this heterocycle was also reported by Belov et al.
14
 Finally, in 2010, 
Jurckak and co-workers reported the solid-supported synthesis of a library of -turn mimics based on 
the general structure reported in Figure 2.7, using the original Golebiowski‟s strategy (three-
component Petasis condensation and 2,5-DKP formation) but starting from optically pure (S)-
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piperazine-2-carboxylic acid, with the purpose of decreasing the number of diastereomers of the final 
bicyclic scaffolds.
15
 
Burgess and co-workers described the use of diketopiperazine scaffolds in antagonists of tropomysin 
receptor kinase C.
16
 Selectivities for this particular receptor were achieved by using amino acid side 
chains corresponding to those present in the β-turn regions of the parent neurotrophin ligands. The 
diketopiperazine scaffolds used in this work (Figure 2.8) are functionalized at the N1 and C3, and the 
substituents at these two positions were calculated to overlay well with the side chains of the i+1 and 
i+2 residues of a type-I -turn. 
 
Figure 2.8 – DKP mimics of a type I -turn. 
 
 
1.2.2 -  DKPs as β-hairpin inducers 
The second class of -turn mimics consists of a rigid scaffold, which, when incorporated into a peptide 
or pseudo-peptide chain, causes a reversal of the chain.
17
 In strictest terms, these structures themselves 
should adopt a -turn conformation, but quite often they lack substitution at the important i+1 and i+2 
residues of the turn region or the means to introduce significant diversity at these positions. As -
hairpin inducers, the scaffolds can promote the formation of parallel or antiparallel -sheets depending 
whether the side chains contain the same (e.g., two amine or carboxylic groups) or complementary 
functionalities (one amine and one carboxylic function). Gellerman and co-workers have reported the 
synthesis of orthogonally protected optically pure diketopiperazine scaffolds, starting from N-
carboxymethyl -Alloc ornithine and orthogonally protected L-lysine.18,19 The resulting non-
symmetrical diketopiperazine scaffold 29 (Figure 2.9) bears two amine functionalities [AllocNH-
(CH2)3, generated from Orn and FmocNH-(CH2)4, generated from Lys] in the arms of the DKP core 
and a complementary N-carboxymethyl group, which could be further manipulated via solid-phase 
organic chemistry (SPOC). 
 
 
Figure 2.9 – example of DKP-based -turn mimic 
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Alternatively, two different functionalities can be created in the lateral chains of the two amino acids 
forming the DKP core, such as an amine (e.g., derived from Lys, Orn or diaminobutyric acid) and a 
carboxylic acid (e.g., derived from Asp or Glu). Davies and co-workers performed some calculations 
on the minimum constraint requirement for a -turn, which would fit tightly at the turn without 
causing steric hindrance, and preserve the polar backbone at the -turn.20 The result turned out to be a 
reverse cis-amide link in the form of a DKP ring containing an amino and a carboxylic groups in a cis-
orientation, which would mimic a -turn (correct angles and distances) and induce the formation of -
sheet structures. 
 
1.2.3 -  DKPs in cyclic peptidomimetics, as external β-turn inducers 
In the case of external β-turn inducers, a rigid template is used to constrain the backbone of a cyclic 
peptide in order to stabilize the peptidic residue into a β-turn conformation. Notable examples of this 
type of β-turn mimic, based on a DKP scaffold, have been reported by Robinson and co-workers.21 
 
 
Figure 2.10 - Examples of diketopiperazine-based scaffolds as “external” β-turn mimics. 
 
The authors have reported an extensive investigation of proline-based diketopiperazine templates 
(Figure 2.10), that were used to stabilize turn and hairpin conformations in cyclic peptides containing 
the Asn-Pro-Asn-Ala (NPNA) sequence. This tetrapeptide motif, which is found as a repeated unit in 
the circumsporozoite (CS) surface protein of the malaria parasite Plasmodium falciparum, has a 
tendency to adopt type-I -turns in aqueous solution in linear peptides containing tandemly repeated 
NPNA sequence, and this secondary structure appears to be important for immune recognition of the 
folded CS protein. Several bifunctional bi- and tri-cyclic diketopiperazine scaffolds were prepared and 
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inserted into cyclic peptides containing the ANPNAA sequence. The first bicyclic scaffolds 30 derives 
from the cyclization of L-aspartic acid and (2S,4S)-4-aminoproline
21
 or (2R,4S)-4-amino-2-
carboxymethylproline
22
 which are obtained starting from readily available (2S,4R)-4-hydroxyproline. 
These were incorporated into the cyclic loop mimics 34 containing the tetrapeptide motif Asn-Pro-
Asn-Ala (NPNA), by solid-phase peptide synthesis, using Fmoc-chemistry. The conformational 
studies of loop mimics 34 were performed by 
1
H-NMR spectroscopy and MD calculations.
23
 Structure 
calculations using NOE-derived distance restraints indicate that the NPNA motif in 34 adopts a type-I 
β-turn conformation, while a bulged loop backbone conformation, rather than a stable -hairpin is 
induced in the cyclopeptide by the pseudoequatorial position of 4-amido substituent of the pyrrolidine 
ring. Immunological studies revealed that these compounds can elicit anti-sporozoite antibodies in 
mice. Template 31 is closely related to 30, but the additional pyrrolidine ring provides an extended 
framework for incorporating new functional groups. The synthesis of this scaffold started again from 
readily available (2S,4R)-4-hydroxyproline and L-proline. The template was then incorporated into 
cyclic peptide mimic 35 containing the sequence ANPNAA.
24
 The solution conformation of 35 was 
studied by NMR in 10% D2O/H2O at pH 5.0. Average solution structures calculated with NOE 
restraints showed again the NPNA motif in a type-I β-turn conformation, and indeed the entire loop 
backbone conformation was very similar to that found with template 30 in mimic 34. On the other 
hand, the tricyclic template 32 comprises a cis-fused bis-proline-derived diketopiperazine, where both 
proline rings are functionalized at the C4 position with an amino and carboxymethyl functionalities. 
Scaffold 32 was incorporated into cyclic peptide mimic 36 containing the usual ANPNAA sequence.
25
 
 
 
Figure 2.11 - β-Hairpin structure in the cyclic peptidomimetic 37, containing the DKP template 33. 
 
 Compared to templates 30 and 31, the N- and C-termini of the peptide are anchored to template 32 in 
a quite different geometric relationship, which enforces a different backbone conformation on the 
peptide loop. This was confirmed by NMR spectroscopy in aqueous solution.
25
 In particular, the 
tetrapeptide NPNA motif populates an extended conformation, rather than the β-turn seen in mimics 
34 and 35. Finally, template 33 was synthesized with the purpose of creating an additional N-
substituent at the Cβ position of the pyrrolidine ring, that should remain axial and so be ideally 
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positioned as an anchoring group to restrain a peptide loop into a β-hairpin geometry. Template 33 
was synthesized using (2S, 3R, 4R)-3,4-diaminoproline as a building block and was used to construct 
loop mimic 37 (Figure 2.11) whose conformation was studied by NMR and MD methods.
26
  
A relatively stable β-hairpin conformation in the backbone of 37 was detected in the NOESY spectra 
(DMSO-d6 solutions), by means of NOE contacts connecting HAla
1
) as well as NH(Asn
2
) with 
NH(Ala
5). In addition, a β-turn in the NPNA motif was also indicated by a relatively strong Asn4 to 
Ala
5
 dN,N NOE, as well as NOE contacts between Asn
2
 H(β)s and Ala5 NH, as observed in earlier 
studies of 34. Average solution structures were determined by dynamic simulated annealing (SA) 
using distance restraints derived from NOESY spectra. The SA structures revealed a well defined β-
hairpin backbone conformation, including a type I β-turn in the NPNA motif (Figure 2.11). 
 
Scaffold 30 (R = H) was also introduced into the cyclic peptide 38 containing the Arg-Gly-Asp (RGD) 
sequence (Figure 2.12).
21
 
 
 
Figure 2.12 - Cyclic RGD peptidomimetics containing bicyclic DKP template 30. 
 
A conformational study to determine the three-dimensional presentation of the RGD motif in 
peptidomimetic 38 was performed by 
1
H-NMR spectroscopy. However, no conclusive evidence of a 
defined conformation could be found, and it seems very likely that the peptide backbone of 38 is 
interconverting rapidly between two or more conformational states in aqueous solution. 
 
 
Figure 2.13 - cyclic RGD peptidomimetics containing cyclo[Lys-Asp]. 
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In a similar approach, Royo, Albericio and co-workers have prepared cyclic peptidomimetics 
containing cyclo[Lys-Asp] as a template (39, Figure 2.13).
27
 The side arms of the diketopiperazine 
were then used to link the amino and carboxy termini of three different peptides containing the RGD 
sequence (RGD, RGDG, and GRGDG), following a solid phase approach. 
 
 
1.3 -  DKPs in helical structures 
Bis-peptides were recently introduced by Schafmeister and co-workers as “synthetic oligomers 
assembled from cyclic, stereochemically pure monomers coupled through pairs of amide bonds to 
form rigid spiroladder oligomers with predefined and programmable three-dimensional structures”.28 
 
 
Figure 2.14 
 
 A “molecular rod” 40 (Figure 2.14) was synthesized starting from the “bis-amino acid” 4-amino-4-
carboxy proline 41.
29
 This substituted proline was prepared in multi-gram quantities in nine synthetic 
steps from commercially available trans-4-hydroxy-L-proline. The synthesis of the “molecular rod” 40 
occurred in two stages: a first “assembly” stage where the linear oligomer was grown, coupling the 
proline COOH to the primary amine in 4-position, by solid-phase peptide synthesis. A “rigidification” 
stage followed after cleavage from the resin. In this step, the diketopiperazines were cyclized by an 
intramolecular aminolysis reaction, in which the secondary amine of each monomer attacked the 
methyl ester of the previous monomer. 
 
 
Figure 2.15 - Bis-peptide 42 with a left-handed helical arrangement. 
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Interestingly, when the bis-amino acid 41 was functionalized by reductive alkylation with different 
aldehydes at the primary amine group, the bis-peptide 42 resulting from the coupling of the 
corresponding homochiral monomers, adopted a left-handed helical arrangement, and the nitrogen 
substituents superimposed well on the side chains of a model -helical peptide (Figure 2.15).30 
 
 
2 -  Previous work of our research group in the field 
Recently, our group reported the synthesis of a new class of bifunctional
 
DKP scaffolds (DKP1, 
DKP2, Figure 2.16), formally derived from aspartic acid and 2,3-diaminopropionic acid, bearing a
 
carboxylic acid and an amino functionalities.
31
 As a consequence
 
of the absolute configuration of the 
two α-amino acids forming the cyclic dipeptide unit, the two reactive functionalities (amino and 
carboxylic acid) are locked in a cis- (DKP1) or trans-configuration (DKP2). In addition, while being 
derived from α-amino acids, these DKP scaffolds can be seen as a conformationally constrained 
dipeptide formed by two β-amino acids (see Figure 2.16), and in particular a β2- and a β3-amino acids 
(following Seebach‟s nomenclature).32 
 
 
Figure 2.16 - Structure of bifunctional DKP scaffolds highlighting the conformationally constrained β2–β3 dipeptide 
sequence. 
 
In particular, the bifunctional scaffold DKP1, derived from L-aspartic acid and (S)-2,3-
diaminopropionic acid, bears the amino and carboxylic acid functionalities in a cis relationship and, as 
such, can be seen as a -turn mimic and promoter of antiparallel -sheet. In view of these potential 
properties, the synthesis of several peptidomimetics was performed by solution phase peptide 
synthesis (Boc strategy). Conformational analysis of these derivatives
31 
was carried out by a 
combination of 
1
H-NMR spectroscopy (chemical shift and NOE studies), IR spectroscopy, CD 
spectroscopy and molecular modeling, and revealed the formation of -hairpin mimics involving 10- 
and 18-membered H-bonded rings and a reverse turn of the growing peptide chain (43, 44, Figure 
2.17). The -hairpin conformation of the longer derivatives (44 a and b) was detected also in 
competitive, dipolar and even protic solvents such as dimethylsulfoxide and methanol, thus showing 
the high stability of these structures and the very good turn-inducing ability of the scaffold. 
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Figure 2.17 - Peptidomimetics containing scaffold DKP1. 
 
This attitude was further confirmed in the conformational analysis of two oligomers of DKP1, namely 
the trimer Boc-(DKP1)3-NHnBu (45, Figure 2.18), and the tetramer Boc-(DKP1)4-NHnBu (46, Figure 
2.18).
33
 The conformational preferences in solution of these foldamers were investigated by 
1
H-NMR 
and CD spectroscopy and molecular modeling. In the case of the trimeric structure, the conformational 
studies suggest the possible formation of two turns for the first and third residues, while the tetramer 
Boc-( DKP1)4-NHnBu (46, Figure 2.18) is best described as a -bend ribbon conformation which is 
characterized by a succession of -turns forming a linear peptide with a ribbon-like shape. 
 
 
Figure 2.18 - Structure of trimer 45 and tetramer 46. 
 
The most peculiar feature of the -turn structure present both in the hairpin and -bend ribbon are the 
CD spectra which display a rather strong minimum around 200 nm and a weaker one at 225 nm with a 
negative maximum at 215 nm (Figure 2.17). This was shown, by NMR studies, to adopt a turn-like 
conformation with a 10-membered H-bonded ring induced by the 2–3 unit.  
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Figure 2.19 - CD spectrum of the tetramer 46 and the hairpin peptidomimimetic 44a. The data of the latter compound have 
been multiplied by a factor 10 to magnify the appearance of the curve. 
 
Our group has reported the synthesis, conformational analysis and investigation of the biological 
activity of cyclic RGD-peptidomimetics 47 and 48 (Figure 2.20), containing the bifunctional 
diketopiperazine scaffolds DKP1 (cis) and DKP2 (trans) (Figure 2.16).
34
  
 
 
Figure 2.20 - Cyclic RGD peptidomimetics containing scaffolds DKP1  and DKP2. 
 
The conformational studies of cyclic RGD peptidomimetics were performed by NMR spectroscopy 
(
1
H-NMR and NOESY spectra of dilute H2O/D2O 9:1 solutions) and by computational methods 
[Monte Carlo/Stochastic Dynamics (MC/SD) simulations]. 
RGD-peptidomimetic 47 exists in two different preferred conformations: one characterized by a -turn 
centered at the Gly residue and a II‟-turn at Gly-Asp and the second featuring a -turn at Arg and a 
II‟-turn at Arg-Gly (respectively, 47 A and B in Figure 2.21). In both cases, the RGD sequence 
displays a kinked, non-extended arrangement with a rather short (6.5-7.4 Å) C(Arg)–C(Asp) 
distance. On the contrary, compound 48 adopts a single extended arrangement of the RGD sequence 
[C(Arg)–C(Asp) average distance = 9.3 Å] characterized by a pseudo -turn at DKP-Arg and the 
formation of an inverse -turn at Asp (Figure 2.21). 
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Figure 2.21 - Preferred intramolecular hydrogen-bonded patterns proposed for compound 47 and 48 on the basis of 
spectroscopic data. The arrows indicate significant NOE contacts. 
 
 
3 -  Library of DKP scaffolds 
On the basis of the goals previously achieved by our research group, a library of bifunctional 
diketopiperazines structurally similar to DKP1 and DKP2 (see Figure 2.16) was prepared, varying 
their stereochemistry and substitution pattern (DKP3-DKP8, Figure 2.22). A second generation of 
scaffolds DKP1-DKP3 was also prepared (DKP1*, DKP2*, DKP3*, Figure 2.22), in which the 
amino group is masked as azide. 
 
 
Figure 2.22 – Library of bifunctional diketopiperazine scaffolds DKP1-DKP8 and second generation scaffolds DKP1*-
DKP3*  
 
3.1 -  Conception of the library 
DKP1 and DKP2 already revealed interesting and valuable constrained rigid scaffolds which, bearing 
a
 
carboxylic acid and an amino functionalities, could be successfully employed as secondary structure 
inducers for several applications. 
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Tiny variations in their stereochemistry, ring substitutions or degrees of freedom, may dramatically 
change the behavior of these scaffolds when inserted into a peptidomimetic moiety.  Having a wide 
range of scaffolds available may be of great impact expecially when aiming at the modulation of a 
biological target. For these reasons a library of eight diketopiperazines (Figure 2.22), structurally 
similar to DKP1 and DKP2, was conceived. 
In particular the scaffolds in the library differ for their relative stereochemistry, namely cis (DKP1) or 
trans (DKP2–8). The trans scaffolds differ for their absolute stereochemistry [either 3R,6S (DKP2, 
DKP4, DKP5) or 3S,6R (DKP3, DKP6, DKP7, DKP8)], for the substitution at the endocyclic 
nitrogens, which can be either hydrogen or benzyl (DKP2, DKP3, DKP4, DKP6, DKP8) or dibenzyl 
(DKP5, DKP7), and for the length of side-arm bearing the carboxylic group, which can be either 
carboxymethyl (DKP1–7) or carboxyethyl (DKP8). 
A second generation of scaffolds, containing an amino functionality masked as azide (DKP1*-
DKP3*), was created when we attempted to use this kind of scaffolds as building blocks for Fmoc 
solid phase synthesis. The azido function, which is stable in certain solid-phase peptide coupling 
conditions, stands here in place of a protecting group, alternative to Fmoc. 
 
3.2 -  Synthesis 
A solution phase Boc-strategy was chosen for the synthesis of  all the scaffolds. Different synthetic 
approaches were devised depending on the diketopiperazine nitrogen substitution. 
 
3.2.1 -  Synthesis of DKP1 - DKP3 and DKP1* - DKP3* 
The synthesis of DKP-1, DKP-2 and DKP-3 (bearing a benzyl group at nitrogen N-4, Figure 2.22) 
was performed according to procedures already developed in the group.
31 
Hydroxymethyl diketopiperazine 49 was identified as a suitable precursor. 
 
 
Scheme 2.1 – retrosynthetic approach to DKP1-DKP3. 
 
The diketopiperazine ring was supposed to be provided by the cyclization of the dipeptide methylester 
derived from suitably protected and functionalized L- or D-aspartic acid and L- or D-serine (Scheme 
2.1). 
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Therefore, aspartic acid was protected orthogonally to Boc and methylester on the  carboxylic acid 
functionality as an allylester. Either L- or D-aspartic acid were accordingly esterified by treatment with 
acetyl chloride in allyl alcohol to give aspartic acid -allylester hydrochloride 50 (Scheme 2.2). The 
reaction of acetyl chloride with an alcohol (allyl alcohol here) is used to generate HCl in situ leading 
to the formation of allyl acetate, which can be removed if necessary by evaporation under reduced 
pressure. This procedure is reported to be selective for the -carboxylic group esterification, but some 
bis-allylation can still take place.
35
 In order to minimize the -carboxylic acid esterification the 
reaction was performed at low temperature (0–10 ºC). The amino group was then protected as its N-
tert-butoxycarbonyl derivative, under standard conditions, to give N-(tert-butoxycarbonyl)-aspartic 
acid -allyl ester (51, Scheme 2.2). On the other hand, the OH group of the serine side-chain was 
thought not to interfere with the subsequent coupling reaction. Hence, only -carboxylic acid group 
was protected as its methyl ester. Serine methyl ester hydrochloride 52 was obtained by esterification 
of the corresponding free amino acid in refluxing methanol, in the presence of acetyl chloride. The 
serine -amino group was then alkylated through a reductive alkylation, thus obtaining N-benzylserine 
methyl ester 53. As we mentioned previously (see Chapter 1.3.1), the presence of a tertiary amine 
decreases the energy difference between cis and trans peptide bond isomers, thus facilitating the 
cyclization step and DKP formation. 
 
 
Scheme 2.2 – Synthesis of precursors: a) CH3COCl, CH2=CHCH2OH: 80%; b) Et3N, Boc2O, 1:1 H2O/THF: 96%; c) 
CH3COCl, CH3OH: 100%; d) Et3N, PhCHO, CH3OH, then NaBH4: 93%. 
 
The hydrochloric salt 52 was treated with benzaldehyde in methanol, in the presence of iPr2EtN to 
obtain the corresponding imine, that was subsequently reduced with sodium borohydride (Scheme 
2.2). In order to minimize racemization during this latest step, special attention should be given to both 
temperature (-10°C during addition of reagents) and reaction time.
36
 A procedure using sodium 
triacetoxyborohydride was recently attempeted, obtaining more reproducible results in terms of optical 
purity, but slightly lower yields. 
It was then envisaged to couple protected aspartic acid 51 with N-benzylserine 53. This reaction was 
reported using Carpino‟s reagent HATU, and the formation of dipeptides 54 was declared to occur in 
good yield (72%).
31
 After Boc-deprotection with TFA in dichloromethane, and subsequent basic 
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activation in a biphasic medium (NaHCO3 aq. 1M, AcOEt), diketopiperazines 49 were to be formed 
through an intramolecular 6-exo ring closing (Scheme 2.3). 
 
 
Scheme 2.3 – synthetic route to diketopiperazine 53, as reported in the literature: a) HATU, HOAt, iPr2EtN, DMF, 72%; b) 
CF3COOH/CH2Cl2 1:1; c) NaHCO3 aq. 1M, AcOEt, 77% over two steps. 
 
Indeed diketopiperazines 49 were actually obtained in good yields through these synthetic steps. The 
structure of the cis compound DKP1 (Figure 2.22), which was obtained following the same strategy, 
was in fact confirmed by X-ray.
31
 
Being sure of having obtained compounds of structure 49, we decided to investigate the coupling 
between aspartic acid derivatives 51 and the hydroxyl-unprotected serin derivatives 53 more carefully. 
The spectroscopic properties of the intermediates obtained from the coupling reaction were closer 
inspected, revealing that the formation of the isopeptides 55 had instead occurred, via the selective 
acylation of the unprotected -hydroxy group of either (S)- or (R)-N-benzylserine (Scheme 2.4).37 
 
 
Scheme 2.4 – formation of an isodipeptide by direct coupling of compounds 51 and 53: a) HATU, HOAt, iPr2EtN, DMF, 
72%. 
 
Diagnostic of this outcome were the NMR spectra, studied in particolar for compounds 55a and 55b: 
(i) in the 
1
H NMR spectrum, the O-CH2 protons of serine were rather deshielded [55a:  4.32-4.48, m, 
2H (CDCl3); 55b:  4.30, dd, 1H and  4.39, dd, 1H (CD2Cl2)]; (ii) in the HMBC (Heteronuclear 
Multiple Bond Coherence) spectrum of both compounds, a long range coupling (through three bonds) 
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was clearly evident between the O-CH2 protons of serine and the -carbonyl carbon of aspartic 
(Figure 2.23). 
 
 
 
Figure 2.23 – HMBC spectra of isopeptides a) 55a (CDCl3) and b) 55b (CD2Cl2), highlighting the long range coupling 
(through three bonds) between the O-CH2 protons of Ser and the -carbonyl carbon of Asp; c) scheme 
representing the long range couplings highlighted from the HMBC spectra. 
 
Had we been in presence of dipeptide 54, we might have probably expected other long range 
couplings, in particular between the the -carbonyl carbon of Asp and both the CH2-Ph and the C-H 
of Ser. In order to further prove our hypothesis, an extra experiment was conducted on compound 55b. 
Capping compound 55b with acetic anhydride provided isopeptide 56 (Scheme 2.5). In this case, a 
long range coupling (through three bonds) between the benzylic CH2 protons of benzylserine and the 
acetyl carbonyl carbon was detected, confirming that acetylation had occurred on the secondary amine 
group of serine, which was therefore not involved in an amide bond with the aspartic fragment (Figure 
2.24).  
Thus, as compound 49 was obtained after Boc deprotection of compounds 55 with TFA and 
subsequent treatment with four equivalents of Et3N or iPr2EtN in methanol, it was clear that the 
deprotected isopeptide intermediate had to procede through an O,N-acyl transfer while forming the 
diketopiperazine ring. 
55a 55b 
b) a) 
c) 
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Scheme 2.5 – acetylation of isopeptide 55b: a) Ac2O, pyridine.  
 
 
Figure 2.24 - HMBC spectrum of 56 in CD2Cl2. 
 
Puzzled by this behavior, we decided to investigate the conditions promoting O,N-acyl 
transfer/cyclization reactions, and the relevant mechanism that leads to diketopiperazine 49b from 
isopeptide 55b. Despite the presence of a nucleophilic nitrogen, isopeptide 55b was stable both in 
solid state and in solution (dichloromethane). Instead, a complete degradation of the product was 
observed in methanol after 72 h, which could be attributed (as revealed from 
1
H-NMR spectra) to the 
transesterification of the aspartate β-allyl ester and to the cleavage of the isopeptidic bond, giving rise 
to N-(tert-butoxycarbonyl)-aspartic acid dimethylester and N-benzylserine methyl ester. In any case, 
isomerisation to dipeptide 54b was never observed. 
Since the O,N-acyl transfer indeed occurred during the formation of diketopiperazine 49b upon 
nitrogen deprotection, the Boc group of isopeptide 55b was cleaved by reaction with TFA to give the 
bis-TFA salt 57, which was fully characterized (Scheme 2.6). 
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Scheme 2.6 – cleavage of the Boc group on 59b: a) CF3CO2H/CH2Cl2, 1:1, 2h, quantitative. 
 
In this case too, the HMBC spectrum of 57 confirmed that no O,N-acyl shift had occurred (Figure 
2.25), as, again, no long range couplings were detected between the -carbonyl carbon of Asp and 
either the CH2-Ph or the C-H of Ser. Only  a long range coupling between the O-CH2 of Ser and the 
-carbonyl carbon of Asp was highlighted in the spectrum. 
 
 
 
Figure 2.25 – a) HMBC spectrum of isopeptide bis trifluoroacetate salt 57 (CDCl3), highlighting the long range coupling 
(through three bonds) between the O-CH2 protons of Ser and the -carbonyl carbon of Asp; b) scheme 
representing the long range couplings highlighted from the HMBC spectrum. 
 
Reactivity of bis-TFA salt 57 was then investigated. No O,N-acyl migration was observed after 48 h, 
monitoring a dichloromethane solution of compound 57 by 
1
H-NMR; conversely, when dissolved in 
methanol, complete methanolysis of isopeptide bis-TFA salt was detected in 6 h, giving rise to (2S)-
b) 
a) 
48  Chapter 2 
aspartic acid -allyl ester -methylester and N-benzylserine methyl ester. Isomerization to the 
dipeptide was  not observed, even in this case. 
Upon addition of 4 equivalents of a base (Et3N or iPr2EtN) to a solution of bis-TFA salt 57 in 
methanol, ring closure occurred rapidly and was virtually complete after 2 h. However, monitoring the 
reaction by 
1
H-NMR spectroscopy (CD3OD / 4 eq. Et3N), the dipeptide 54b resulting from the O,N-
acyl shift was never detected, and only signals concerning the starting bis-TFA salt 57 and the 
resulting diketopiperazine 49b were identified. 
As can be clearly seen in Figure 2.26, the two dd at  4.32 and   4.45, belonging to the O-CH2 protons 
of benzylserine in the isopeptide bis-TFA salt 57, decreased in intensity with time, while the dd at  
3.93 and , corresponding to the same O-CH2 protons in 49b, proportionally increased. The same 
holds for the two d of the benzylic CH2 protons, which in the isopeptide salt 57 resonate at 3.73 and 
3.87, while in 49b shift to 4.12 and 5.38, and for the serine C-H which moves from 3.6 to 
3.77. 
The same transformation (bis-TFA salt 57 to 49b) was followed by 
1
H-NMR in an aprotic solvent 
(CD2Cl2 containing 4 eq. of Et3N). In this case too, despite the much reduced reaction rate (only 32% 
conversion was observed after 15 h), no O,N-acyl shift product was ever detected (Figure 2.27). 
 
 
Figure 2.26 - 1H-NMR monitoring of the transformation of isopeptide bis-TFA salt 57 into the diketopiperazine 49b 
(CD3OD / 4 eq. Et3N). 
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Figure 2.27 - 1H-NMR monitoring of the transformation of isopeptide bis-TFA salt 57 into the diketopiperazine 49b (CD2Cl2 
/ 4 eq. Et3N). 
 
Based on these experimental observations, a reasonable mechanistic explanation involves a rate 
limiting O,N-acyl transfer with simultaneous ring closure to DKP, so that no dipeptide intermediate 
can be detected (Scheme 2.7). 
 
 
Scheme 2.7 – proposed diketopiperazine mechanism of formation: a) CF3CO2H/CH2Cl2, 1:1; b) 4 equiv. base (Et3N or 
iPr2EtN), MeOH. 
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On a preparative scale, the synthesis of diketopiperazine 49b from bis-TFA salt 57 was more 
efficiently performed (94% isolated yield) with iPr2EtN (4 eq.) in iPrOH instead of MeOH, that in the 
long run leads to transesterification of aspartic allyl ester.
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Analogous results were also observed while synthesizing of both diketopiperazines 49a (cis) and 49c 
(trans). 
In vision of a scaling up of the synthesis of isopeptide 55, these studies gave us enough information on 
how to improve the coupling reaction between the two aminoacid derivatives 51 and 53. Since an ester 
bond is formed instead of an amide bond, the more appropriate and better value coupling reagent EDC 
(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) in presence of a catalytic amount of DMAP (4-
Dimethylaminopyridine) provided the best results (Scheme 2.8). 
 
Scheme 2.8 -  a) EDC, DMAPcat., CH2Cl2, 94% 
 
Carpino‟s reagents (HATU, HOAt) are very useful to avoid epimerization on the α proton during 
aminoacid coupling, but also this methodology, monitoring temperature and reaction time, gives no 
epimerization on the α proton, as confirmed by 13C-NMR.  Furthermore, the yields we obtained were 
higher. 
Once the coupling reaction and the subsequent diketopiperazine ring closure were improved, we 
focused on the transformation of the hydroxy moiety of 49 into the Boc-protected amino moiety 
present in DKP1-DKP3. 
Functional group interconversion was accomplished by a Mitsunobu type reaction,
38
 followed by 
reduction and in situ Boc-protection by Staudinger reaction of the obtained azides 58 into derivatives 
59. Deprotection of the allyl ester on compounds 59 was succesfully accomplished via a Pd
0
 catalyzed 
Tsuji-Trost reaction, which proceeds quantitatively affording the final scaffolds DKP1-DKP3 
(Scheme 2.9): 
 
 
Scheme 2.9 – a) PPh3, DIAD, H3N.tol, DCM/toluene, -20°C; b) Me3P, Boc-ON, THF,  
-20°C -> r.t; c) [Pd(PPh3)4], PPh3, pyrrolidine, DCM, 0°C. 
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Mitsunobu transformation on substrates 49 is a quite sensitive reaction, since the activated hydroxy 
group could  eliminate before reacting with the pronucleophile (HN3). The C(6) proton can be in fact 
easily extracted due to its acidity, providing a diketopiperazine with an exocyclic double bond (60, 
Scheme 2.10). 
 
 
Scheme 2.10 –  elimination competing with the Mitsunobu nucleophilic attack: a) PPh3, DIAD, H3N.tol, DCM/toluene,        
-20°C. 
 
Monitoring temperature (which should not exceed -20°C), reaction time and order of reagents 
addition, we were able to drastically reduce the amount of 60, reducing the ratio 58a:60a to 3:1, 
58b:60a and 58c:60b to 8:1. Reaction was carried out in a toluene/dichloromethane 2:1 solution, since 
toluene is itself was not sufficient to solubilize diketopiperazines 49 at -20°C.  
 
 
Figure 2.28 
 
 elimination side reaction proved to be particularly competitive in the case of the cis substrate 49a. 
Purification from the by-product revealed even more complicated, as product 58a showed almost the 
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same elution time of the corresponding byproduct 60a, with various eluents. These are the main 
reasons why yields are far lower for the cis product. 
NMR evidence of the formation of azide 58b, namely the shift of Cα-H and Cβ-H2 derived from serine, 
is reported in Figure 2.28. 
 
The next step involved a one-pot Staudinger – Boc protection. The Staudinger reaction, a very mild 
azide reduction, involves the reaction of the azide with a phosphine to generate a phosphazide, which 
loses N2 to form an iminophosphorane. Hydrolysis of this intermediate leads to the amine and the very 
stable phosphine oxide. The mechanism is reported in Scheme 2.11. 
 
 
Scheme 2.11 – Staudinger reaction, mechanism. 
 
In our case the intermediate iminophosphorane reacted directly with 2-(t-butoxycarbonyloxyimino)-2-
phenylacetonitrile (Boc-ON),
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 present in the reaction medium, affording the desired Boc-protected 
amine in very good yield. Finally the DKP scaffold allyl esters 59 (Scheme 2.9), were de-allylated in 
the presence of a catalytic amount of tetrakis(triphenylphosphine) [Pd(PPh3)4] and pyrrolidine, i.e. a 
nucleophile acting as an allyl scavenger to give the amino acid derivatives DKP1-DKP3 in 
quantitative yield. Such methodology is of special interest for peptide synthesis because the 
deprotection conditions are usually mild enough to be compatible with the presence of acid labile t-Bu 
and Boc protections.
40
 
 
 
Scheme 2.12 – synthesis of second generation DKP1*-DKP3* from intermediate 58: a) [Pd(PPh3)4], N-methyl aniline, 
DCM, 1h, r.t., 90%. 
 
When scaffolds DKP1-DKP3 needed to be used as building blocks in Fmoc-solid phase synthesis, a 
second generation of these scaffolds (DKP1*, DKP2*, DKP3*, Figure 2.22) was conceived. We first 
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thought about reducing azides 58 to the corresponding free amines, which could then be Fmoc 
protected and de-allylated with the usual Tsuji-Trost procedure. However, aiming at reducing the 
number of steps, we decided instead to directly de-allylate azides 58, using a similar, milder protocol, 
thus obtaining azido acids DKP1*-DKP3* (Scheme 2.12). Azides are in fact stable under solid phase 
coupling conditions (DCC, HOBt or DIC, HOAt), and can be seen as protecting groups of the amino 
functionality. The in-situ azide reduction is making the amino group available for the subsequent 
coupling step. 
Moreover, de-allylation worked well even when performed on the non-separable mixture of azide 58a 
and dehydroalanine-like elimination by-product 60a, which were obtained from the Mitsunobu 
reaction. The two de-allylated products DKP1* and 61a couldn‟t be separated by silica gel 
chromatography, as degradation occurred. However the remarkably different solubility properties of 
the two compounds allowed us obtain azido acid DKP1* with good purity, by successive 
precipitations of highly insoluble 61a from concentrated dichloromethane solutions. 
 
A scheme of the whole synthetic route to DKP1-DKP3 and DKP1*-DKP3* is reported below 
(Scheme 2.13): 
 
 
Scheme 2.13 – a) CH3COCl, CH2=CHCH2OH; b) Et3N, Boc2O, 1:1 H2O/THF; c) CH3COCl, CH3OH; d) Et3N, PhCHO, 
CH3OH, then NaBH4; e) EDC, DMAPcat., DCM; f) TFA/DCM, 1:1; g) iPr2EtN, iPrOH; h) PPh3, DIAD, 
H3N.tol, DCM/toluene, -20°C; i) Me3P, Boc-ON, THF, -20°C -> r.t; j) [Pd(PPh3)4], PPh3, pyrrolidine, DCM, 
0°C; k) [Pd(PPh3)4], N-methyl aniline, DCM, 1h, r.t.. 
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3.2.2 -  Synthesis of DKP4 and DKP6 
A retrosynthetic analysis of scaffolds DKP4 and DKP6 (bearing a benzyl group at nitrogen N-1) 
suggested that, even in this case, the diketopiperazine ring 62 could be obtained from suitably 
protected aspartic acid and serine in the correct relative configuration (Scheme 2.14): 
 
 
Scheme 2.14 
 
We started investigating the synthesis of scaffold DKP4. As regards the aspartic acid derived 
fragment, both carboxylic acid moieties were protected as methyl esters and nitrogen was 
subsequently reductively alkylated to give derivative 63. Protection of the Ser hydroxyl group was 
necessary to avoid self-condensation: we decided to non-orthogonally protect the hydroxyl (protected 
as -tBu ether) and the amino functionalities (protected as –Boc), which, in this way, can be easily freed 
in an acidic medium (e.g. TFA solution) before diketopiperazine ring closure; such a protected Serine, 
derivative 64, was commercially available (Fluorochem™)  (Scheme 2.15). 
 
 
Scheme 2.15 - a) CH3COCl, CH3OH: 99%; b) NaBH3CN, PhCHO, CH3OH: 67%. 
 
Coupling the two aminoacidic fragments  63 and 64 proved to be very challenging: the secondary 
nitrogen of Asp that should act as the nucleophile is very hindered and, moreover, serine carboxylic 
group is hindered as well, due to the two surrounding tBu groups. The use of classical aminoacid 
coupling agents, such as HATU, DPPA, PyBrOP (reported to be very useful in the coupling of N-
methyl aminoacids),
41
 was attempted first, nevertheless not providing desired dipeptide 65 (curiously, 
reaction with PyBrOP provided a pyrrolidine serine derivative in good yield) (Scheme 2.16).  
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Scheme 2.16 
 
Other methods envisaging carboxyl activation via N-carboxyl anhydride (NCAs) derivatives were 
employed.
42
 Original procedures prompted the treatment of the aminoacid with unprotected carboxy 
functionality with phosgene. Milder reactants, such as diphosgene (ClCO2CCl3) or chlorosilanes (such 
as Cl2SiMe2, were later developed to generate an NCA derivative (these compounds generate silylated 
NCA derivatives). We attempted to use both of these mild methodologies to generate NCA activated 
derivatives of H-D-Ser(tBu)-OH (Fluorochem™). Unfortunately, only reaction with 
dimethylchlorosilane led to the NCA-like compound. Also this kind of activation did not prove 
anyway strong enough to induce dipeptide formation when reacted with nucleophile 63 (Scheme 
2.17). 
 
 
Scheme 2.17 
 
During the „90s, Carpino et al. introduced the use of aminoacid fluorides as active species for 
coupling.
43
 The pKa value of hydrogen fluoride, which is generated as a byproduct during the coupling 
reaction, is far higher than those of hydrogen chloride or bromide, thus allowing this procedure to be 
compatible with acid labile protective groups (e.g.: -Boc). The acyl fluoride derivative of 64 was 
prepared in crystalline form using cyanuric fluoride and was subjected to reaction with compound 63, 
without previous purification: isolated yield after workup and chromatography purification was 
extremely low (only 10%) (Scheme 2.18). 
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Scheme 2.18 
 
We made two last coupling attempts, activating Ser as its mixed and symmetric anhydrides.
44
 The 
mixed anhydride of compound 64, obtained after reaction with isobutylchloroformate (IBCF), was 
made to react in a one-pot procedure with aspartic derivative 63. The nucleophile preferentially 
attacked on the wrong carbonyl carbon of the mixed anhydride (probably due to steric factors), leading 
to a carbamate that regenerated aspartic derivative 63 after workup (Scheme 2.19). 
 
 
Scheme 2.19 
 
Finally, the symmetric anhydride of the serine derivative, generated from DCC, gave the desired 
results. Of course, the coupling procedure needed an extensive synthetic set up to avoid starting 
material waste and to improve yields. The symmetric anhydride was promptly separated from its 
byproduct, DCU, in order to prevent the formation of a useless acylated derivative of 64 derived from 
the condensation between them (Scheme 35). Being DCU mostly insoluble in dichloromethane, the 
symmetric anhydride could be isolated by filtration. Reaction between the symmetric anhydride and 
aspartic derivative 63 led at last to the desired dipeptide 65. Furthermore, almost the whole unreacted 
serine 64, resulting from the breakdown of the symmetric anhydride, was recovered during workup  
(Scheme 2.20). 
 
 
Scheme 2.20 
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Treatment of dipeptide 65 with trifluoroacetic acid (to deprotect both the amino and the hydroxy group 
of serine) and subsequent ring closing reaction in methanol, led to diketopiperazine 62a (Scheme 
2.21). 
 
 
Scheme 2.21 - a) TFA/DCM; b) MeOH, DIPEA, 85%. 
 
Planning to transform hydroxy group of 62a in protected amino group, we ran Mitsunobu reaction 
under the same conditions used for the synthesis of scaffolds DKP1-DKP3 (toluene/DCM, -20 °C), 
but we only recovered starting material. Hence we tried to run the reaction again increasing 
temperature gradually, from -20 °C to 0 °C, without any results. Finally, Mitsunobu reaction 
performed at r.t. led to azide 66, although major product resulted to be the -elimination derivative 67 
(ratio 66/67 2:3) (Scheme 2.22). 
 
 
Scheme 2.22 – a) PPh3, DIAD, HN3Tol, toluene/DCM, r.t. 
 
At this point, aiming at scaling up the syntheses of both DKP4 and DKP6, we realized that we might 
try to circumvent the problem of -elimination, by performing the Mitsunobu reaction on Boc-Ser-
OMe (either L or D) (68), thus directly transforming the Ser OH group into the azide. This could also 
contribute to simplify the synthetic sequence avoiding the use of an additional protecting group (tBu).  
 
 
Scheme 2.23 - Synthesis of symmetric anhydrides 71: a) CH3COCl, CH3OH; b) Boc2O, THF/H2O 1:1; c) HN3, DIAD, PPh3, 
THF; d) LiOH, THF/H2O 1:1; e) DCC, DCM. 
 
The Mitsunobu reaction with HN3 proceeded uneventfully in good  yield (78%) to give compound 69, 
which was then saponified with LiOH. Treatment of freshly prepared acid 70 with DCC afforded the 
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symmetric anhydride 71 in a quantitative yield, which was isolated by filtering off DCU and 
evaporating the solvent, and immediately used in the next synthetic step without further purification 
(Scheme 2.23). 
Coupling of 3-azido-2-N-tert-butoxycarbonylaminopropionic anhydride (71) to either (S)- or (R)- N-
benzyl-aspartic acid dimethylester occurred in 80% yield, while the subsequent Boc cleavage and 
cyclization to diketopiperazines 66 were nearly quantitative (Scheme 2.24). 
 
 
Scheme 2.24 - Synthesis of diketopiperazines 66: a) TFA/DCM 1:2; b) DIPEA, iPrOH. 
 
The same Staudinger-type reaction used for the synthesis of DKP1-DKP3  (see § 4.2.1, in this 
chapter) could be employed to reduce azides 66. Moreover, the absence, in this case, of an allyl ester, 
allowed us to use the more reliable catalytic hydrogenation, which provides amine 74, followed by a 
Boc protection, obtaining compound 75. A final hydrolysis of the methyl ester provided 
diketopiperazines DKP4 and DKP6 in 90% overall yield (Scheme 2.25). 
 
 
Scheme 2.25 - Synthesis of DKP4 and DKP6: a) H2, Pd-C, THF; b) Boc2O, THF; c) LiOH, THF/H2O 1:1. 
 
 
3.2.3 -  Synthesis of DKP5 and DKP7 
The synthesis of scaffolds DKP5 and DKP7 can in principle be achieved through the benzylation of 
the second diketopiperazine nitrogen of an advanced intermediate in the synthesis of either DKP2 and 
DKP4, or DKP3 and DKP6, respectively (Figure 2.29). Aiming at minimizing the use of protecting 
groups, the only suitable intermediate for a nitrogen alkylation was identified in the azide derivative. 
The diketopiperazine intermediates bearing a free hydroxyl group or a Boc protected amino 
functionality could in fact give over-alkylated by-products. The azido group might serve as a 
protecting group here, being stable in the reaction conditions. 
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Figure 2.29 
 
As we had intermediates 58b-c available, we started to investigate N-benzylation on these substrates. 
Nitrogen N-4 alkylation was first attempted using sodium hydride and benzyl bromide in 
dimethylformamide. This typical experimental procedure generally provides good yields for amide 
benzylation but, unfortunately, our major product proved to be an elimination derivative (compounds 
60a-b, Scheme 2.10). –N3 acted as leaving group in presence of a strong non-hindered base, such as 
NaH. Better results were obtained using KHMDS (potassium bis(trimethylsilyl)amide), being a more 
hindered base, in presence of benzyl bromide, lowering temperature of reaction between -70°C and -
40°C. Azides 75 were converted into DKP5 and DKP7 following the same protocols used in the 
synthesis of DKP2 and DKP3; namely, a Staudinger reduction provided N-Boc protected amine 76, 
which underwent a Tsuji-Trost-like ester deallylation (Scheme 2.26). 
 
 
Scheme 2.26 – Synthesis of DKP5 and DKP7, starting from intermediates 58b and 58c, respectively: a) KHMDS, BnBr, 
THF/DMF 7:3, 76%; b) Me3P, BocON, toluene, 65%; c) pyrrolidine, PPh3, [Pd(PPh3)4], DCM. 
 
Intermediates 66a-b resulted even less prone to -elimination under N-alkylation conditions. Azides 
77 are catalytically hydrogenated to the corresponding amines, which could be easily Boc protected 
(78). Methyl ester hydrolysis finally afforded the desired products  (Scheme 2.27). 
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Scheme 2.27 - Synthesis of DKP5 and DKP7, starting from intermediates 66a and 66b, respectively: a) KHMDS, BnBr, 
THF/DMF 7:3; b) ) Me3P, BocON, toluene, 87%; c) LiOH, THF/H2O 1:1; 75% overall. 
 
This last approach seems to be slightly better than the previous one, even if the two methods are 
reliable enough to be considered equivalent. 
 
3.2.4 -  Synthesis of DKP8 
Scaffold DKP-8, bearing a carboxyethyl side chain, was obtained through a synthetic strategy similar 
to the one adopted in the case of compounds DKP1-DKP3 (see § 4.2.1, in this Chapter), starting from 
(S)-N-benzylserine methyl ester 53 (Scheme 2.2) and (R)-N-(tert-butoxycarbonyl)glutamic acid -
methyl ester 79.
45
 In this case too, direct coupling of these fragments afforded isopeptide 80, which 
was deprotected and cyclized to diketopiperazine 81. Azidation of the -CH2OH group via a Mitsunobu 
reaction, reduction by catalytic hydrogenation, protection with Boc2O and final hydrolysis of the 
methylester afforded DKP-8 (Scheme 2.28). 
 
 
Scheme 2.28 – a) 53, HATU, HOAt, DIPEA, DMF; b) TFA/CH2Cl2 1:2; c) DIPEA, iPrOH; d) HN3, DIAD, PPh3, 
CH2Cl2/toluene/DMF; e) H2, Pd-C, THF; f) Boc2O, THF; g) LiOH, THF/30% H2O2 1:1. 
 
This latest step was at first performed in the conditions already described for the synthesis of DKP4-
DKP7, treating 84 with LiOH in a 1:1 mixture of THF and water. The reaction did not procede as fast 
and completely as observed in the other cases and, moreover, extensive racemization problems were 
detected when DKP8 thus obtained was used in the synthesis of a macrocyclic peptidomimetic. Hence 
a milder yet more selective procedure involving the in situ formation of LiOOH was adopted. 
Enantiomerically pure DKP8 was this time obtained quantitatively. 
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 3 SYNTHESIS AND CONFORMATIONAL ANALYSIS OF 
PEPTIDOMIMETICS CONTAINING A BIFUNCTIONAL 
DIKETOPIPERAZINE SCAFFOLD, AS INTEGRIN 
LIGANDS 
3  
 
 
1 -  Targeting Integrins 
Integrins are the major  family of adhesion receptors known in the kingdom Animalia, being involved 
in cell adhesion to extracellular matrix proteins and also playing important roles, in vertebrates, in 
certain cell-cell adhesions. In addition to mediating cell adhesion, integrins make transmembrane 
connections to the cytoskeleton and activate many intracellular signaling pathways. Since the 
recognition of the integrin receptor family around 20 years ago,
1
 they have become the best-
understood cell adhesion receptors. Integrins and their ligands play key roles in the pathogenesis of 
inflammatory disease, leukocyte traffic, aggregation, tumor progression as well as osteoporosis and 
macular degeneration. The role of integrins in pathological conditions makes them attractive 
pharmacological targets.
2
  
Research in the last two decades has been directed to the discovery and the development of integrin 
antagonists for clinical applications.
3
 The early discovery of the structural basis of the recognition 
between integrins and their natural ligands by means of short amino acid sequences,
4
 together with 
outstanding crystallographic, electron microscopy, and computational analyses
5,6
 on selected integrin 
subfamilies provided a breakthrough for the rational design of a wide variety of class-selective or 
promiscuous integrin inhibitors. 
 
1.1 -  Integrins: family, function, structure 
Integrins are heterodimeric membrane glycoproteins comprised non-covalently associated - and -
subunits, mediating dynamic linkages between extracellular adhesion molecules and the intracellular 
actin cytoskeleton. They are expressed by all multicellular animals, but their diversity varies widely 
among species; for example, 19 α and 8 β subunit genes are present in mammals, encoding for 25 
diﬀerent heterodimers, whereas the Drosophila and Caenorhabditis genomes encode only five and two 
integrin α and β subunits respectively. 
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Each integrin subunit consists of an extracellular domain, a single transmembrane region, and a short 
(∼30–40 amino acids) cytoplasmic region. Figure 3.1 depicts the mammalian subunits and their αβ 
associations; 8 β subunits can assort with 18 α subunits to form 24 distinct integrins.7 
 
 
Figure 3.1 
 
Each integrin subunit consists of an extracellular domain, a single transmembrane region, and a short 
(∼30–40 amino acids) cytoplasmic region. 
The N-terminus of the -chain consists of a -propeller domain that is formed by seven repeats of 60 
amino acids each.
8
 The -propeller domain is linked to the transmembrane domain by three regions 
that have been named the Thigh, Calf-1, and Calf-2 domains (Figure 3.2 a). In addition, a highly 
flexible region is present between the Thigh and Calf-1 domains.5 Half of all -chains have an 
additional 200 amino acid inserted domain between repeats two and three of the - propeller (the I-
domain) (Figure 3.2 a).
9
 The I-domain functions as the major ligand-binding site in those integrins 
with this domain, whereas the -propeller serves as the ligand binding in integrins without I-
domains.
10
 Cytoplasmic tail domains of individual -subunits are well-conserved across species 
boundaries.
11
 
The N-terminal region of the -subunit consists of a cysteine-rich region termed the plexin-
semaphorin-integrin (PSI) domain. C-terminal to this domain is an evolutionarily conserved I-like 
domain flanked on either side by immunoglobulin folds called hybrid domains. The membrane 
proximal region of the -subunit contains four EGF-like repeats. The -subunit also has a flexible 
“knee” region, which is formed by the hybrid domain and the first two EGF-like repeats (Figure 3.2 
b).
10
 The intracellular regions of the -subunits are more conserved between subunits than are the -
subunit cytoplasmic tails.
12
 These beta chain cytoplasmic tails play significant roles in regulating 
integrin activity.
5b 
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Figure 3.2 - Integrin structure: (a) Primary structure of 
integrin -subunits. Half of the -subunits also have an 
I-domain inserted between -propeller repeats 2 and 3; 
(b) Primary structure of integrin -subunits. 
 
 
 
 
 
 
 
Each -chain combines with a -chain to form a unique heterodimer with selectivity for ECM 
proteins, cell surface molecules, plasma proteins, or microorganisms.
13
 Integrins bind to their ligands 
in a divalent cation-dependent fashion.
14
 Although some integrins recognize primarily a single ECM 
protein ligand (e.g., 51 recognizes primarily fibronectin), others can bind several ligands (e.g., 
integrin v3 binds vitronectin, fibronectin, fibrinogen, denatured or proteolyzed collagen, and other 
matrix proteins). Many integrins recognize the tripeptide Arg–Gly–Asp (RGD) (e.g. v3, 51, IIb3, 
v6, and 31), but sequences flanking the RGD peptide are also important for selectivity.
13a,b
 Other 
integrins recognize alternative short peptide sequences (e.g., integrin 41 recognizes Glu lle Leu Asp 
Val (EILDV) and Arg Glu Asp Val (REDV) in alternatively spliced CS-1 fibronectin and IIb3 binds 
KQAGDV in the fibrinogen  chain).15 In addition, some integrins can also bind cell surface receptors 
to induce cell–cell adhesion.13b,c 
The ligands bound by common integrins and their recognition sites are shown in Table 3.1.
16
 
 
Table 3.1 - Integrin ligands and recognition sequences 
Integrin Ligands (recognition sequences) 
11 Collagen (GFOGER, fibrillar collagen domain) and laminin 
21 Collagen (GFOGER, fibrillar collagen domain), laminin, and 31 
31 Fibronectin (RGD), collagen, laminin, epiligrin, entactin, and 21 
41 CS-1 fibronectin (EILDV) and VCAM-1 (QIDS) 
51 Fibronectin (RGD), fibrinogen (RGD), and L1-CAM 
61 Laminin (several sites), merosin, and Kalinin 
71 Laminin 
81 Fibronectin (RGD) and tenascin 
91 Tenascin (AEIDGIEL), collagen, and laminin 
101 Collagen 
111 Collagen 
L2 ICAM-1, ICAM-2, and ICAM-3 (ICAM peptides) 
M2 iC3b, fibrinogen (P1 and P2 peptide in -chain), factor X, and ICAM-1 (ICAM peptides) 
X2 iC3b and fibrinogen (GPR in -chain) 
D2 ICAM-3 and VCAM-1 
v1 Fibronectin (RGD) and vitronectin (RGD) Fibronectin (RGD), vitronectin (RGD), von Willebrand 
Factor (RGD dependent), 
v3 thrombospondin (Cryptic RGD site), tenascin (RGD), Del-1 (RGD), osteopontin (RGD), MMP2 
(PEX domain), and bFGF (DGR) 
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v5 Vitronectin (RGD and KKQRFRHRNRKG), osteopontin, and Del-1 (RGD) 
v6 Fibronectin (RGD) and tenascin (DLXXL) 
v8 Collagen, laminin, and fibronectin 
IIb3 Fibronectin (RGD), Fibrinogen (KQAGDV), vitronectin (RGD), and von Willebrand factor (RGD) 
64 Laminin (several sites) 
47 CS-1 fibronectin, VCAM-1, and MAdCAM-1 (LDT) 
E7 E-Cadherin 
 
Integrins are not constitutively active, but rather exist in multiple activation states (Figure 3.3).
17
 
Integrin activation status is regulated by the delicate balance in a bidirectional signaling mechanism 
which drives reversible changes in integrin conformation and affinity for their ligands. Both extra- and 
intracellular stimuli are allowed to regulate activation.
7,18
  
 
 
Figure 3.3 – representation of integrin activation states. 
 
High affinity binding of integrins to ligands is promted in response to intracellular signaling events 
converging on the cytoplasmic domain that alter the tertiary and quaternary structure of the 
extracellular region, making the integrin ligand-competent (inside-out signaling). 
Extracellular factors that influence integrin activation are ligand binding, divalent cation 
concentration, chemokine signaling and mechanical stress. Integrins transmit signals to the cell 
interior, which regulate organization of the cytoskeleton, activate kinase signaling cascades, and 
modulate the cell cycle and gene expression (outside-in signaling). Through this mechanism, integrins 
behave as mechanochemical transducers, orchestrating a synergic cross-talk with other extracellular 
matrix constituents and providing anchorage for endothelial cells. 
The integrin tails serve as a site for the docking of various kinases and related adaptor proteins that 
comprise focal adhesions. Signals emanating from focal adhesions have been shown to promote 
survival, differentiation and proliferation.
19
 In the absence of integrin ligation, these processes are 
abrogated therefore pharmacological inhibition of integrin ligation is of great interest for the therapy 
of numerous diseases resulting from abberant integrin mediated signaling. 
Integrins are transducing information both into and out of the cell to promote cell adhesion, spreading 
and motility. Disruption of focal adhesions prevents integrin mediated cell adhesion and impaired cell 
motility and migration. Prolonged integrin inhibition in adhesion dependent cells results in anoikis, 
apoptotic cell death due to ECM deprivation.
20
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1.2 -  Role in Angiogenesis 
Angiogenesis is the process whereby new vessels form from pre-existing vessels. The growth of new 
blood vessels promotes embryonic development, wound healing, the female reproductive cycle, and 
also plays a key role in the pathological development of solid tumor cancers, hemangiomas, diabetic 
retinopathy, age-related macular degeneration, psoriasis, gingivitis, rheumatoid arthritis, and possibly 
osteoarthritis and inflammatory bowel disease.
21
 
Several cell types within tumors, including tumor cells, monocytes, and fibroblasts, secrete growth 
factors, such as VEGF, that induce blood vessel growth into tumors (Figure 3.4).22 
 
 
Figure 3.4 – a) Secretion of growth factors and Chemokines from tumor cells in vicinity of already existing blood vessels; b) 
activation or expression upregulation of integrins such as 11, 21, 41, 51 and V3 on blood vessels; c) 
integrins promoting endothelial cell migration and survival during invasion of tumour tissue. New vessel 
sprouts are produced promoting tumour growth and providing a way to metastasis to local and distant sites, 
such as lung. 
 
Studies have shown that angiogenesis plays a major role in tumor growth and that inhibiting 
angiogenesis can inhibit tumor progression and metastasis. Although growth factors and their 
receptors play key roles in angiogenic sprouting, adhesion to the ECM also regulates angiogenesis.  
Formation of new vasculature requires endothelial cell attachment and migration on ECM proteins. 
One ECM protein, fibronectin is associated with vascular proliferation.
23
 As integrins are critical for 
the cell to bind ECM, many integrins play crucial roles in regulating vascular growth, both during 
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embryonic development and in various pathologies. Proliferating endothelial cells express several 
integrins that are not expressed on quiescent blood vessels. 
Recent studies suggest that inhibition of both v3 and 51 may be required for optimal effects on 
angiogenesis.
24
 
 
1.2.1 - Integrins v3 and v5 
Integrin v3 is expressed on angiogenic blood vessels
25
 but not on resting vessels. Inhibitors of v3 
antibody block angiogenesis in a variety of animal models. A key role of v3 in vasculogenesis and 
angiogenesis has been outlined. Peptide and antibody antagonists of v3 also block tumor 
angiogenesis and growth. Further analysis showed tumor regression related to apoptosis in the 
vasculature, induced by these antagonists.
26
 
Different members of the integrin v subfamily transduce angiogenic signals by different growth 
factors. in vivo angiogenesis assays showed that bFGF or TNF- depend on v3 to initiate 
angiogenesis, whereas v5 is required for TGF-- and VEGF-mediated angiogenesis.
27
 These data 
taken together have established a role for v3 and v3 integrins in angiogenesis and as important 
therapeutic targets. 
One study showed that animals lacking 3 or 3 and 5 subunits displayed increased tumor 
angiogenesis.
28
 This led to the controversial conclusion that v3/v5 integrins might actually be 
involved in suppressing angiogenesis. However, it is likely that the apoptotic mechanism, which is 
generally induced by unligated integrins and controls tumor vascular growth, is responsible for the 
increased vascularization in 3 - and 5 -deficient tumors.
16,29
 
 
 
Figure 3.5 – a) Crystal structure of the extracellular segment of integrin V3; b) Crystal structure of the extracellular 
segment of V3 integrin in complex with the cyclic pentapeptide ligand Cilengitide, in its binding 
conformation. 
 
The complete crystal structure of v3 integrin ectodomain including an  transmembrane fragment 
has been very recently determined.
30
 The earlier determination of the crystal structure of the 
V3 
Chapter 3  69 
ectodomain of v3 (∆TM-v3) (Figure 3.5 a) in the absence and presence of a prototypical RGD 
ligand (Cilengitide) (Figure 3.5 b), already revealed the modular nature of integrins and pivotal 
information on its divalent cation–mediated binding interactions with extracellular ligands. 
A homology model for the closely related  V5 receptor was developed. The two integrins were found 
to mostly differ in the region comprising residues 159-188 in the 3 subunit. A „roof‟ was described 
for V5 integrin featuring Tyr and Lys residues, which would hamper the binding of compounds 
containing bulky substituents nearby their Asp-mimicking group. Because of this difference, a few 
inhibitors of V3 integrin displaying selectivity over V5 have actually been found,
31
 but specific 
inhibitors of V5 integrins have not been described yet. 
 
1.2.2 - Integrins 51 
Integrin 51 is significantly upregulated in tumor angiogenesis in both mice and humans but is not 
expressed on quiescent endothelium. Antagonists of 51 also inhibited tumor angiogenesis in chicks 
and mice, thus leading to tumor regression.
 23
 
Integrin 51 -mediated adhesion promotes endothelial cell survival in vivo and in vitro
29
 by 
suppressing the activity of protein kinase A (PKA). Integrin 51 antagonists activate both PKA and 
caspase-8, thereby inducing apoptosis and inhibiting angiogenesis.
32
 Although inhibition of integrin 
ligation can prevent cell attachment to the ECM, recent studies show that integrin 51 antagonists 
also actively suppress signal transduction that leads to cell survival. Antagonists of 51 suppress cell 
migration and survival on vitronectin, but not cell attachment to vitronectin, indicating that these 
antagonists affect the migration and survival machinery rather than integrin receptors for 
vitronectin.
16,33
 
 
  
Figure 3.6 - Surface-rendered density maps of the 51 headpiece in a) the unliganded closed and b) the ligand-bound open 
conformation. 
 
The threedimensional structure of the ligand-binding headpiece of integrin 51 complexed with 
fragments of its physiological ligand fibronectin was determined by mean of a molecular electron 
a) b) 
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microscopy. The density map for the unliganded 51 headpiece shows a „closed‟ conformation 
similar to that seen in the V3 crystal structure. By contrast, binding to fibronectin induces an „open‟ 
conformation (Figure 3.6).
34
 
The lack of reliable structural data in the past, however, excluded α5β1 as target for structure based 
drug design. However, the high homology between the different integrin subtypes makes them 
promising targets for homology modeling, which was achieved for αVβ5 integrin by Kessler and co-
workers.
35,31b
 Homology modeling of proteins is considered to be possible for a homology of 40% or 
greater.
36
 This precondition is met by the integrins αvβ3 and α5β1 with 53% homology for αv/α5 and 
55% for β3/β1.  
 
1.3 -  Role in hemostasis and thrombosis 
Thrombosis is a desease-related process consisting in the formation of a blood clot inside a blood 
vessel. It occurs when platelets adhere to damaged blood vessels and become activated,
37
 thus 
recruiting other platelets. As a result a haemostatic plug is formed. This is an essential mechanism for 
preventing blood loss, but inappropriate thrombus formation can lead to a stroke or to a heart attack. It 
is probably the first clearly integrin associated process. 
In the 1970s, it was noted that some patients suffering from Glanzmann‟s thrombasthenia, a known 
severe bleeding disorder, lacked two functional glycoproteins (GPIIb and GPIIIa) on their blood 
platelets, which are now known as the integrin IIb3.
38
 It was subsequently found that the platelet–
platelet interaction that mediates thrombus formation is facilitated by fibrinogen binding to the 
platelet-specific integrin IIb3 following platelet activation caused by thrombotic stimuli.
39,40
 
 
1.3.1 - Integrins IIb3 
IIb3 integrin (GPIIa/IIIb) is highly expressed on the surface of platelets,
41
 comprising approximately 
80% of the total surface proteins found on platelets. The final common pathway in blood coagulation 
involves the engagement of this integrin induced by platelet activation. Under normal conditions 
integrin IIb3 is maintained in the inactivated state. Soluble factors in the blood such as thrombin, 
bind their respective platelet receptors to activate inside-out signaling pathways that cause 
conformational changes in IIb3 integrin.
41
 Changes in conformation lead to increases in receptor 
affinity and avidity, which promote platelet aggregation and clot formation through increased cell-to-
cell contacts and cell-matrix contacts. Aberrant platelet aggregation or thrombosis is central to the 
pathophysiology of multiple Acute Coronary Syndromes (ACS), unstable angina, ischemic stroke and 
sickle cell anemia. Inhibition of IIb3 prevents platelet aggregation and therefore has shown efficacy 
in the prevention of thrombosis for the treatment of ACS. Some IIb3 integrin targeted drugs have 
already been approved so far. 
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The complete ectodomain structure of integrin IIb3 was determined,
42
 thus living information about 
its binding site, better understanding its biniding mode and conformation (Figure 3.7). The binding 
mode of RGD-based IIb3 antagonists was established through mutagenesis experiments
43
 and 
crystallographic analysis of the platelet fibrinogen receptor.
44
 
 
 
Figure 3.7 - Crystal structure of the extracellular segment of integrin IIb3. 
 
 
1.4 -  RGD and isoDGR recognition motifs 
The arginine-glycine-aspartic acid (RGD) cell adhesion sequence was discovered in fibronectin 27 
years ago.
45
 Other adhesion proteins such as vitronectin, fibrinogen, von Willebrand factor, 
thrombospondin, laminin, entactin, tenascin, osteopontin, bone sialoprotein, and, under some 
conditions, collagens were then discovered to include RGD sites. It was soon confirmed with regard to 
fibronectin and then extended to other proteins that the RGD sequence is the endogenous recognition 
motif for cell attachment to proteins. 
Cells expressing several V integrins (e.g. 1,3,5,6 and 8), as well as integrins IIb3, 51 and 
81, recognize the ubiquitous RGD sequence in their ligands. Naturally occurring integrin inhibitor 
proteins bearing the RGD motif are showing an extremely varied selectivity and potency in targeting 
RGD-recognizing integrins. Elucidations on their structure suggest that proper restriction of the RGD 
flexibility can lead to integrin inhibition.
46
 
Hence, monomeric linear or confomationally constrained RGD-containing cyclic peptides, pseudo-
peptides, and mimetics thereof displaying high potency and selectivity were conceived. The most 
significant advances in this field have led to the development of agents targeting IIb3 integrin on 
platelets for inhibiting thrombosis
47
 and inhibitors of V3 andV5 integrins against angiogenesis, 
cancer and bone resorption.
48
 Among these, it is important to recall the nanomolar V3/V5 binder 
cyclic pentapeptide c-RGD-(D-Phe)-N-methyl-V developed by Kessler (known as Cilengitide or 
IIb3 
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EMD121974, which has recently entered phase III clinical investigation for patients with glioblastoma 
multiforme).
48j
  
As already mentioned, a crucial enhancement in this field was achieved with the crystal structure 
resolution of the ectodomain of V3 integrin, both unligated and complexed with Cilengitide,
5b
 as 
well as the better crystal structure resolution of IIb3 integrin complexed with the synthetic anti-
trombotic drug Eptifibatide.
6d,49 
 
Besides the well defined RGD and other binding motifs, it has been proposed that the NGR and DGR 
sequences might also have a role in integrin recognition. Controversial results have however been 
reported. 
The importance of the isoDGR sequence as an integrin binding motif was discovered by serendipity 
by Corti research group (S.Raffaele/MolMed).
50
 
The NGR sequence, present in several endogenous molecules as well as in fibronectin FN-I5 and FN-
I7, can easyly deamidate (also in vivo) on asparagine, giving isoDGR and DGR (Scheme 3.1). 
Although protein modifications typically causes loss of activity/function, it was recently suggested 
that isoDGR formation at NGR or DGR sites might result in a gain of function. The isoDGR sequence 
can in fact mimic RGD and interact with the RGD-binding site of integrins.
51
 
 
 
Scheme 3.1 – formation of DGR and isoDGR sequences by asparagine deamidation 
 
isoDGR containing peptides can recognize members of the RGD-dependent integrin family, such as 
v3, v5, v6, v8 and 51, but not other.
52
 Both affinity and specificity of the interaction between 
isoDGR and integrin binding site is reported to be highly dependent on the flanking residues. 
Notably, isoDGR docks onto the integrin binding site in an inverted orientation respect to RGD. This 
orientation allows isoDGR to bind to the v3  binding pocket maintaining all the typical electrostatic-
clamp interactions of the RGD motif. The acidic and basic residues are at the correct distance and 
orientation to engage stabilizing interactions with the polar regions of integrin: the isoAspartic 
carboxylic side chain is interacting with MIDAS, Asn
215
, Tyr
122
 and Arg
214
, while Arginine 
guanidinium interacts with Asp
218
, Asp
150
 and Gln
180
. Moreover, additional stabilizing interactions are 
present: glycine recognizes the receptor via polar interactions and an H-bond between its amide and 
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carbonyl of Arg
216
.
51
 Therefore, isoDGR can be considered as a natural fit for the RGD binding pocket 
of v3 integrin, suggesting that the naturally occurring transformation of NGR and DGR into isoDGR 
functions as a molecular switch able to activate integrin recognition. 
Although isoDGR- and RGD-containing ligands can share the same integrin binding site, their effects 
on integrin finction might not be necessarily the same.
53
  
 
1.4.1 - RGD integrin ligands: state of the art 
The potential of v3  inhibitor EMD121974 (85, Cilengitide, Figure 3.8) by Kessler was soon 
recognized by various clinical programs, opening the era of the integrin inhibitor class as 
investigational agents for antiangiogenic and anticancer therapies. The crystal structure analysis of the 
ectodomain of v3 complexed with Cilengitide offered the first clear picture 
of the RGD binding mode, which revealed a Cilengitide conformation featuring an inverse -turn 
centred on Asp, and a distorted II'-turn with Gly and Asp at the i+1and i+2 positions, respectively. A 
distance of 8.9 Å between the C of Asp and Arg, accounting for an almost extended conformation of 
the RGD motif were observed. The most important interactions between the ligand and the receptor 
involved the Arg guanidinium group, which was forming salt bridges with Asp150 and Asp218 in the 
subunit, and the Asp carboxylic group of the ligand, which interacts with the Mn2+ ion at MIDAS 
(Metal-Ion-Dependent Adhesion Site) in the subunit. Moreover, several hydrophobic interactions 
were engaging the Gly residue, positioned at the interface between the and subunits. 
An earlier example of RGD-based cyclic peptide had already been identified by Kessler, c(RGDfV)
54
 
86 (Figure 3.8), which can be considered as an ancestor of Cilengitide. This compound was selectively 
active against  V3 integrin, and its overall conformation allowed the lateral chains of Asp and Arg to 
adopt a unstretched arrangement (distance C(Asp)- C(Arg) 6.9 Å). 
Representative examples of semipeptidic V3 inhibitors, bearing a non-peptidic and rigid turn-
inducing motif to appropriately constrain the RGD motif, are reported in the literature. 
Classic bicyclic, but also monocyclic scaffolds and simple linear tethers have been used to properly 
fold the RGD sequence within a macrocyclic template, to better fit within V3 integrin binding site.
55
 
Bicyclic heterocycles stand among the most popular constrained mimetics of natural amino acids in 
the structure-based design of peptidomimetics. Various successful examples of peptide are validating 
their use as preferred conformation inducing scaffolds.
56
 
Kessler exploited azabicycloalkane and spyrocyclic systems, traditionally known as -turn inducers, to 
prepare cyclic RGD-containing peptidomimetics.
57
 The most active and less constrained compound of 
the series (87, Figure 3.8) was a fully promiscuous antagonist. 
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Figure 3.8 
 
A stereoisomeric library of RGD pentapeptide mimetics incorporating 5,6- and 5,7-fused 
azabicycloalkane amino acids was generated by the group of Scolastico.
58
 Among the high affinity 
ligands found within the collection, the most active compounds (88 and ST1646 (89), Figure 3.9) 
demonstrated low nanomolar binders of V3 and V5 integrins. 89 was completely selective towards 
V3 integrin respect toIIb3 and 51 integrins. Moreover, significant antiangiogenic activity of this 
compound emerged from in vitro experiments showing inhibition of the proliferation of endothelial 
cells.
59
 
 
 
Figure 3.9 
 
A strong dependence of the overall conformation of the cyclic peptides on the lactam ring size and 
stereochemistry was revealed. Almost the same interactions observed in the crystal structure of V3 
complexed with Cilengitide 85 were maintained. They observed an  average distance between Arg and 
Asp C of 8.8 Å in the case of 88, and 8.5 Å in 89, indicative of an almost extended conformation of 
the RGD sequence. 
Cyclopeptide 90 (Figure 3.9) emerged as a nanomolar antagonist of both V3 and V5 integrins 
comparable to ST1646 89. Docking studies revealed that the conformationscontaining an inverse -
turn on Asp conserved the main contacts observed in the X-ray crystal structure with Cilengitide 85.
60
 
 
Also monocyclic turn-inducing scaffolds were used in the search for non peptidic RGD-containing 
systems, based on II'/ arrangement with the -turn centred on Gly. 
Kessler inserted amino pyrrolidinone based motifs to hold the RGD moiety, providing macrocycles 
91a and 91b (Figure 3.10).
61
 A II' turn conformation with Gly at the i+1 position was unexpectedly 
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observed for  these compounds. 91a was a moderate and selective antagonist of V3 integrin, while 
91b proved to be a more active V3 inhibitor, even though aspecific. The main difference between the 
two analogues was the orientation of the lactam bond in the turn-motif, which was found to be rotated 
by 180° in the two isomers, and involved in a H-bond with the receptor in the case of 91b. 
 
 
Figure 3.10 
 
D- and L-morpholines were exploited by Guarna and co-workers to replace the N-Me-Val motif of 
Cilengitide 85, grafting compounds 92 (Figure 3.11).
62
 The different conformation of the peptide bond 
between D-Phe and the morpholine scaffold provided distinct structural arrangements for the two 
compounds. 92b showed in particular a cis conformation in the docking analysis, with an RGD 
sequence arrangement comparable to that observed in the V3-Cilengitide complex. 
 
 
Figure 3.11 
 
Kessler and Overhand designed several pyranoid and furanoid sugar - and -amino acid based 
compounds. Due to their high flexibility, they proved to be aspecific antagonists of V3 and IIb3 
integrins. This aspecificity was also supported by the conformational analysis of this compounds, 
which showed an arrangement standing in between the typical kinked conformation of V3-selective 
antagonists and the extended one required for targeting IIb3  integrin. The two most representative 
members of this class of compounds are sketched in Figure 3.12 (93, 94).
63,48k
  
Casiraghi and colleagues, following an analogous inspiration, exploited furanoid carbasugar -amino 
acid equivalents to generate four stereoisomeric macrocycles (most active members 95, Figure 3.12). 
Although an improvement in the affinity towards V3 and V5 was observed, their activity 
surprisingly proved to be almost irrespective of the configuration at the carbons bearing the amino 
acid functions. An inverted -turn, centered on Asp was revealed by NMR, displaying a C(Asp)- 
C(Arg) distance in the range of 8.0-8.4 Å.
64
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Figure 3.12 
 
The same group incorporated 4-amino proline (Amp) scaffolds into a library of RGD peptides, to 
further extend these findings.
65
 The compounds reported in Figure 3.13 (96 a-d) displayed 
exceptionally high affinity towards V3 and V5 integrins. A picomolar activity was observed for 
V3 integrin in the high affinity status. A preferential conformation featuring an inverse -turn motif 
around Asp for the macrocycles containing a cis-disposed -amino acid motif was detected by NMR 
conformational analysis. On the contrary the macrocycles proved to be more flexible when a trans -
amino acid was present. All the macrocycles showed a C(Asp)- C(Arg) distance in the 7.8-8.2 Å 
range. The most active analogues maintain the relevant key interactions observed for Cilengitide 85. 
Compound 96a was stabilized by a strong H-bonding contact between the NH in the aminoproline 
motif and Tyr178. Quite interestingly, the alkyl and acyl chains of 96 b and c provided additional 
contacts for binding, pointing towards a large hydrophobic hollow rich with aromatic residues.  
 
 
Figure 3.13 
 
Pseudopentapeptides containing both enantiomers of cis--aminocyclopropanecarboxylic acid (-Acc) 
were conceived, the most interesting of the two being sketched in Figure 3.13 (97).
48e 
Compound 97 resulted more active towards both V3 and 51 integrins, respect to the reference 
compound c(RGDfV) 86. The C(Asp)- C(Arg) distance found for compound 97 resulted 
considerably shorter than expected (7.06 Å). Moreover, a -turn centered on Gly and a pseudo -turn 
wherein (+)--Acc occupied the i+1 position were observed. 
Despite the impressive work dedicated to the identification of semipeptide analogues, Cilengitide (85) 
is the only investigational agent of this class that has been developed for clinical testing on cancer 
patients. The growth inhibitory activity of Cilengitide observed in the clinic is likely due to a 
Chapter 3  77 
combination of multifaceted mechanisms. These might depend on whether the drug is administered 
alone or in combination, and include  inhibition of angiogenesis, direct cytotoxic activity on tumor 
cells, increase of endothelial cell permeability, and inhibition of cell adhesion, migration and 
invasion.
55,66
  
Very recently, a paradoxical proangiogenic activity of low doses of Cilengitide was observed in 
certain preclinical studies.
67
 
 
1.4.2 - isoDGR integrin ligands 
As regards isoDGR-containing cyclic peptides or pseudo-peptides, not many examples appeared in the 
literature so far.  
 
 
Figure 3.14 
 
Being a relatively young research field (the earliest evidences dating back to 2006),
68
 a lot more as 
been published on the structural basis for the interaction of isoDGR with the RGD-binding site of 
integrins, on the molecular switch ability of the NGR sequence to isoDGR and its possible 
applications in the discovery of innovative drugs. Still, extensive efforts in the understanding of the 
isoDGR motif potential need to be profused. 
The most interesting examples appeared in the literature are reported in Figure 3.14. 
Compound 98a was the first to be discovered, by Corti and co-workers.
50,51
 The efficacy of the cyclic 
motif CisoDGRC was demonstrated exchainging cysteine residues with glycine, and analogues such 
as 98b were also prepared, obtaining enhanced affinity towards most of the integrins tested.
52 
These compounds have been tested for their competitive binding with ACDCRGDCFC-TNF to V3 
integrin. Being ACDCRGDCFC-TNF a quite weak ligand of V3 integrin, the strikingly low 
nanomolar activity of these compounds might not be compared to other already shown activities. 
 
Kessler and colleagues started an investigation in the field, synthesizing a small library of compounds 
based on the retrosequence of the highly active integrin-binding cyclic peptide c(RGDfV) 86, for 
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example c(VfisoDGR), obtaining moderate to poor results. Far better results were obtained flanking 
the isoDGR moiety with an aromatic aminoacid and a glycine (99-101, Figure 3.14). Hints on the 
importance of the flanking residues and, in particular, on the effects of a flanking aromatic moiety 
were given, and interesting selectivity towards 51 integrin respect to V3 integrin were obtained.
69
 
 
2 -  Cyclic [DKP-RGD] compounds 
 
Figure 3.15 - Cyclic RGD-peptidomimetics (47, 48, 102-107) containing bifunctional diketopiperazine scaffolds DKP1-
DKP8. 
 
Our research group recently reported the synthesis of two cyclic peptidomimetic compounds containg 
the RGD sequence and bearing either DKP1 or DKP2 as a rigid scaffold (47-48, Figure 3.15).
70
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These compounds were examined in vitro for their ability to inhibit biotinylated vitronectin binding to 
the purified v3 and v5 receptors, giving strikingly different yet encouraging results. High 
micromolar IC50 values were obtained by compound 47 (IC50 (v3): 3898 ± 418 nm; IC50 (v5):  > 
10
4
), while compound 48 gave low nanomolar values and demonstrated 50 fold more selective for the 
v3 integrin with respect to the v5 (IC50 (v3): 3.2 ± 2.7; IC50 (v5): 114 ± 99), in this kind of 
assay. 
NMR characterization and conformational studies helped in giving an explanation of the different 
behavior of these two compounds. As already mentioned, a distance of ca. 9 Å between the C atoms 
of Asp and Arg,  imparted by an extended conformation of the Arg-Gly-Asp sequence, is necessary for 
the best fitting into the active site of the V3 integrin.The cis scaffold DKP1 is inducing a less 
extended conformation in the RGD sequence (distance C(Asp)-C(Arg) = 5.9-7.9 Å)respect to what a 
trans scaffold like DKP2 is doing (distance C(Asp)-C(Arg) = 9.4 Å). 
Though, we decided to incorporate also diketopiperazine scaffolds DKP3-8 into cyclic compounds of 
this kind (Figure 3.15). 
 
2.1 -  Synthesis 
A solution phase synthetic strategy was adopted for the synthesis of the cyclic compounds 
reported in Figure 3.  
 
 
Scheme 3.2 – Synthesis of 47 and 48 as reported in the literature: a) HBTU, HOBt, DIPEA, HCl.Gly-OMe, DMF: 78%; b) 
H2/Pd(OH)2, MeOH: 98%; c) DKP1 or DKP2, HBTU, HOBt, DIPEA, DMF; d) TFA/DCM 1:2; e) Cbz-
Asp(OtBu)-OH, HATU, HOAt, DIPEA, DMF; f) BnOH (100 eq), Ti(iPrOH)4 (1.05 eq), THF, 4Å MS, 90°C; g) 
H2, Pd(OH)2, MeOH; h) HATU, HOAT, collidine, DMF. 
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The reported synthesis of 47 and 4870 (Scheme 3.2) started from Cbz-Arg(Mtr)-OH, HCl.Gly-
OMe and Cbz-Asp(tBu)-OH, and envisaged the coupling of Arg(Mtr)-Gly-OMe to the acid of 
the appropriate diketopiperazine scaffold. After subsequent Boc deprotection of 108 the 
aspartic derivative Cbz-Asp(tBu)-OH, was coupled. After transesterification of the glycine 
methyl ester 109 to the corresponding benzyl ester,  the linear pentapeptides Cbz-D-DKP-RG-
OBn 110 could be subjected to hydrogenolysis and subsequent macrolactamization. 
The late stage transesterification on the linear pentapeptides resulted very capricious, giving 
non-reproducible yields. It was anyway an elegant idea to get to a non-orthogonally protected 
linear precursor. I decided then to by-pass transesterification using as starting materials Boc-
Arg(Mtr)-OH and HCl.Gly-OBn, thus directly obtaining Cbz-D-DKP-RG-OBn in better 
yields (Scheme 3.2). 
Linear pentapeptide precursors were deprotected in hydrogenolytic conditions at both the carboxyl 
group of glycine and the aspartic amino group, in presence of a catalytic amount of palladium on 
charcoal in methanol under an H2 atmosphere. This was a quite slow reaction: the Cbz group was the 
last and harder to be cleaved, as revealed by HPLC-MS profiles. We recently realized that, performing 
the reaction in methanol, a methylated by-product is forming. In most cases, we were able to separate 
it from the main product by preparative HPLC after the cyclization step, but we thought we might 
better avoid its formation performing the reaction in a 1:1 THF/water mixture. These conditions are 
providing pure product in quantitative yields. 
 
Table 3.2 – Optimization of macrolactamization conditions, on compound NH2-D-DKP3-RG-OH (115). 
Reagents and conditions Purification Yield 
DPPA, DIPEA, 1.4 mM in DMF, 48 h Flash silica gel column cromatography 75% 
PyBrOP, DIPEA, 1.4 mM in DMF, 48 h Flash silica gel column cromatography 28% 
FDPP, DIPEA, 1.4 mM in DMF, 48 h Flash silica gel column cromatography 73% 
HATU, HOAt, collidine, 2 mM in DMF, 48 h Flash silica gel column cromatography 30-40% 
 
The macrocyclization step was optimized on DKP3 containing compound 115, screening several 
synthetic procedures and reactants. All the results are reported in Table 3.2. 
It is clear that the best results were obtained when using DPPA or FDPP (75 and 73% respectively). 
DPPA was chosen, as FDPP left some impurities, visible from HPLC-MS profiles, that could not be 
removed with a mere flash chromatographic column. 
 
Anyway, in order to avoid purification problems, all the other linear intermediates 115 (containing 
DKP4-8) were efficiently macrolactamized using the more conventional HATU, in presence of HOAt 
and iPr2EtN. 
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Scheme 3.3 – Synthesis of cyclic RGD peptidomimetics 102-107 containing scaffolds DKP3-DKP8: a) Cs2CO3, MeOH; b) 
BnBr, DMF: 95%; c) TFA/DCM 1:2; d) HBTU, HOBt, DIPEA, DMF: 90%; e) TFA/DCM 1:2; f) HATU, 
HOAt, iPr2EtN, DMF: 67%; g) TFA/DCM 1:2; h) Cbz-Asp(OtBu)-OH, HATU, HOAt, iPr2EtN, DMF; i) H2, 
Pd/C, THF/H2O 1:1. 
 
Final cleavage of the side chain protecting groups (Mtr on Arg and tBu on Asp) was accomplished 
treating cyclized products 116 with a strongly acidic “cleavage cocktail”. A first receipe envisaged a 
mixture TFA/triethylsilane/1,2-ethandithiol/phenol/thioanisole/H2O 80:2.5:5:5:5:2.5. Far better results 
and cleaner crudes were however obtained with a mixture TFA/thioanisole/ethanedithiol/anisole 
90:5:3:2. 
 
In the case of the N-dibenzyl derivatives containing DKP5 and DKP7 (104, 106), the molecules are 
displaying planar chirality. They can in fact exist as two different separable conformers 
(diastereomers) due to hindered rotation of one ring around the other (i.e., the DKP N-benzyl group 
cannot pass inside the macrolactam ring). We were able to isolate only one of the two diastereomers of 
104, either because it was formed exclusively or because it was formed predominantly and the minor 
one was not detected/isolated. Two diastereomers of compound 106 were instead isolated in a 2 (A) : 1 
(B) ratio, Scheme 3.4). 
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Scheme 3.4 - non-interconverting stereoisomers 106 A and B. 
 
 
2.2 -  Biological evaluation 71 
The cyclic RGD peptidomimetics were examined in vitro for their ability to inhibit biotinylated 
vitronectin binding to the purified v3 and v5 receptors (Table 3.3).  
 
Table 3.3 - Inhibition of biotinylated vitronectin binding to v3 and v5 receptors  
[a] IC50 values were 
calculated as the 
concentration of compound 
required for 50% inhibition of 
biotinylated vitronectin 
binding as estimated by 
GraphPad Prism software; all 
values are the arithmetic mean 
± SD of triplicate 
determinations. 
 
 
 
 
 
Screening assays were performed incubating the immobilized integrin receptors with various 
concentrations (10
-10–10-5 M) of the RGD ligands 47, 48, 102-107 in the presence of biotinylated 
vitronectin (1 µg/mL), and measuring the concentration of bound vitronectin in the presence of the 
competitive ligands. The ability of the new compounds to inhibit the binding of vitronectin to the 
isolated v3 and v5 receptors was compared with that of the reference compounds c(RGDfV)
72
 (86, 
Figure 3.8) and ST1646
58
 (89, Figure 3.9). 
Compound Structure 
V

3
 IC
50
 [nM]a 
V

5 
IC
50
 [nM]a 
47 Cyclo [DKP1-RGD] (cis) 3898 ± 418 > 10
4
 
48 Cyclo [DKP2-RGD] (trans) 3.2 ± 2.7 114 ± 99 
102 Cyclo [DKP3-RGD] (trans) 4.5 ± 1.1 149 ± 25 
103 Cyclo [DKP4-RGD] (trans) 7.6 ± 4.3 216 ±  5 
104 Cyclo [DKP5-RGD] (trans) 12.2 ± 5.0 131 ± 29 
105 Cyclo [DKP6-RGD] (trans) 2.1 ± 0.6 79 ±  3 
106 A Cyclo [DKP7-RGD] (A-major) 220.2 ± 82.3 > 10
4
 
106 B Cyclo [DKP7-RGD] (B-minor) 0.2 ± 0.09 109 ± 15 
107 Cyclo [DKP8-RGD] (trans) 7.5 ± 0.6 > 10
3
 
ref 1 c(RGDfV) 3.2 ± 1.3 7.5 ± 4.8 
ref 2 ST1646 1.0 ± 0.5 1.4 ± 0.8 
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Low nanomolar values were obtained with all the ligands except cyclo[DKP1-RGD] (47) which 
incorporates a cis DKP and ligand 106 A. The behavior of this last ligand is peculiar, considering that 
the diastereomeric compound 106 B (see above for the definition of the two diastereomers) is the most 
potent ligand of this series, effectively inhibiting the binding of vitronectin to the isolated v3 
receptor at a 200 picomolar concentration. Interestingly, unlike reference compounds c(RGDfV) and 
ST1646, the RGD-peptidomimetics 47, 48, 102-107 were ca. 10-1000 fold more selective for the v3 
integrin with respect to the v5, in this kind of assay, being 107 the most selective of the series. 
 
2.3 -  NMR characterization and conformational studies 73 
The structure and connectivity of ligands 47, 48, 102-107 and of their fully protected precursors were 
unambiguously assigned by means of mono- and bidimensional 
1
H- and 
13
C-NMR spectra.  
The preferred conformations of the cyclic RGD peptidomimetics 47, 48, 102-107 in aqueous solution 
were then investigated, with the aim of rationalizing the affinity of these compounds for the v3 
receptor at a molecular level. In fact, as already mentioned, the high activity and selectivity of 
Cilengitide (85) has been attributed to an extended conformation of the RGD motif displaying a 
distance of ca. 9 Å between the C atoms of Asp and Arg, imparted by an extended conformation of 
the Arg-Gly-Asp sequence.
5
 In such extended conformations, the carboxylate and guanidinium groups 
are properly positioned to effectively exert their function of electrostatic clamp. 
Monodimensional 
1
H-NMR experiments were conducted to detect intramolecular hydrogen bonds, by 
measuring the chemical shift of the N–H protons and their temperature coefficients (/T). NOESY 
spectra were recorded to investigate both sequential and long-range NOE's that provide evidences of 
preferred conformations. The relevant NMR data are summarized in Table 3.4, while graphic in Figure 
3.16 displays the temperature coefficients. 
 
 
Figure 3.16 - Graphical illustration of temperature coefficients (T) for compounds 47, 48, 102-106 in H2O/D2O 9:1 
between 290 K and 320 K. 
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As already reported in the literature,
70 
ligand 47 exists as an equilibrium of two different preferred 
conformations. The NOESY spectrum shows two mutually exclusive long-range NOE contacts. The 
cross peak between DKP-NH10 and NHAsp (strong) is indicative of a -turn conformation at Gly-Asp 
stabilized by a hydrogen bond between DKP-NH10 and Arg-C=O (Type I H-bonding pattern, Figure 
3.17 A). The chemical shift value (7.46 ppm) and the /T value (-2 ppb/K) of the amide proton 
DKP-NH10 indicate that this proton is strongly locked in an intramolecularly H-bonded state. The 
cross peak between NHGly and NHAsp (medium) is indicative of an alternative -turn conformation at 
Arg-Gly, stabilized by a hydrogen bond between Asp-NH and C(8)=O (Type II H-bonding pattern, 
Figure 3.17 B). 
 
 
Figure 3.17 - Preferred intramolecular hydrogen-bonding pattern proposed for compound 47 on the basis of spectroscopic 
data. The arrows indicate significant NOE contacts. A) Type I H-bonding pattern, Gly-Asp β-turn motif. B) 
Type II H- H-bonding pattern, Arg-Gly β-turn motif . 
 
Ligands 48 and 102 are characterized by a high conformational equilibrium, as ascertained by the 
values of chemical shifts and Δδ/ΔT reported in Table 3.4. The only exception is proton NH-Asp (7.85 
ppm and the /T value -3,5 ppb/K) of  27, which might be involved in a Type II H-bonding pattern. 
 
On the other hand, the presence in both cases of a NOE contact between NHGly and NHArg suggests the 
formation of a -turn motif at DKP-Arg, stabilized by a hydrogen bond between NHGly and C(5)=O 
(appointed as Type III H-bonding pattern, Figure 3.18). The presence of this H-bond is also supported 
by the rather upfield chemical shift value of NHGly in these two ligands (8.18 and 8.00 ppm for 48 and 
102, respectively) and the relatively low temperature dependence (-5.7 and -4.5 ppb/K, respectively). 
 
The similarity of the NMR data and hence of the conformation of these two ligands is quite surprising, 
considering the opposite configuration of the diketopiperazine scaffold (DKP2, 3R,6S in 48; DKP3, 
3S,6R in 102) which should impart a different stereochemical orientation to the two side arms of the 
diketopiperazine. 
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Table 3.4 - 1H-NMR and NOE data of cyclic RGD-peptidomimetics 47, 48, 102-107  in water.  
 
 NH1 NH4 NH10 NHArg NHGly NHAsp Significant NOE contacts 
47 
cyclo[DKP1-RGD] 
 (ppm) 8,35 - 7,46 8,40 8,75 8,10 
NHAsp-NH10; NHAsp-NHGly 
 (ppb/K) -7.3 - -2.0 -7.0 -8.0 -3.7 
48 
cyclo[DKP2-RGD] 
 (ppm) 8.35 - 8.78 8.57 8.18 8.29 
NHArg-NHGly 
 (ppb/K) -8.7 - -10.7 -7.0 -5.7 -7.7 
102 
cyclo[DKP-3-RGD] 
(ppm) 8.10 - 8.28 8.80 8.00 7.85 
NHArg-NHGly 
 (ppb/K) -5.7 - -8.5 -6.0 -4.5 -3.5 
103 
cyclo[DKP4-RGD] 
(ppm) - 8.17 7.59 8.29 8.27 8.88 
-- 
 (ppb/K) - -9.1 -0.7 -9.3 -8.2 -9.3 
104 
cyclo[DKP5-RGD] 
(ppm) - - 8.58 8.48 8.23 8.42 
NHArg-NHGly 
 (ppb/K) - - -11.0 -7.5 -4.7 -8.2 
105 
cyclo[DKP6-RGD] 
 (ppm) - 8.07 7.90 8.32 8.35 8.80 
NHAsp-NH10; NH4-NH10; 
 (ppb/K) - -4.9 -5.1 -7.6 -6.7 -8.0 
106 A 
cyclo[DKP7-RGD]-A 
(ppm) - - 8.04 8.66 7.93 7.76 
NHArg-NHGly; NHAsp-NHGly 
 (ppb/K) - - -7.5 -5.0 -3.0 -1.0 
106 B 
cyclo[DKP7-RGD]-B 
 (ppm) - - 7.72 8.34 8.45 8.55 
NHAsp-NH10 
 (ppb/K) - - -4.0 -7.0 -7.0 -5.0 
107 
cyclo[DKP8-RGD] 
 (ppm) 7.82 - 7.43 8.64 8.04 7.90 
- 
 (ppb/K) -8.0 - -6.0 -6.8 -4.4 -5.2 
 
This conformational similarity can be interpreted in terms of a quasi-enantiomeric structure of the two 
ligands (excluding the configuration of the remote RD amino acid side chains, Figure 3.18).  
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Figure 3.18 - Preferred intramolecular hydrogen-bonding pattern proposed for compound 48 and 102 on the basis of 
spectroscopic data. The arrows indicate significant NOE contacts. The DKP-Arg β-turn motif is referred as 
Type III H-bonding pattern.  
 
Ligands 103 and 105, featuring the diketopiperazine scaffolds DKP4 (3R,6S) and DKP6 (3S,6R) 
respectively (with the benzyl substitution at the endocyclic nitrogen N1, instead of N4), show a 
different NMR pattern. In particular, ligand 105 is characterized by a rather strong NOE contact 
between NHAsp and NH10 and a moderate/weak one involving NH4 and NH10. These two contacts are 
mutually exclusive and hence indicative of an equilibrium between two different conformations, 
respectively Type I and Type IV H-bonding patterns (Figure 3.19 A and B).  
 
Figure 3.19 - Preferred intramolecular hydrogen-
bonded pattern proposed for compound 105 on the 
basis of spectroscopic data. A) Type I H-bonding 
pattern is characterized by a -turn motif at Gly-Asp 
stabilized by a hydrogen bond between NH10 and Arg-
C=O. B) Type IV H-bonding pattern which is 
characterized by a pseudo -turn at Asp-DKP 
stabilized by a hydrogen bond between NH4 and Gly-
C=O. The arrows indicate significant NOE contacts. 
 
The hydrogen bonded status of the two amide protons NH4 and NH10, as indicated by their rather low 
temperature dependence (-4.9 and -5.1 ppb/K, respectively) and quite upfield chemical shift values 
(8.07 and 7.90 ppm, respectively), corroborate this assumption. The Type IV H-bonding pattern could 
feature a pseudo -turn at Asp-DKP stabilized by a hydrogen bond between NH4 and Gly-C=O (NOE 
contact between NH4 and NH10). 
Ligand 103, on the other hand, is characterized by the absence of relevant NOE contacts, a very low 
temperature dependence (-0.7 ppb/K) and a quite upfield chemical shift value (7.59 ppm) for proton 
NH10. These two features suggest a Type I H-bonding pattern, notwithstanding the apparent lack of 
NOE contact between NHAsp and NH10. 
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The dibenzylated diketopiperazine containing peptidomimetics 104 and 106 were eventually studied. 
Ligand 104 shows NMR features similar to ligand 48 (Type III H-bonding pattern): a NOE contact 
between NHGly and NHArg and a rather shielded NHGly (8.23 ppm) with a relatively low temperature 
coefficient (-4.7 ppb/K). As discussed above, ligand cyclo[DKP7-RGD] was obtained as a mixture of 
two diastereomers 106 A and 106 B, whose conformations in solution were studied separately. In 
particular, 106 A displays two mutually exclusive NOE contacts between NHArg and NHGly and 
between NHAsp and NHGly. These three protons, on the other hand, show also a rather strong hydrogen 
bonded status, as indicated by their low temperature dependence and, at least for NHAsp and NHGly, 
their upfield chemical shift (Table 3.4). These data indicate an equilibrium between two different 
conformations: one displaying a Type III H-bonding pattern and a second one showing a Type II H-
bonding pattern (-turn at Arg-Gly), like the low-affinity ligand 47, i.e. cyclo[DKP1-RGD]. Finally, 
ligand 106 B shows a single NOE contact between NHAsp and NH10 and a hydrogen bonded status for 
NH10 ( 7.72 ppm and T -4 ppb/K, see Table 3.4). These values are indicative of a Type I H-
bonding pattern. 
No NOE contacts were identified for compound 107, containing the superior omologous of DKP3 (i.e. 
DKP8). Moreover, also temperature coefficients of  the amide protons are not relevant for the 
identification of H-bonds. 
 
Conformational analysis. Conformational studies of the cyclic RGD-peptidomimetics were performed 
by mixed-mode Metropolis Monte Carlo/Stochastic Dynamics (MC/SD) simulations, using the 
implicit water GB/SA solvation model
2
 and the OPLS_2001 force field. 
As already reported in a preliminary communication,
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three-dimensional structures satisfying long-
range NOE contacts were generated for RGD peptidomimetic 47 performing two 10 ns restrained 
MC/SD simulations and applying the DKP-NH10/NHAsp or the NHAsp/NHGly distance restraint derived 
from NOESY spectra. 
More than 90% of the conformations sampled during the first simulation adopted a non-extended 
arrangement of the RGD sequence characterized by a -turn at Gly-Asp and the presence of the 
corresponding hydrogen bond between DKP-NH10 and Arg-C=O. In addition, the formation of a -turn 
at Gly stabilized by the hydrogen bond between NHAsp and Arg-C=O was observed for 40% of the 
simulation. A C(Arg)–C(Asp) average distance of 7.4 Å was obtained during this MC/SD 
calculation. A representative energy minimized conformation selected by cluster analysis and 
featuring both H-bonds is shown in Figure 3.20 A (Type I-cis H-bonding pattern). Approximately 60% 
of the conformations sampled during the simulation of 47 featuring the NHAsp/NHGly distance restraint, 
adopted a non-extended arrangement of the RGD sequence characterized by a -turn at Arg-Gly and 
the corresponding hydrogen bond between NHAsp and C(8)=O. In addition, the formation of a -turn at 
Arg stabilized by the hydrogen bond between NHGly and C(8)=O was observed for 40% of the 
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simulation. The C(Arg)–C(Asp) average distance in this MC/SD calculation was 6.8 Å. A 
representative energy minimized conformation selected by cluster analysis and featuring both H-bonds 
is shown in Figure 3.20 B (Type II H-bonding pattern). 
 
 
Figure 3.20 - Structures of 47 as obtained by restrained MC/SD simulations based on experimental distance information, 
after energy minimization. A) Type I-cis H-bonding pattern, -turn at Gly and II‟-turn at Gly-Asp [CArg)–
C(Asp)=7.9 Å]. B) Type II H-bonding pattern, -turn at Arg and II‟-turn at Arg-Gly [C(Arg)–C(Asp)=6.6 
Å]. 
 
The NOESY spectra of compounds 48 (containing N-4-benzylated DKP2, 3R,6S), 102 (containing N-
4-benzylated DKP3, 3S,6R) and 104 (containing N-dibenzylated DKP5 3R,6S) show only one relevant 
long-range interaction between NHGly and NHArg: this NOE is indicative of a -turn motif at DKP-
Arg stabilized by a hydrogen bond between NHGly and C(5)=O (Figure 3.18, Type III H-bonding 
pattern). The distance restraint corresponding to the NOE contact between NHGly and NHArg was 
applied in the 10 ns MC/SD simulations of compounds 48, 102 and 104. More than 90% of the 
conformations sampled during each of these simulations adopted an extended arrangement of the RGD 
sequence characterized by a pseudo -turn at DKP-Arg and the formation of the corresponding 
hydrogen bond between the NHGly and C(5)=O. Interestingly, only for compound 102, the additional 
formation of a -turn at Arg-Gly stabilized by the hydrogen bond between NHAsp and C(8)=O was 
observed for 15% of the simulation. These results and the NMR data (showing  7.85 ppm and T 
-3.5 ppb/K for NHAsp of 102) suggest the contribution of a Type II/Type III H-bonding pattern to the 
conformational equilibrium of 102 (mainly populated by a Type III H-bonding pattern).  
C(Arg)-C(Asp) average distances of 9.3, 8.8, and 9.1 Å were obtained during the MC/SD 
calculations of 48, 102 and 104, respectively. A representative energy minimized conformation 
selected by cluster analysis and featuring the H-bond between the Gly-NH and C(5)=O (Type III H-
bonding pattern) is shown in Figure 3.21 for RGD peptidomimetic 48. 
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Figure 3.21 - Structure of 48 as obtained by restrained MC/SD simulations based on experimental distance information, after 
energy minimization (Type III H-bonding pattern, distorted inverse -turn at Asp and pseudo -turn at DKP-Arg, 
CArg)–C(Asp)=9.4 Å). 
 
Due to the absence of relevant long-range NOE contacts, several 10 ns runs of unconstrained MC/SD 
simulations were performed for RGD peptidomimetic 103 (containing N-1-benzylated DKP4, 3R,6S) 
starting from different 3D structures. Most of the conformations sampled during these simulations 
adopted an extended arrangement of the RGD sequence (C(Arg)-C(Asp) average distance of 8.8 Å) 
and approximately 40% of them are characterized by a -turn at Gly-Asp and the presence of the 
corresponding hydrogen bond between DKP-NH10 and Arg-C=O. These results provide a structural 
model in agreement with NMR data showing a low temperature dependence (-0.7 ppb/K) and an 
upfield chemical shift value (7.59 ppm) for proton NH10. 
A representative energy minimized conformation selected by cluster analysis and featuring the H-bond 
between DKP-NH10 and Arg-C=O (Type I-trans H-bonding pattern) is shown in Figure 3.22 for RGD 
peptidomimetic 103. It is worth noting how the combination of the trans DKP4 scaffold with the Gly-
Asp -turn occurs by generating an extended RGD arrangement, while the combination of the cis 
DKP1 scaffold with the same secondary motif resulted in a non-extended RGD disposition (see above, 
Figure 3.20 A). Accordingly, two Type I H-bonding patterns have been defined, depending on the cis 
or trans relative stereochemistry of the diketopiperazine scaffold. 
Three-dimensional structures satisfying long-range NOE contacts were generated for RGD 
peptidomimetic 105 (containing N-1-benzylated DKP6, 3S,6R) performing two 10 ns restrained 
MC/SD simulations and applying the DKP-NH10/NHAsp or the NH4/NH10 distance restraint derived 
from NOESY spectra (Table 3.4, Figure 3.19). 
Most of the conformations sampled during the first simulation adopted an extended arrangement of the 
RGD sequence (C(Arg)-C(Asp) average distance of 9.0 Å) and approximately 40% of them are 
characterized by a -turn at Gly-Asp and the corresponding hydrogen bond between DKP-NH10 and 
Arg-C=O. A representative energy minimized conformation selected by cluster analysis and featuring 
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this H-bond is shown in Figure 3.23 A (Type I-trans H-bonding pattern). Approximately 70% of the 
conformations sampled during the simulation of 105 featuring the NH4/NH10 distance restraint, 
adopted an extended arrangement of the RGD sequence (C(Arg)-C(Asp) average distance of 8.8 Å) 
characterized by a pseudo -turn at Asp-DKP and the corresponding hydrogen bond between NH4 and 
Gly-C=O. In addition, the formation of a -turn at Asp stabilized by the hydrogen bond between NH10 
and Gly-C=O was observed for 50% of the simulation A representative energy minimized 
conformation selected by cluster analysis and featuring these H-bonds is shown in Figure 3.23 B 
(Type IV H-bonding pattern). 
 
 
Figure 3.23 - Structures of 105 as obtained by restrained MC/SD simulations based on experimental distance information, 
after energy minimization. A) Type I-trans H-bonding pattern, inverse -turn at Asp and distorted II‟-turn at 
Gly-Asp [CArg)–C(Asp)=9.0 Å]. B) Type IV H-bonding pattern, inverse -turn at Asp and pseudo -turn 
at Asp-DKP [C(Arg)–C(Asp)=8.8 Å]. 
 
Three-dimensional structures satisfying long-range NOE contacts were generated for RGD 
peptidomimetic 106 (containing N-dibenzylated DKP7 3S,6R) performing three 10 ns restrained 
MC/SD simulations and applying the distance restraints derived from NOESY spectra of 
diastereoisomers 106A and 106B (Table 3.4): in the first simulation NHArg/NHGly relevant in 106A, in 
the second simulation NHAsp/NHGly also relevant in 106A, and in the third simulation DKP-
NH10/NHAsp relevant in 106B. 
All the conformations sampled during the first two simulations adopted a non-extended arrangement 
of the RGD sequence [C(Arg)-C(Asp) average distance of 6.6 Å] characterized by the simultaneous 
presence of different turn motifs (pseudo -turn at DKP-Arg, -turn at Gly and pseudo -turn centered 
at the DKP unit). The structural models provided by these restrained MC/SD simulations differ from 
the conformations hypothesized on the basis of NMR data of 106A [equilibrium between Type III 
(pseudo -turn at DKP-Arg) and Type II (-turn at Arg-Gly) H-bonding patterns, see the NMR 
section]. However, also the calculated structures are able to provide an explanation for the NOE 
contacts and the NMR temperature coefficients observed for 106A. 
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The distance restraint corresponding to the NOE contact between DKP-NH10 and NHAsp (observed in 
the NOESY spectrum of 106B) was applied in the third 10 ns MC/SD simulation of compound 106. 
Most of the conformations sampled during this simulation adopted an extended arrangement of the 
RGD sequence (C(Arg)-C(Asp) average distance of 9.0 Å) and approximately 50% of them are 
characterized by a -turn at Gly-Asp and the corresponding hydrogen bond between DKP-NH10 and 
Arg-C=O. A representative energy minimized conformation selected by cluster analysis and featuring 
this H-bond is shown in Figure 3.24 (Type I-trans H-bonding pattern). 
Contrary to what observed for the other cyclic RGD peptidomimetics containing DKP scaffolds, 
rotation of the DKP ring can not be observed during the simulations performed on compound 106, 
confirming 106A and 106B as two different separable conformers (diastereomers) due to hindered 
rotation of one ring around the other. 
 
 
Figure 3.24 - Structure of 106B as obtained by restrained MC/SD simulations based on experimental distance information, 
after energy minimization (Type I-trans H-bonding pattern, distorted inverse -turn at Asp and II‟-turn at Gly-
Asp, CArg)–C(Asp)=9.2 Å). 
 
Due to the absence of relevant long-range NOE contacts, two 10 ns runs of unconstrained MC/SD 
simulations were performed for RGD peptidomimetic 107 (containing N-4-benzylated DKP8, 3S,6R).  
 
Figure 3.25 - Structure of 107 as obtained by MC/SD simulations, after energy minimization (CArg)–C(Asp)=9.5 Å). 
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All the conformations sampled during these simulations adopted an extended arrangement of the RGD 
sequence (C(Arg)-C(Asp) average distance of 9.8 Å) characterized by the formation of hydrogen 
bonds between NHAsp and C(2)=O and between NH1 and Arg-C=O. 
A representative energy minimized conformation selected by cluster analysis and featuring these H-
bonds is shown in Figure 3.25 for RGD peptidomimetic 107. 
 
Molecular docking. In order to rationalize, on a molecular basis, the affinity of cyclic RGD 
peptidomimetics for the v3 receptor, docking studies were performed starting from the 
representative conformations obtained from the MC/SD simulations. The crystal structure of the 
extracellular segment of integrin v3 complexed with the cyclic pentapeptide Cilengitide (1L5G, pdb 
code) was taken as a reference model for the interpretation of the docking results in terms of ligand-
protein interactions. In the X-ray complex, Cilengitide binds to the interface of the  and  units 
forming specific electrostatic interactions.The acid and basic pharmacophoric groups and their 
orientation are essential for binding to the v3 because they act like an electrostatic clamp, interacting 
with charged regions of the receptor binding site. 
Docking calculations starting from geometries featuring the Type I-cis and Type II H-bonding patterns 
produced top-ranked poses conserving optimal interactions only with the  subunit of the v3 
receptor. Probably, the short C(Arg)-C(Asp) distances (values less than 8 Å) of these geometries 
prevent the guanidine and carboxylic groups from achieving the required separation for binding to the 
v3 integrin. On the other hand, docking calculations starting from the RGD extended conformations 
featuring the Type I-trans, Type III and Type IV H-bonding patterns, produced top-ranked poses 
conserving all the important interactions of the X-ray complex (Figure 3.26).  
 
 
Figure 3.26 - Top-ranking binding mode of compounds A) cyclo[DKP3-RGD] (102) and B) cyclo[DKP7-RGD] (106 B) 
into the crystal structure of the extracellular domain of αVβ3 integrin overlaid on the bound conformation of 
Cilengitide (green).  
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The positively charged Arg guanidinium group of the ligand interacts with the negatively 
charged side chains of Asp218 and Asp150 in the  unit, one carboxylate oxygen of the 
ligand Asp side chain is coordinated to the metal cation in the metal-ion-dependent adhesion 
site (MIDAS) region of the  unit, while the second carboxylate oxygen forms hydrogen 
bonds with the backbone amides of Asn215 and Tyr122 in the  unit. Further stabilizing 
interaction involves the formation of a hydrogen bond between the ligand backbone NH of the 
Asp residue and the backbone carbonyl group of Arg216 in the  unit. 
In light of all these considerations, the micromolar affinity of RGD peptidomimetics 47 and 106A (3.9 
and 0.2 M, respectively) for v3 (Table 1) can be explained in terms of their low pre-organization 
for binding. In fact, as determined by the computational and NMR studies, these compounds in 
solution mainly feature non-extended RGD conformations which, according to the docking results, are 
not able to properly fit into the v3 receptor. On the contrary, the nanomolar affinity of RGD 
peptidomimetics 48, 102-105, 106B and 107 for v3 can be attributed to their high structural pre-
organization. In fact, as determined by the computational and NMR studies, these compounds in 
solution mainly feature extended RGD conformations (principally determined by Type I-trans, Type 
III and Type IV H-bonding patterns) similar to the RGD bound conformation of Cilengitide. 
 
2.4 -  Depsipeptide side-project 
Most of the problems in the synthesis of the compounds shown so far are probably related to the 
introduction of an amino moiety on the diketopiperazine scaffolds. This was accomplished, most of 
the times, thorugh a Mitsunobu-type reaction on compounds 49 in presence of HN3 in toluene to give 
azides 58 (Scheme 2.9, Chapter 2, §3.2.1). A major drawback of this reaction was apart for the very 
low atom economy, the formation of varying amounts, depending on the substrate, of a 
dehydroalanine-like elimination by-product (60, Scheme 2.10, Chapter 2, §3.2.1). 
At some point we wondered whether it was really necessary to introduce an amino functionality on our 
scaffolds, or if we could in principle incorporate into RGD-containing macrocyclic compounds a 
scaffold bearing an hydroxyl functionality, thus obtaining a depsipeptide (117, Figure 3.27). 
 
 
Figure 3.27 – Depsipeptide containing the RGD-sequence and DKP3-like scaffold. Depsi bond is highlighted in red. 
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This might have reduced the number of steps in the synthesis of RGD-cyclic compounds, enhacing 
most probably the overall yields. A depsi bond in the macrocycle might also have an effect, which we 
could not a priori define as positive or negative, on the conformation assumed and, hence, on their 
biological activity. The lower stability of the ester bond respect to the amide bond, expecially in vivo, 
might represent a major drawback. 
We investigated the synthesis of compound 117 starting from diketopiperazine 49c, a precursor in the 
synthesis of scaffold DKP3 (Scheme 3.5). 49c was coupled with Cbz-Asp(OtBu)-OH in presence of 
EDC, DMAP and a catalytic amount of scandium triflate,
74
 forming the ester bond. This mild 
procedure gave the best results among the other more common ones tried. The mechanism seems to 
procede through a carboxylic acid activated species (with carbodiimide, N-hydroxysuccinimide, or 
other reagents) which react with N-dimethylaminopyridine forming an acyl pyridinium intermediate. 
The role of Sc(OTf)3 may be to coordinate with the carbonyl oxygen of this acyl pyridinium 
intermediate, providing a highly reactive species. 
 
 
Scheme 3.5 – Reagents and conditions: a) Sc(OTf)3, EDC, DMAP, DCM, -8°C  r.t, 2h: 90%; b) [Pd(PPh3)4], PPh3, 
pyrrolidine, DCM, 0°C: 100%; c) TFA/DCM 1:2, 3h; d) HATU, HOAt, DIPEA, DMF, 0°C  r.t., 2.5 days: 
73 %; e) Pd/C 10%, H2, MeOH, 2 days 
 
Allyl ester was then cleaved quantitatively in the already described conditions, and the free carboxylic 
acid thus obtained was coupled with the Arg(Mtr)-Gly-OBn fragment in presence of HATU, HOAt 
and iPr2EtN (Scheme 3.5). 
Several protocols were employed while trying to hydrogenolytically cleave both benzylester and Cbz 
(Pd/C 10%, MeOH; Pd(OH)2/C 20%, MeOH; Pd/C 10% THF; Pd(OH)2/C 20%, THF; Pd/C 10%, 
DCM; Pd(OH)2/C 20%, DCM). Milder procedures provided a partially deprotected intermediate, in 
which Cbz had not been cleaved, while prolonging reaction times resulted in the break of the depsi 
bond. Feeling not confident enough on the efficacy of a depsipeptide in vivo (ester bond stability), and 
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considering that affording this new synthetic target revealed more troublesome and time consuming 
than expected, we decided to discontinue the project. 
 
3 -  Cyclic [DKP-isoDGR] compounds 
The growing interest towards the isoDGR recognition motif and the encouraging results obtained by 
our cyclic RGD-containing compounds (see §2) led us to conceive a new class of cyclic 
peptidomimetics bearing the isoDGR sequence and incorporating a bifunctional diketopiperazine 
scaffold, which could serve as integrin antagonists. 
 
 
Figure 3.28 – isoDGR containing compounds c[DKP2-isoDGR] and c[DKP3-isoDGR]. 
 
However, it must be kept in mind that simply replacing the RGD sequence with isoDGR within the 
context of an already existing compound might not provide the expected results, because an inverted 
orientation of the ligand is required to interact with the RGD-binding pocket. Moreover, flanking 
residues contribution in enhancing binding affinity and specificity might be affected. Lacking a 
reliable model for aprioristic prediction of binding affinities/ docking to the most interesting 51 
integrin, we decided to start an investigation synthesizing two compounds bearing our two progenitor 
trans diketopiperazines, namely DKP2 and DKP3, as a scaffold (118, 119, Figure 3.28). 
 
3.1 -  Synthesis 
A synthesis in solution, very similar to the one adopted in the case of our RGD-containing 
pentapeptidomimetics, was planned at first. Considering the commercially available starting material, 
a Fmoc strategy was needed (Scheme 3.6). Thus, we envisaged the synthesis of dipeptide Fmoc-
isoAsp(tBu)-Gly-OBn, which was easily achieved in good yields using Carpino‟s coupling reagents 
(HATU, HOAt), and of a modified N-Fmoc protected diketopiperazine scaffold. Nevertheless, we 
soon discouraged from pursuing this approach, due to the annoing dirty cleavage of the Fmoc 
protecting group in solution. 
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The recent success in the synthesis of a DKP-containing decapeptide on solid phase (see Chapter 4),  
suggested to take advantage of a similar strategy, envisaging a solid phase synthesis of a linear 
advanced intermediate which could therefore be cyclized in solution. 
 
 
Scheme 3.6 – in solution approach to the synthesis of  isoDGR-containing compounds, using Fmoc strategy. 
 
I already had experience with the synthesis of modified diketopiperazine DKP1* (see Chapter 2), 
bearing the usual carboxy acid group and an amino group masked as azide. Similarly, modified 
versions of DKP2 and DKP3, which could serve as building blocks in a Fmoc solid phase synthetic 
approach, were easily obtained (DKP2* and DKP3*, Chapter 2). 
We planned to build a linear pentapeptide on resin starting from commercially available Fmoc-Gly-
OH, Fmoc-Asp(OH)-OtBu and Cbz-Arg(Mtr)-OH, and easy accessible DKP2* or DKP3* (Scheme 
3.7).  
 
Scheme 3.7 – solid phase approach to the synthesis of  isoDGR-containing compounds, using Fmoc strategy. 
 
Cleavage from the resin needed to be orthogonal respect to side chain deprotection (acid labile tBu-
ester and Mtr-sulfonamide), thus SASRIN
TM
 (Super Acid Sensitive resIN) was chosen  as the solid 
support (Figure 3.29).  
 
Figure 3.29 
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The first aminoacid, namely Gly, was treated with diisopropylcarbodiimide (DIC) and a catalytic 
amount of dimethylaminopyridine (DMAP) in dimethylformamide in order to form an ester bond with 
the resin linker (Scheme 3.8).  
 
 
Scheme 3.8 – SPPS of linear pentapeptide intermediates: a) Fmoc-Gly-OH, DIC, DMAPcat, DMF, 2h; b) piperidine 20%, in 
DMF; c) Fmoc-Asp(OH)-OtBu, DIC, HOAt, DMF, 3h; d) piperidine 2%, DBU 2%, in DMF; e) DKP2* or 
DKP3*, DIC, HOAt, DMF, 18h; f) Me3P, dioxane/water 4:1; g) Cbz-Arg(Mtr)-OH, DIC, HOAt, DMF, 18h; h) 
1% TFA, DCM: 88% overall yield. 
 
Fmoc deprotections were performed either with 20% solutions of piperidine in DMF or, in milder 
conditions, with DMF solutions of piperidine (2%) and diazabicycloundecene (DBU) (2%), while all 
coupling reactions were performed using activated –OAt esters which were generated treating the 
corresponding amino acids with  DIC and HOAt in DMF. The activated ester mixture was added to the 
resin, which was shaken at r.t.. Reaction times varied from 2h to 18h in the case of more challenging 
couplings (Scheme 3.8). 
After coupling the diketopiperazine scaffold, an interesting in situ azide reduction was performed to 
free the amino group in presence of Me3P (1M in toluene) in a 4:1 mixture of dioxane and water, 
which served to hydrolyze the iminophosphorane intermediate. After washing the resin, the free amine 
obtained was ready for the subsequent coupling reaction. 
Only linear intermediate 120 was isolated, after cleavage form the resin in weakly acidic conditions 
(1% TFA in DCM) (Scheme 3.8). 
After being cleaved from resin, linear peptide intermediate 120 needed extensive purification. Cbz 
hydrogenolytical cleavage in presence of Pd/C 10% in THF and subsequent macrolactamization using 
HATU, HOAt and DIPEA, in DMF, were then carried out in solution (Scheme 3.9). Both cyclization 
and final side-chain deprotection were performed in the same conditions already described for our 
RGD-containing peptides (see §2.1). 
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Scheme 3.9 – a) H2, Pd/C 10%, THF/water 1:1; b) HATU, HOAt, DIPEA, 1.4 mM, DMF; c) TFA/thioanisole/EDT/anisole 
90:5:3:2. 
 
The latest step, in particular, provided products 118 and 119 in unexpected low yields, an will be 
hence object of  optimization. 
 
3.2 -  Biological evaluation 71 
The cyclic isoDGR peptidomimetics were examined in vitro for their ability to inhibit biotinylated 
vitronectin binding to the purified v3 and v5 receptors (Table 3.5).  
Screening assays were performed incubating the immobilized integrin receptors with various 
concentrations (10
-10–10-5 M) of the isoDGR ligands 118-119 in the presence of biotinylated 
vitronectin (1 µg/mL), and measuring the concentration of bound vitronectin in the presence of the 
competitive ligands. The ability of the new compounds to inhibit the binding of vitronectin to the 
isolated v3 and v5 receptors may be compared with that of isoDGR-containing compounds 
reported in the literature by Kessler et al. such as c(G-isoDGR-phg) (101, Figure 3.14), which where 
tested in the same kind of assay (Table 3.5).
69 
Compound 119, incorporating diketopiperazine scaffold DKP3, displays low nanomolar affinity 
towards V3 integrin (IC50: 9.2 ± 1.1 nM), with a slight selectivity respect to V5 integrin (IC50: 312 
± 21 nM). Moreover, 119 appears ten fold more active in the inhibition of biotinylated vitronectin 
binding to V3 integrin respect to c(G-isoDGR-phg) (101), which was chosen as a reference. These 
low nanomolar IC50 values are also comparable to those obtained by RGD containing compounds, 
such as c(RGDfV) (86) or ST1646 (89). 
 
Unfortunately, the results related to compound 118 are still not available. This preliminary results 
should anyway be considered very promising. 
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Table 3.5 - Inhibition of biotinylated vitronectin binding to v3 and v5 receptors  
[a] IC50 values were calculated as the 
concentration of compound required for 
50% inhibition of biotinylated vitronectin 
binding as estimated by GraphPad Prism 
software; all values are the arithmetic 
mean ± SD of triplicate determinations. 
 
NMR studies and conformational analysis are in progress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Structure 
V

3
 IC
50
 [nM]a 
V

5 
IC
50
 [nM]a 
118 Cyclo [DKP2-isoDGR] n. a. n. a. 
119 Cyclo [DKP3-isoDGR] 9.2 ± 1.1  312 ± 21  
ref c(G-isoDGR-phg) 89 ± 19  -  
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 4 DESIGN, SYNTHESIS AND CONFORMATIONAL 
ANALYSIS OF AN /-PEPTIDE FOLDAMER 4  
 
 
As part of my project, I spent six months (October 2010 – March 2011) in the group of Prof. Oliver 
Reiser at the University of Regensburg, working on the design of/peptide foldamers, containing 
diketopiperazine repeating units as secondary structure inducers. 
 
1 -  Foldamers 
Foldamers were first defined by Gellmann in the mid-„90s as oligomers of modest length with a strong 
tendency to adopt a specific compact conformation in solution.
1
 
Protein–protein interactions (PPIs) are involved in a large number of biological processes. As many 
diseases originate from their malfunction, inhibiting PPIs may represent a promising strategy for drug 
discovery. Small molecule inhibitors often failed in targeting protein surface motifs.
2
 Over the past 
two decades many researchers have been looking for biopolymer-like folding behavior in unnatural 
oligomers,
3
 with the aim of using compact and specific conformations to mimic biopolymer-like 
functions. Protein surface recognition by mimicking distinct folding patterns along with proteolytic 
stability is the main advantage of foldamers compared to -peptides or small drug molecules. 
Early efforts in the field focused on -peptides,4 and they remain subjects of intensive investigation 
today.
5
 Other prominent representatives of this field are the γ-peptides,6 azapeptides7 and oligoureas8 
(Figure 4.1). 
 
 
Figure 4.1 – Selected aliphatic foldamer backbones 
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However, foldamers with heterogeneous backbones having various periodic motifs,
9,10
 such as /-
peptides, gained interest in recent years. Heterogeneous backbones are intriguing at a fundamental 
level, since they diverge from the homogeneous backbones of the biological precedents, proteins and 
nucleic acids. 
  
1.1 -  /-Peptide foldamers 
Foldamer design based on heterogeneous backbones offers benefits relative to an exclusive reliance on 
homogeneous backbones. For a given set of monomer classes, the number of candidate foldamer 
backbones is vastly larger if we include heterogeneous backbones than if we are limited to 
homogeneous backbones. Considering, for example, only - and -amino acids as building blocks, 
then the homogeneous approach limits us to -peptides or -peptides. The 
heterogeneous approach, in contrast, allows many different combinations 
(e.g., ------, ------, ------, ----, to name just 
a few).
11The study of heterogeneous backbone foldamers has several 
advantages over that of their homogeneous backbone counterparts, 
including access to many new molecular shapes based on variations in the 
stoichiometries and patterns of the subunit combinations and improved 
prospects for side chain diversification. 

Figure 4.2 - Crystal structure of an /-peptide, with 1:1 : alternation in the backbone, 
in the 14/15-helical conformation. -amino acid residues are yellow, and -amino acid 
residues are blue.12 
 
Recent efforts to develop /-peptide foldamers (Figure 4.2) can be divided into two conceptually 
distinct classes.
13
 The first includes entities prepared using a “block” strategy, in which -peptide 
segments and -peptide segments are combined to form a hybrid oligomer. The second class 
encompasses designs in which - and -amino acid monomers are interspersed in a regular pattern 
throughout an oligomer sequence. 
 
Figure 4.3 – Hydrogen bonding patterns observed in different helices formed by -peptides with 1:1 backbone 
alternation.10 
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The “block” approach was mainly adopted to study sheet secondary structures, introducing reverse 
turn motifs within a strand-forming segment, thus promoting a hairpin.
14
 
The first systematic structural studies of linear oligomers with backbone alternation of - and -
residues were conducted independently by the groups of Reiser
15
 and Gellman.
16
  
Reiser and coworkers document the formation of a 13-helix (Figure 4.3, A) by /-peptides containing 
L-alanine residues alternating with 3-substituted cis-2-aminocyclopropanecarboxylic acid residues. 
Indicative of the adopted helical conformation is the i → i – 2 C=O· ·H-N H-bonding pattern showed 
by heptamer 121 (Figure 4.4) in methanol. 
 
 
Figure 4.4 
 
Earlier pharmacological studies showing that incorporation of a single cis-2-
aminocyclopropanecarboxylic acid residue into a peptide corresponding to the C-terminus of 
neuropeptide Y gave rise to substantial affinity and unique selectivity toward the natural receptor 
proteins, inspired this structural work.
17
 
On the other hand, Gellman and co-workers prepared hexamers and octamers containing either (S,S)-
2-aminocyclohexanecarboxylic acid (ACHC) or (S,S)-2-aminocyclopentanecarboxylic acid (ACPC) 
alternating with either L- or D--amino acid residues, in order to find new foldamers. In fact, -peptide 
sequences containing trans-ACHC or trans-ACPC already proved the ability of these 
conformationally preorganized structures to promote stable secondary structures (i.e. -peptide 
helices) within short oligomers.
3b
 Only the combination of (S,S)-ACPC with L--amino acid (122, 
Figure 4.4) gave rise to nonsequential NOEs, which resulted indicative of two different rapidly 
interconverting helical conformations: one involving i → i + 3 and the other i → i + 4 C=O· ·H-N H-
bonds (11-helix and 14/15 helix, Figure 4.3 B,C). These H-bonding patterns are typically observed in 
-peptide backbones, and correspond to 310- and -helices respectively.
18
 
A “mixed” H-bonding pattern such as 9/11-helix, featuring two distinct types of backbone C=O· ·H-N 
H-bonds with opposite orientations relative to the backbone direction (Figure 4.3 D), was also 
identified by Sharma, Kunwar, and co-workers (123, Figure 4.5).
19
 Compounds of this type, 
108  Chapter 4 
containing 3-residues, are probably adopting a 14/15-helix-like conformation lacking intramolecular 
H-bonds, as postulated by Seebach and co-workers.
20
 
 
 
Figure 4.5 
 
Foldameric behavior is not limited to /-peptides with a 1:1 / residue alternation. For example, 
both 2:1 and 1:2 / backbone patterns (such as 124 and 125, respectively, Figure 4.5) were recently 
found to promote helix formation in short oligomers.
21
 
Overall, the structural data obtained with short oligomers suggest that the propensity to form i → i + 3 
and/or i → i + 4 C=O· ·H-N H-bonded helices, typical of 310- and -helices, may be a common feature 
of foldamers that contain homochiral - and -amino acid residues, for most : proportions and 
sequence patterns.
10
 
 
1.2 -  Observed structures 
The propensity of such diverse backbones to fold may be governed by many internal or external 
parameters. The overall shape and rigidity of the molecule and its ability to establish attractive or 
repulsive intramolecular non-covalent interactions depend on monomer size and shape, linkage 
orientation, rotational restrictions, local intramolecular interactions, and interactions between 
monomers remote from each other in a sequence. A common feature to all foldamers is a certain 
degree of backbone rigidity that limits the entropic cost of adopting an organized conformation. A 
further contribution to folding tendency is given by solvent effects such as hydrophobic effects.
22
 
However, the secondary structures found in foldamers are much less diverse than the variety of their 
backbones. The typical motifs of biopolymers (helices, linear strands, turns and sheets) are present in 
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most classes of foldamers, being the helix the most frequently observed structure. Sheets are probably 
not less common, but less tractable and still awaiting to be discovered. 
On the other hand, many unknown or uncommon folding motifs such as pillar-like architectures 
(stacks of aromatic rings),
23
 knots,
24
 spiral-like objects („tail-biters‟),25 or non-canonical helices,26 are 
displayed by foldamers.
22
 
 
1.3 -  De novo foldamer design 
Mándity et al. developed an innovative concept of the so called stereochemical patterning approach, as 
a very promising tool for the de novo foldamer design based on the analysis of backbone torsion 
angles in -peptides as well as in /-peptides.27 The signs of the peptide bond-flanking dihedrals ((n-
1)][n, where ][ indicates the CONH group) revealed to be crucial for the type of secondary structure 
that is induced. In particular, helical structures were observed when dihedrals of adjacent residues had 
the same sign. By correlating the signs of torsion angles and the absolute stereochemistry of building 
blocks, peptide sequences that would undergo a distinct helical folding could be readily predicted.  
In order to test the predictive ability of the method, cis- or/and trans-ACPC residues along with 
acyclic - and -amino acids were employed for the synthesis of - and -peptide sequences either 
based on this ][ sign, stereochemical pattern, or generated under quasi-randomized control. 
Theoretical predictions and experimental findings were in excellent agreement. 
 
Table 4.1 - Signs of dihedral 
angles ([ and ]) induced by 
the configurations of the 
backbone atoms. 
 
 
Table 4.2: The secondary 
structure preference of the ][ 
building blocks.  
 
 
This strategy may be of great impact in the fast rational design of molecules with tailored properties.
9
 
 
1.4 -  Biological applications 
An emerging and challenging foldamer application is to mimic folded peptide segments found in 
proteins, in particular the -helix. Indeed, the use of short -peptide fragments to target 
biomacromolecules (e.g. proteins) is limited because they generally do not maintain their secondary 
structure once extracted from the protein context.
6a
 
Residue type Backbone configuration Structuring effect 
 (S)-C  
 (R)-C [+ 
 (S)-C  
 (R)-C [+ 
 (S)-C  
 (R)-C [+ 
Signs of ][ Secondary structure 
+][+ helix 
][ helix 
+][ strand 
][+ strand 
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Recently, optimized careful combinations of - and -amino acids mimicking helical sequences, 
namely a mixed  heptamer, have been shown to effectively imitate the binding surface of a 
known -peptide HIV inhibitor targeting the gp41 central trimeric coiled coil.28 It is noteworthy that 
these foldamers were equipotent to the parent -peptide in cell–cell fusion inhibition assays and in 
inhibition of HIV-1 infectivity.
22
 
A major advance toward the development of biologically active foldamers was the identification of a 
chimeric peptide foldamer consisting of N-terminal / segment and a C-terminal -peptide segment, 
which binds to the BH3-recognition cleft of the anti-apoptotic protein Bcl-xL.
29
 The crystal structure of 
the complex with Bcl-xL reveals that the helical foldamer has the same orientation as the natural BH3 
domains. The /-segment adopts a 14/15-helical structure with some cyclic -amino acid residues 
making contacts with the protein surface, thus inhibiting the interaction between Bcl-xL and its 
proapoptotic partner, that can trigger cancer.
30
 
 
2 -  Design, synthesis and conformational analysis of an /-peptide foldamer, containing DKP 
repeating units as secondary structure inducers 
2.1 -  Conception 
As previously mentioned (Chapter 2, §3), the ability of DKP1 to form well-defined folded structures, 
when introduced in peptide sequences had already been studied in our research group.
31
 In particular, 
while inserted in hexapeptides, DKP1 acts as a -hairpin inducer, while oligomers of DKP1 form a -
bend ribbon conformation starting from four units of DKP1. 
As inferred from these evidences, DKP1 results well pre-organized to induce a reverse turn of the 
growing peptide chain, favouring the formation of  regular H-bonding patterns throughout the 
backbone. Thus, the synthesis of longer hybrid peptides containing more than one DKP1 repeating 
units alternated with alpha units might represent an improvement in the study of the behavior of our 
scaffold as a folding inducer. 
 
 
Figure 4.6 
 
Very nice examples of highly pre-organized structures, such as helices, were obtained by the group of 
Reiser alternating two - and two - amino acids. 
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They have in fact just designed unprecedented 9/12/9/10 helical structures featuring the  
sequential motif, by applying the stereochemical patterning approach.
27
 The most representative of the 
9-mers and 13-mers synthesized, which contain cis-ACPC and -amino acid units, is sketched in 
Figure 4.6 (126). Properties and structures characterizing their foldamers were studied by means of 
CD and NMR spectroscopy, subsequent computational structure refinement. In contrast to the 
corresponding foldamers characterized by an , sequential motif, the helices formed tend to be 
very stable also in aqueous solutions. 
Highly contributing to this outcome are also the favorable electrostatic interactions between the side-
chains of -amino acids such as Glu and Lys, as well as the hydrophobic interactions of the ACPC-
rings. It is worth noticing is the behavior of N-terminal -amino acids, which maintain significant 
flexibility.
32
  
Taking advantage of the constrained -dipeptide nature of DKP1 we envisaged the design of a 
foldamer featuring the promising  sequential motif. 
Taking into account the outcome of previous studies, we decided to investigate the synthesis of a 
pseudodecapeptide containing three DKP1 units, two of them at the C- and N- termini, alternated with 
L-Ala-L-Ala units (127, Figure 4.7). 
 
 
Figure 4.7 
 
Although the design of 127 is in accordance with the stereochemical patterning approach, this peptide 
lacks the potential stabilizing electrostatic interactions between -amino acid side chains. As we 
considered MM studies not predictive enough, we decided, on the basis of the already reported results, 
to gather preliminary evidences on DKP1 behavior by preparing and analyzing a simple system. This 
study did not mean to be exhaustive, but, depending on the experimental results, it might represent a 
good starting point for the design of analogous DKP containing systems. 
 
2.2 -  Synthesis 
As the coupling of -amino acids can be challenging,33 a solid-phase synthetic approach, using Fmoc 
chemistry, was adopted. Peptide 127 was built on Rink amide resin from C to N-terminus on a 0.1 
mmol scale, and purified by preparative HPLC after cleavage. 
DKP1* (Figure 4.8), which was chosen as the  building block, was synthesized in solution as 
already described in chapter 2 (§ 4.2.1). This scaffold is bearing a free carboxylic acid function and  an 
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amino function masked as azide. Our diketopiperazine azido acids, and in particular DKP1* (cis), 
were shown to be very sensitive to basic conditions, as the azido moiety is prone to -eliminate, giving 
a dehydroalanine-like derivative. For this reason, neutral carboxylic acid activation conditions were 
used for the synthesis of the linear peptide. Standard DCC/HOBt peptide coupling techniques revealed 
effective for the coupling of DKP1*. Its –OBt activated ester was formed, adding a solution of HOBt 
and DCC in DCM to the carboxylic acid solution in DMF. The white precipitate (DCU) needed to be 
filtered off before adding the activated ester solution to the resin, which was shaken at room 
temperature. Reaction times varied from 3 h to 18 h, depending on the ease of the coupling. 
 
 
Figure 4.8 – DKP1* scaffold, used as the  building block. 
 
Succinimidyl active esters of -amino acids were employed in the synthesis. These kinds of active 
esters are sufficiently stable to be isolated and stored, and still react rapidly in peptide coupling. They 
are prepared treating the free carboxylic acid with DCC in presence of N-hydroxysuccinimide, in THF, 
and once isolated and purified by crystallization, they are merely dissolved and added to the resin. 
 
 
Scheme 4.1 – Epimerization via oxazolone formation. 
 
Notably, the base-free conditions employed during coupling reactions allowed us to think about a 
more convergent synthesis, coupling, in one case, a Fmoc-L-Ala-L-Ala-OSu building block. Even 
though epimerization is a main concern in convergent peptide synthesis, due to the easy formation of 
oxazolones upon activation of the carboxylic acid participating in the amide bond formation (Scheme 
4.1), we were able to avoid this problem. 
The - dipeptide building block was synthesized in solution according to procedures reported in the 
literature, starting from commercially available Fmoc-L-Ala-OH, whose activated succinimidyl ester 
was isolated, and unprotected L-Ala.
34
 A succinimidyl ester of the dipeptide thus obtained was 
prepared (Scheme 4.2). 
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Scheme 4.2 – Reagents and conditions: a) NHS, DCC, THF, 0°C, 20h: 94%; b) H-L-Ala-OH, NaHCO3, acetone/EtOH/water 
1:4:1, 20h: 76%.  
 
A general synthetic scheme is here reported in Scheme 4.3. 
 
 
Scheme 4.3 – SPPS of peptide 127. 
 
Fmoc deprotections were performed treating the resin with either a 20% piperidine solution in DMF, 
or with a milder 2% piperidine, 2% DBU solution in DMF, and washing the resin carefully afterwards. 
Azides were reduced in situ in the presence of Me3P (1 M solution in toluene) in a 4:1 dioxane/water 
solution, in order to obtain a free amine.  
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As the peptide grows (expecially after the sixth amino acid residue), coupling reactions are of course 
becoming more and more challenging. For this reason a step-wise approach was preferred after 
coupling the second diketopiperazine. Fmoc-L-Ala succinimidyl ester was used in two successive 
steps. 
In order to monitor the coupling efficiency after each coupling step a slightly modified Kaiser test was 
performed and non-quantitative steps were repeated. When Kaiser test gave a positive result after the 
third coupling cycle, capping in presence of acetic anhydride and pyridine was performed, thus 
acetylating the amines still free. 
A small cleavage from the resin was performed after the coupling of the -dipeptide, treating a few 
beads with a 90:5:5 mixture of TFA, triisopropylsilane (TIS) and water, to check whether 
epimerization had occurred. LC/MS analysis and 
13
C-NMR confirmed that only one species was 
present. 
After the last coupling/azide reduction step cleavage of the linear peptide from the resin was carried 
out by treating the latter with a solution of TFA, TIS and water (90:5:5) for 2.5 h. The cleaved peptide 
was obtained with a C-terminal amide group that facilitated NMR assignment. 
Subsequently, the peptide was precipitated from cold diethyl ether and dissolved in 10 % acetic acid in 
water. After lyophilization the peptide was purified by reversed phase preparative HPLC (RP-HPLC) 
in order to yield a pure compound, crucial for detailed structure analysis. 
 
2.3 -  Conformational Analysis 
2.3.1 -  Variable temperature measurements 
VT-NMR measurements were carried out in order to get an insight into the backbone H-bonding 
pattern of peptide 127. 
As already mentioned in previous chapters, amide protons chemical shifts, as well as their dependence 
on temperature, may give first hints on the secondary structure. It has been shown that for -peptides 
in water the analysis of temperature coefficients alone is not sufficient for the prediction of secondary 
structure formation. However, supported by lots of data for peptidic foldamers in various solvents 
together with other structural data we believe that the temperature gradients may help analyzing the 
structures of peptidic foldamers.
35
 Temperature coefficients /T (ppb/K) relating to amide protons 
were calculated to detect the presence of hydrogen bonds within the peptide backbone. 
Indeed, protons involved in H-bonding are usually characterized by rather upfield chemical shifts and 
a low dependence on temperature (low negative temperature coefficient values), while downfield 
chemical shifts and high absolute values of the temperature coefficient are indicative of solvent 
exposed amide protons, not involved in hydrogen bonding. Figure 4.9 shows the amide region of the 
1
H-NMR spectra of peptide 127 in dimethylsulfoxide (DMSO-d6) in a temperature range from 290 to 
320 K. 
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Figure 4.9 - Amide region in the 1H-NMR spectra of peptide 127 in DMSO-d6 in a temperature range from 290 to 320 K 
(temperature increases from bottom to top; increment = 10 K). 
 
Herein the changes of chemical shifts with increasing temperature can be observed.  The temperature 
coefficients calculated for peptide 127 in DMSO-d6 are reported in Table 4.3. 
 
Table 4.3 – Variation of backbone 
NH-protons chemical shifts () with 
temperature, and corresponding 
temperature coefficients (T) in 
DMSO-d6 between 290 K to 320 K. 
 
 
 
 
 
T [K] 290 300 310 320 
T [ppb K
-1
]  
Spin system  [ppm] 
  
DKP-1 8.6474 8.6094 8.5708 8.5317 -3.86 
Ala-2 8.3712 8.3465 8.3137 8.2796 -3.05 
Ala-5 8.3712 8.3211 8.2771 8.2328 -4.61 
DKP-4 INTRA 8.3115 8.2576 8.2037 8.1502 -5.38 
DKP-7 INTRA 8.2970 8.2362 8.1756 8.1152 -6.06 
Ala-6 - - - - - 
DKP-4 EXTRA - - - - - 
Ala-3 - - 8.0464 7.9856 -6.08 
DKP-7 EXTRA 8.0792 8.0393 7.9990 7.9583 -4.03 
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Unfortunately, protons NH5 (DKP-4extra), NH8 (Ala-6), and in some extent NH4 (Ala-3) are 
overlapped. Therefore, no temperature coefficients could be calculated for NH5 and NH8, and a non-
relevant value of /T was reported for NH4. Thus little can be said on their tendency to be involved 
in H-bonding. N-terminal (/T = -0.81) and C-terminal (/T = -4.00; -4.83) NH protons are 
usually not taken into account in the prediction of a peptide secondary structure. Figure 4.10 gives a 
visual representation of the temperature coefficients values obtained. 
 
Figure 4.10 - Graphical illustration of 
temperature coefficients (T) for compound 
127  in DMSO-d6 between 290 K and 320 K. 
 
 
 
 
 
 
 
NH3 (Ala-2) displays the lowest /T absolute value. This proton, as well as protons NH2 (DKP-1) 
and NH9 (DKP-7EXTRA), having temperature coefficients in the range between -3 and -4 (ppb/K), may 
be involved in backbone H-bonding. Anyway, no strong H-bonding tendency was detected for 127.. 
 
2.3.2 -  2D NMR measurements 
A detailed NMR solution analysis was performed on peptide 127 in DMSO-d6 to determine its 
structure in solution. For the assignment of the peptide standard homonuclear 2D NMR methods such 
as total correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) as 
well as rotating frame nuclear Overhauser effect spectroscopy (ROESY) were applied.
36
 2D spectra 
were recorded at 310 K, in order to get the best signal resolution for the resonance assignment of the 
protons. Of course, the conspicuous presence of repeating alanine and DKP1 residues did not make it 
an easy issue to unambiguously assign the whole structure.  
Unfortunately only few ROE contacts were clearly detected from the ROESY spectrum, due to the bad 
signal resolution in some regions. The most relevant ROESY crosspeaks are depicted in Figure 4.11. 
 
 
Figure 4.11 – Relevant medium-range ROE contacts. 
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The ROESY crosspeaks, which were found between NH3 and NH4 and between NH7 and NH8 amide 
protons as well as between NH2 and H9A and between NH6 and H9B, are not much contributing to 
the determination of the three-dimentional structure, as they are almost sequential. 
On the other hand, the ROESY crosspeaks between NH5 and H7B and between NH9 and H7C, which 
were highlighted in Figure 4.11 in red and shown in the spectrum in Figure 4.12, may account for a -
turn induced by DKP1, forming a 10-membered H-bonding pattern which involves diketopiperazine 
extracyclic amide proton (NH5, NH9) and extracyclic C(8)=O carbonyl (B, C). The same kind of ROE 
contact was already observed for the DKP1- trimer and tetramer reported in the literature.
31b
  
Not much can instead be inferred on the behavior of the rest of the backbone, as other relevant 
ROESY crosspeaks could not be unambiguously assigned so far. Further studies will be performed. 
 
 
Figure 4.12 – Extract from the ROESY spectrum (grayscale) superimposed to the TOCSY spectrum (red) of peptide 127 in 
DMSO-d6 at 310 K, showing: A) NH5/H7B ROE contact; B) NH9/H7C ROE contact (relevant crosspeaks 
marked with green arrows). 
 
2.3.3 -  CD spectroscopy 
CD spectra of the designed -peptide were recorded between 190 and 280 nm in three different 
solvents, in order to identify regular structures in solution.  
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Figure 4.13 – Superimposed CD spectra of compound 127 recorded in MeOH, TFE and water. 
 
In general, stabilization of secondary structures is higher in organic solvents. For these reason 
methanol was used at first. Trifluoroethanol (TFE) was then used. TFE is in fact known to further 
stabilize peptide secondary structures, removing alternative hydrogen-bonding partners and providing 
a low dielectric environment that favours the formation of intrapeptide hydrogen bonds.
37
 
Additionally, water was tested in order to check the behaviour of 127 under pseudo-physiological 
conditions. 
 
 
Figure 4.14 – Superimposed CD spectra of DKP1-tetramer, trimer,31b and the hairpin peptidomimetic Boc-ValAla-DKP1-
ValAla-NHnBu.31a The data of the latter compound have been multiplied by a factor 10 to magnify the 
appearance of the curve. 
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All CD spectra were normalized to peptide concentration, the number of amide bonds (13), and the 
curves were smoothed (FFT filter 5% cutoff with the Origin 8.0 program). 
In all three cases, two minima around 195-200 nm and around 220 nm as well as a maximum around 
210-215 nm were observed. These results resemble the ones reported in the literature for linear 
peptides containing DKP1 as a template (Figure 4.14).
31
 
Hence, also CD spectroscopy is giving evidence of DKP1 tendency to induce a -turn, and its 
prevailing contribution to the peptide secondary structure. 
 
2.3.4 -  Computational studies 
Having evidences of a regular secondary structure in hands, a preliminary computational study, was 
performed for compound 127 applying the NH5/H7B and NH9/H7C distance restraints derived from 
ROE contacts. Our hypothesis of successive -turns induced by the diketopiperazine scaffolds was 
confirmed by the results of constrained MC/SD simulations (Figure 4.15). Some of the representative 
conformations obtained show a characteristic C=O· ·H-N 10-membered hydrogen bonding pattern 
induced by both the C-terminal and the central DKP. 
Of course, more ROE contacts might have been detected to achieve a more comprehensive result, 
which could take into account also the behavior of the -portions. 
 
 
Figure 4.15 – Representative conformation obtained by 10ns MC/SD (AMBER* force field) restrained simulations. 
 
 
 
 
 
 
 
120  Chapter 4 
References: 
                                                 
[1] a) D. H. Appella, L. A. Christianson, I. L. Karle, D. R. Powell, S. H. Gellman, J. Am. Chem. Soc. 1996, 118, 13071–
13072; b) S. H. Gellman, Acc. Chem. Res. 1998, 31, 173–180. 
[2] M. R. Arkin, J. A. Wells, Nat. Rev. Drug Discov. 2004, 3, 301–317. 
[3] a) D. J. Hill, M. J. Mio, R. B. Prince, T. S. Hughes, J. S. Moore, Chem. Rev. 2001, 101, 3893–4011; b) R. P. Cheng, S. 
H. Gellman, W. F. DeGrado, Chem. Rev. 2001, 101, 3219–323; c) I. Huc, Eur. J. Org. Chem. 2004, 17–29; d) 
Foldamers: Structure, Properties, and Applications, S. Hecht, I. Huc, Eds.; Wiley-VCH: Weinheim, Germany, 2007. 
[4] R. P. Cheng, S. H. Gellman, W. F. DeGrado, Chem. Rev. 2001, 101, 3219-3232. 
[5] D. Seebach, J. Gardiner, Acc. Chem. Res. 2008, 41, 1366-75. 
[6] a) D. Seebach, A. K. Beck, D. J. Bierbaum, Chem. Biodev. 2004, 1, 1111; b) G. V. M. Sharma, K. R. Reddy, P. R. 
Krishna, A. R. Sankar, K. Narsimulu, S. K. Kumar, P. Jayaprakash, B. Jagannadh, A. C. Kunwar, J. Am. Chem. Soc. 
2003, 125, 13670. 
[7] P. Le Grel, A. Salaun, M. Potel, B. Le Grel, F. Lassagne, J. Org. Chem. 2006, 71, 5638. 
[8] V. Semetey, D. Rognan, C. Hemmerlin, R. Graff, J. P. Briand, M. Marraud, G. Guichard, Angew. Chem. Int. Ed. 2002, 
41, 1893. 
[9] L. K. A. Pilsl, O. Reiser, Amino acids 2011, 41, 709-718. 
[10] W. S. Horne, S. H. Gellman, Acc. Chem. Res. 2008, 1399-1408. 
[11] P. G. Vasudev, S. Chatterjee, N. Shamala, P. Balaram, Chem. Rev. 2011, 111, 657-87.  
[12] “FOLDAMERS: FROM DESIGN TO PROTEIN RECOGNITION”, 
http://foldamer.org/files/book_of_abstract_foldamers2010.pdf (20.12.2011) 
[13] B. R. Huck, J. D. Fisk, S. H Gellman, Org. Lett. 2000, 2, 2607–2610. 
[14] a) S. Krauthäuser, L. A. Christianson, D. R. Powell, S. H. Gellman, J. Am. Chem. Soc. 1997, 119, 11719–11720; b) H. 
N. Gopi, R. S. Roy, S. R. Raghothama, I. L. Karle, P. Balaram, Helv. Chim. Acta 2002, 85, 3313–3330. 
[15] S. De Pol, C. Zorn, C. D. Klein, O. Zerbe, O. Reiser, Angew. Chem. Int. Ed. 2004, 43, 511–514. 
[16] A. Hayen, M. A. Schmitt, F. N. Ngassa, K. A. Thomasson, S. H. Gellman, Angew. Chem. Int. Ed. 2004, 43, 505–510. 
[17] N. Koglin, C. Zorn, R. Beumer, C. Cabrele, C. Bubert, N. Sewald, O. Reiser, A. G. Beck-Sickinger, Angew. Chem. Int. 
Ed. 2003, 42, 202–205. 
[18] K. A. Bolin, G. L. Millhauser, Acc. Chem. Res. 1999, 32, 1027–1033. 
[19] a) G. V. M. Sharma, P. Nagendar, P. Jayaprakash, P. R.Krishna, K. V. S. Ramakrishna, A. C. Kunwar, Angew. Chem., 
Int. Ed. 2005, 44, 5878–5882; b) G. Srinivasulu, S. K. Kumar, G. V. M. Sharma, A. C. Kunwar, J. Org. Chem. 2006, 
71, 8395–8400. 
[20] D. Seebach, B. Jaun, R. Sebesta, R. I. Mathad, O. Flögel, M. Limbach, H. Sellner, S. Cottens, Helv. Chim. Acta 2006, 
89, 1801–1825. 
[21] M. A. Schmitt, S. H. Choi, I. A. Guzei, S. H. Gellman, J. Am. Chem. Soc. 2006, 128, 4538–4539. 
[22] G. Guichard, I. Huc, Chem. Commun. 2011, 47, 5933-5941. 
[23] R. S. Lokey, B. L. Iverson, Nature 1995, 375, 303. 
[24] J. Brüggemann, S. Bitter, S. Müller, W. M. Müller, U. Müller, N. M. Maier, W. Lindner, F. Vögtle, Angew. Chem. Int. 
Ed. 2007, 46, 254. 
[25] C. A. Hunter, A. Spitaleri, S. Tomas, Chem. Commun., 2005, 3691. 
[26] a) N. Delsuc, F. Godde, B. Kauffmann, J.-M. Léger, I. Huc, J. Am. Chem. Soc. 2007, 129, 11348; b) D. Seebach, S. 
Abele, K. Gademann, G. Guichard, T. Hintermann, B. Jaun, J. Mathews, J. V. Schreiber, Helv. Chim. Acta 1998, 81, 
932. 
Chapter 4  121 
                                                                                                                                                        
[27] a) A. Hetényi, Z. Szakonyi, I. M. Mándity, E. Szolnoki, G. K. Tóth, T. a Martinek, F. Fülöp, Chem. Commun. 2009, 
177-179; b) I. M. Mándity, E. Wéber, T. A. Martinek, G. Olajos, G. K. Tóth, E. Vass, F. Fülöp, Angew. Chem. Int. Ed. 
2009, 48, 2171-2175. 
[28] W. S. Horne, L. M. Johnson, T. J. Ketas, P. J. Klasse, M. Lu, J. P. Moore, S. H. Gellman, Proc. Natl. Acad. Sci. U. S. A. 
2009, 106, 14751. 
[29] a) J. D. Sadowsky, M. A. Schmitt, H.-S. Lee, N. Umezawa, S. Wang, Y. Tomita, S. H. Gellman, J. Am. Chem. Soc. 
2005, 127, 11966–11968; b) J. D. Sadowsky, W. D. Fairlie, E. B. Hadley, H.-S. Lee, N. Umezawa, Z. Nikolovska-
Coleska, S. Wang, D. C. S. Huang, Y. Tomita, S. H. Gellman J. Am. Chem. Soc. 2007, 129, 139–154; c) J. D. 
Sadowsky, J. K. Murray, Y. Tomita, S. H. Gellman, ChemBioChem 2007, 8, 903–916. 
[30] a) E. F. Lee, J. D. Sadowsky, B. J. Smith, P. E. Czabotar, K. J. Peterson-Kaufman, P. M. Colman, S. H. Gellman, W. D. 
Fairlie, Angew. Chem. Int. Ed. 2009, 48, 4318–4322; b) B. Baptiste, G. Godde, I. Huc, ChemBioChem 2009, 10, 1765–
1767. 
[31] a) A. S. M. Ressurreição, A. Bordessa, M. Civera, L. Belvisi, C. Gennari, U. Piarulli, J. Org. Chem. 2008, 73, 652-660; 
b) R. Delatouche, M. Durini, M. Civera, L. Belvisi, U. Piarulli, Tetrahedron Lett. 2010, 51, 4278-4280. 
[32] L. Berlicki, L. Pilsl, E. Wéber, I. M. Mándity, C. Cabrele, T. A. Martinek, F. Fülöp, O. Reiser, Angew. Chem. Int. Ed., 
in press.  
[33] C. Zorn, F. Gnad, S. Salmen, T. Herpin, O. Reiser, Tetrahedron Lett. 2001, 42, 7049-7053. 
[34] a) G. Sosnovsky, M. Baysal, E. Erciyas, J. Pharm. Sci. 1994, 83, 999–1005; b) Y. Zhang, H. Gu, Z. Yang, B. Xu, J. 
Am. Chem. Soc. 2003, 125, 13680-13681. 
[35] It has been shown that for -peptides in water the analysis of temperature coefficients alone is not sufficient for the 
prediction of secondary structure formation. However, supported by lots of data for peptidic foldamers in various 
solvents together with other structural data we believe that the temperature gradients may help analyzing the structures 
of peptidic foldamers: N. H. Andersen, J. W. Neidigh, S. M. Harris, G. M. Lee, Z. Liu, H. Tong J. Am. Chem. Soc. 
1997, 119, 8547–8561. 
[36] For compounds with a molecular weight of about 1000 Da, NOE crosspeak intensities in NOESY spectra can be very 
low, therefore ROESY spectra are the better alternative in this case. 
[37] a) A. Kentsis, T. R. Sosnick, Biochem. 1998, 37, 14613-14622;  b) D. Roccatano, G. Colombo, M. Fioroni, A. E. Mark, 
Proc. Nat. Ac. Sci. U.S.A. 2002, 99, 12179–12184. 
 
 5 CONCLUSIONS 5  
 
 
Diketopiperazines (DKPs) are the smallest, simplest cyclic peptides known, being derived from the 
cyclization of a dipeptide. They are very easily synthesized, and in several cases the cyclization occurs 
from the dipeptide as an undesired side reaction.
1
 Diketopiperazines are simple heterocyclic scaffolds 
in which diversity can be introduced at up to four positions (N1, N4, C3, C6) and stereochemically 
controlled at two (C3, C6). Constraining the nitrogen atom of an -amino amide into a DKP ring alters 
its physical properties, reduces the susceptibility to metabolic amide bond cleavage and induces 
conformational rigidity. These changes in structural and physical properties, as well as the presence of 
groups that can act as donors and acceptors of hydrogen bonds enhance favorable interactions with 
biological targets. For all these reasons, diketopiperazines have recently been considered privileged 
structures for drug discovery, useful scaffolds for peptidomimetics and also interesting candidates as 
organocatalysts.
2
 
A library of 11 bifunctional 2,5-diketopiperazine scaffolds (DKP1-DKP8, DKP1*-DKP3*), derived 
from L- or D-Ser and either L- or D-Asp (DKP1-DKP7, DKP1*-DKP3*) or D-Glu (DKP8), was 
designed and prepared. All the scaffolds feature a carboxylic acid functionality and an amino moiety, 
either protected as Boc (DKP1-DKP8) or masked as azide (DKP1*-DKP3*), which can be locked in 
a cis- (DKP1, DKP1*) or trans-relationship (DKP2-DKP8, DKP2*-DKP3*) as a consequence of the 
absolute configurations of the two -amino acids. Moreover, the DKP scaffolds differ each from the 
other for the substitution at the intracyclic nitrogens (N-1, N-4), as they are either mono (DKP1-
DKP4, DKP6, DKP8, DKP1*-DKP3*) or bis-benzylated (DKP5, DKP7). While being derived from 
-amino acids, they can be seen as a constrained dipeptide formed by two - or a - and a -amino 
acids. 
Two different synthetic strategies were devised to obtain the mono-benzylated scaffolds, depending on 
the nitrogen substitution. In particular, the synthesis of DKP1-DKP3, DKP1*-DKP3* and DKP8 
(bearing a benzyl group at nitrogen N-4, derived from serine) was realized making use of the serine 
ligation strategy.
3
 Selective O-acylation of the unprotected -hydroxy group of N-benzylserine methyl 
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ester is preferred to the formation of the tertiary amide during the coupling reaction with the 
appropriate N-Boc protected amino acid.  The resulting isopeptide is stable in solution to O,N-acyl 
transfer. 
O,N-acyl migration was triggered by cleavage of the Boc protecting group and treatment of the 
corresponding trifluoroacetate salt in a polar protic solvent with a base, which also promotes 
immediate cyclization to diketopiperazine. The nitrogen functionality was introduced, in these cases, 
with a Mitsunobu-type reaction in presence of hydrazoic acid, thus affording an azide. 
On the other hand, the synthesis of DKP4 and DKP6 (bearing a benzyl group at nitrogen N-1, aspartic 
acid derived) occurred via dipeptide, without formation of a isopeptide intermediate. The -hydroxy 
group of serine was converted into azide with a Mitsunobu-type reaction prior to the formation of the 
symmetric anhydride, which was used in the coupling with a N-benzyl dimethyl aspartate derivative. 
Bis N-benzyl substituted scaffolds (DKP5, DKP7) could be easily accessed benzylating mono-
substituted advanced intermediates. 
The 11 scaffolds of the prepared library were used as templates in the synthesis of cyclic integrin 
ligands containing either the RGD- or the isoDGR recognition sequences, and in the preparation of a 
linear -decapeptide, whose folding properties were studied. 
Integrins are transmembrane heterodimeric cell adhesion receptors, consisting of an - and a -
subunit, involved in many fundamental  processes, such as cell growth, cell division, cell survival, 
cellular differentiation, apoptosis. As a consequence, integrin malfunction is connected to a large 
variety of diseases (e.g. thrombosis, cancer, osteoporosis, inflammation), and integrins themselves 
represent attractive targets for pharmacological research. 
Of the 24 different heterodimers known, the RGD-binding integrins V3, V5, 51 are key-factors 
of angiogenesis, i.e. the formation and maturation of new blood vessels. A small localized tumor 
releases angiogenic growth factors, promoting the generation of abnormal blood vessels which can 
feed the tumor. Hence, angiogenesis plays a pivotal role in tumor growth and metastatic spreading. 
 
Particular integrins are able to selectively bind different spatial presentations of a single binding motif 
(RGD) in multiple ECM proteins. Therefore, synthetic RGD-ligands can bind and inhibit endogenous-
ligand-binding to integrins with an RGD-recognition specificity (V3, V5, 51), thus significantly 
inhibiting angiogenesis, tumor growth and metastasis. 
 
An efficient synthesis in solution of constrained peptides (47, 48,
4
 102-107) containing the Arg-Gly-
Asp (RGD) motif and diketopiperazine scaffolds DKP1-DKP8 was developed and optimized. 
Notably, two different separable conformers (diastereomers) formed during the cyclization of 
compound 106, containing bis-benzylated scaffold DKP7, due to hindered rotation of  one ring around 
the other. 
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Ligands 47, 48, 102-107 were tested for their ability to inhibit biotinylated vitronectin binding to αvβ3 
and αvβ5 receptors. All the ligands, except for the one containing a cis-scaffold, displayed low 
nanomolar affinity for both αVβ3 and αVβ5 integrins, with a slight selectivity towards the former 
receptor. Interestingly, the two diastereomeric compounds showing atropoisomerism (106 A, 106 B) 
are the most and the least selective and potent of the series. 
Our ligands were fully characterized by NMR spectroscopy, detecting both H-bondings and long-
range NOE contacts. Moreover, three-dimensional structures satisfying long-range NOE contacts were 
generated by restrained simulations. Five different H-bonding patterns were observed for our ligands 
on the basis of the conformational analysis, each one featuring at least a -turn motif. A C (Asp)-C  
(Arg) distance of around 9 Å was detected from the structures obtained by restrained MC/SD 
simulations for the ligands displaying good affinity towards αVβ3 and αVβ5 integrins, while shorter 
distances were observed for the cis compound (47). Hence, a distance of ca. 9 Å, which accounts for 
an extended arrangement of the RGD motif, may be relevant for a positive binding to integrin. The 
extended arrangement of the RGD sequence in Cilengitide (85, C(Arg)-C(Asp) = 8.9 Å), one of the 
most potent compounds of this class, whose crystal structure in the bound conformation is known, 
corroborates this assumption. In order to rationalize, on a molecular basis, the affinity of cyclic RGD 
peptidomimetics for the v3 receptor, docking studies were performed starting from the 
representative conformations obtained from the MC/SD simulations. The crystal structure of the 
extracellular segment of integrin v3 complexed with the cyclic pentapeptide Cilengitide (1L5G, pdb 
code) was taken as a reference model for the interpretation of the docking results in terms of ligand-
protein interactions. In most of the cases the electrostatic clamp interactions of the pharmacophoric 
groups were maintained; moreover, further stabilizing interactions were observed in the case of higher 
affinity compounds. 
 
Besides the well defined RGD motif, it was proposed that also the isoDGR sequence might be 
involved in integrin recognition. In fact, isoDGR sequence can mimic RGD and interact with RGD 
binding site of integrins (such as v3, v5 and 51) in an inverted orientation, maintaining all the 
typical electrostatic-clamp interactions of the RGD motif and presenting additional stabilizing 
interactions. Hence, two constrained peptides (118-119) containing the isoAsp-Gly-Arg (isoDGR) 
motif and diketopiperazine scaffolds DKP2*-DKP3* were prepared, combining a solid phase and an 
homogeneous synthetic approach. Very promising results (low nanomolar) were obtained for their 
ability to inhibit biotinylated vitronectin binding to αvβ3 and αvβ5 receptors. 
 
As part of my project, I spent six months (October 2010 – March 2011) in the group of Prof. Oliver 
Reiser at the University of Regensburg, working on the design of -peptide foldamers, containing 
diketopiperazine repeating units as secondary structure inducers. 
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Foldamers were defined by Gellman as “any polymer with strong tendency to adopt a specific 
compact conformation”. Major advances have been made in the last decades, showing the ability of 
foldamers to adopt specific conformations able to mimic biopolymer-like functions. Thus, they have 
been used with success in the inhibition of protein protein interactions. In particular, protein surface 
recognition by mimicking distinct folding patterns along with proteolytic stability is the main 
advantage of foldamers compared to -peptides or small drug molecules. 
On the wake of the good results recently obtained by the group of Reiser in the design of helices,5 
alternating 2 - and 2 -amino acids, a linear decapeptide (127) was prepared alternating DKP1*, 
which serves as a -constrained dipeptide, and Ala-Ala, as the -subunit. 
A conformational analysis was performed with NMR spectroscopy, CD spectroscopy and 
computational methods. The results obtained, though not exhaustive, are indicative of a turn inducing 
ability of DKP1, that had already been reported in the literature.
6
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1 -  General remarks and procedures 
MATERIALS AND METHODS: All manipulations requiring anhydrous conditions were carried out 
in flame-dried glassware, with magnetic stirring and under a nitrogen atmosphere. All commercially 
available reagents were used as received. Anhydrous solvents were purchased from commercial 
sources and withdrawn from the container by syringe, under a slight positive pressure of nitrogen. (S)-
and-(R)-serine methyl ester hydrochloride,
1
 (S)-N-benzylserine methyl ester,
2
 (2R)-aspartic acid β-allyl 
ester hydrochloride,
3
 N-(tert-butoxycarbonyl)-(2R)-aspartic acid β-allyl ester,3 (S)-and-(R)-N-Boc-
serine methyl ester,
4
 (S)-and-(R)-methyl 3-azido-2-(tert-butoxycarbonylamino)propanoate,
5
 (S)-and-
(R)-3-azido-2-(tert-butoxycarbonylamino) propanoic acid,
5
 (S)-and-(R)-dimethyl aspartate 
hydrochloride,
6
 (S)-and-(R)-N-benzyl-dimethyl aspartate,
7
 -methyl glutamate hydrochloride8 and N-
Boc-glycine benzyl ester
9
 were prepared according to literature procedures and their analytical data 
were in agreement with those already published. The reactions were monitored by analytical thin-layer 
chromatography (TLC) using silica gel 60 F254 pre-coated glass plates (0.25 mm thickness). 
Visualization was accomplished by  
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution or 
ninhydrin. Flash column chromatography was performed according to the method of Still and co-
workers
10
 using Chromagel 60 ACC (40-63 µm) silica gel. Melting points were obtained in an open 
capillary apparatus and are uncorrected. Proton NMR spectra were recorded on a spectrometer 
operating at 400.16 MHz. Proton chemical shifts are reported in ppm (δ) with the solvent reference 
relative to tetramethylsilane (TMS) employed as the internal standard. The following abbreviations are 
used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = 
broad signal, dd = doublet of doublet. Carbon NMR spectra were recorded on a spectrometer operating 
at 100.63 MHz, with complete proton decoupling. Carbon chemical shifts are reported in  ppm (δ) 
relative to TMS with the respective solvent resonance as the internal standard. Infrared spectra were 
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recorded on a standard FT-IR. Optical rotation values were measured on an automatic polarimeter with 
a 1 dm cell at the sodium D line and are given in units of 10
-1 
deg cm
2
 g
-1
. High resolution mass 
spectra (HRMS) were performed on a  Fourier Transform Ion Cyclotron  Resonance (FT-ICR) Mass 
Spectrometer APEX II & Xmass software (Bruker Daltonics) – 4.7 T Magnet (Magnex) equipped with 
ESI source, available at CIGA (Centro Interdipartimentale Grandi Apparecchiature) c/o Università 
degli Studi di Milano. Low resolution mass spectra (MS) were recorded on Waters Acquity UPLC-MS 
(ESI ion source). 
Circular dichroism (CD) spectra were measured on a JASCO J-710/720 spectrometer at the Institute of 
Analytical Chemistry at the University of Regensburg at room temperature between 180 and 350 nm 
in the specified solvents. The length of the cylindrical cuvettes was 0.2 mm and of the rectangular 
cuvettes was 1.0 mm. The resolution was 0.2 nm, the band width 1.0 nm, the sensitivity 100 mdeg, the 
response 0.25 s and the speed 20 nm/min. The background was subtracted for each spectrum. The 
absorption values were measured as molar ellipticies (deg cm
2
 dmol
-1
) and normalized to unit 
chromophore (number of residues). 
 
GENERAL PROCEDURES: 
In solution: 
GENERAL PROCEDURE FOR Boc-DEPROTECTION REACTIONS: 
GP1: To a solution of the N-Boc-protected  amino acid or peptide in CH2Cl2 (0.13 M) was added half 
volume of TFA. The reaction mixture was stirred at for 2 h r.t. and then concentrated at reduced 
pressure. The excess TFA was azeotropically removed from the residue with toluene. Diethyl ether 
was added to the residue and the resulting suspension was evaporated under reduced pressure to afford 
the corresponding TFA salt.  
GENERAL PROCEDURE FOR COUPLING REACTIONS: 
GP2: To a solution of the N-protected amino acid in DMF, under nitrogen atmosphere and at 0 ºC, 
HATU (1.2 eq.), HOAt (1.2 eq.) and DIPEA (4 eq.) were added successively. After 30 min, a solution 
of the N-deprotected TFA salt of the peptide in DMF was added and the reaction mixture was stirred at 
0 ºC for 1 h and at r.t. overnight. The mixture was afterwards diluted with EtOAc and consecutively 
washed with 1 M KHSO4 (2×), aqueous NaHCO3 (2×) and brine (2×), and dried over Na2SO4. 
Volatiles were evaporated under reduced pressure to afford the crude product. 
 
GENERAL PROCEDURE FOR Cbz AND OBn HYDROGENOLYTIC CLEAVAGE:  
GP3: protected compound (1 eq.) was dissolved in a mixture of THF/H2O (1:1) and Pd/C 10% (0.1 
eq.) was added. The reaction mixtures were subjected to three vacuum/hydrogen cycles and then left 
stirring overnight at room temperature under 1 bar of hydrogen. The mixture was filtered through 
Celite, and the cake thus obtained was washed thoroughly with THF/H2O (1:1). The filtrate was 
concentrated and dried to give the crude product as white solid (100%). 
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GENERAL PROCEDURE FOR MACROLACTAMIZATION: 
GP4: to a 1.4 mM solution of deprotected linear compound (1 eq.) in DMF, under nitrogen 
atmosphere and at 0 ºC, HATU (4 eq.), HOAt (4 eq.) and DIPEA (6 eq.) were added successively. 
After stirring the reaction mixture at 0 ºC for 1 h, it was allowed to reach r.t., and stirred overnight. 
DMF was then removed under reduced pressure and the residue was purified by flash chromatography 
on silica gel to afford the product as white foam (31-74%). 
GENERAL PROCEDURE FOR Mtr AND OtBu ESTER REMOVAL: 
GP5: protected macrolactams was treated with TFA (0.01 M solution), in the presence of ion 
scavengers: thioanisole (5%), ethanedithiol (3%), anisole (2%). After TFA removal, under reduced 
pressure, the residue was dissolved in a 1:1 mixture of diisopropyl ether/water. Phases were separated 
and the aqueous layer was washed several times with diisopropyl ether. The aqueous phase was 
concentrated under reduced pressure to give the crude product, which was purified by HPLC to give 
the desired compound as white solid (60-80%). 
 
Solid phase peptide synthesis: 
Fmoc DEPROTECTION: 
GP 6: The washed and swollen resin was treated twice with a solution of piperidine (20%) in DMF 
(v/v), 5 min and 15 min, respectively and washed with DMF (5x), DCM (5x), and again DMF (4x). 
GP 7: The washed and swollen resin was treated twice with a solution of piperidine (2%) and DBU 
(2%) in DMF (v/v), 5 min and 15 min, respectively and washed with DMF (5x), DCM (5x), and again 
DMF (4x). 
AZIDE REDUCTION: 
GP 8: Azidopeptidyl resin (0.1 mmol, 1 eq.) was suspended in a 4:1 mixture of dioxane/water. 
Trimethylphosphine (1M solution in toluene, 0.6 ml, 0.6 mmol, 6 eq.) was added and the reaction 
vessel was shaken for 40 min. The resin was washed with dioxane (3x). 
CAPPING 
GP9: Acetic anhydride (50 eq.) and pyridine (50 eq.) were dissolved in DMF (1M) and added to the 
washed peptidyl resin, which was shaken for 30 min. at r.t.. The solution was sucked away, and the 
resin was washed in the order with DMF (4x) and iPrOH (3x). Kaiser test was performed before 
proceeding to the next step. 
GP10: A 2M solution of acetic anhydride in DMF (1M) was added to the washed peptidyl resin, 
which was shaken for 20 min. at r.t.. The solution was sucked away, and the resin was washed in the 
order with DMF (4x) and iPrOH (3x). Kaiser test was performed before proceeding to the next step. 
KAISER TEST: 
Phenol (80% solution in ethanol), ninhydrin (6% solution in ethanol) and pyridine (two drops each) 
were added to a small sample of the resin and then heated in a boiling water bath for 60 s. If the color 
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of the solution maintained yellow, quantitative coupling was achieved. In the case of a slight blue 
color the coupling step was not fully completed and had to be repeated. 
 
2 -  Synthesis of diketopiperazine scaffolds DKP1-DKP8 and DKP1*-DKP3* 
Preparation of hydrazoic acid  
      
In a three-necked flask were dissolved 3 g of NaN3 in 3 ml H2O. Once totally diluted,  20 ml  of  
toluene  were  added  and  the  reaction  flask  was  put  in  an  ice  bath  under  vigorous stirring. 
When  the solution was at 0°C, 1.2 ml of concentrated H2SO4 were  added extremely slowly  in order 
not  to exceed 10°C for  the solution temperature. The  reaction was let one hour at 0°C and was then 
filtered on cotton wool. The salt residue was washed  twice with more  toluene. The  toluene  solution 
was  titrated by diluting 1 ml of the toluene solution in distilled water in a total volume of 50 ml. 
Titration was accomplished by addition of 0.1 M NaOH controlled with a pH meter allowing  to 
calculate  the  HN3  concentration  in  the  mother  solution  when  the  equivalence  volume  was  
reached. 
 
2.1 -  DKP1-DKP3 and DKP1*-DKP3* 
(R)- and (S)--allyl aspartic acid hydrochloride (50) 
 
In a round bottom flask cooled at 0°C were diluted 5 g (37.57 mmol) of L- or D- aspartic acid in 45 mL 
of allylic alcohol. Acetyl chloride (10.4 mL, 146.5 mmol, 3.9 eq.) were then slowly added dropwise 
with a dropping funnel into the reaction mixture. Once the addition was finished, the reaction flask 
was removed from the ice bath and let react at room temperature for 18 h. The reaction mixture was 
diluted in Et2O making the product precipitate entirely. The salt was filtered through a glass filter and 
washed twice with more Et2O. The salt was recovered and dried under vacuum affording 5.94 g (80%) 
of the monoallylated aspartic acid hydrochloride white solide. 
[]D20=+22.7 (S-; MeOH, c=1.00); mp: 181 - 183 °C. litt. = 184 - 185 °C; 1H NMR (400 MHz, D2O) 
 5.96-5.86 (m, 1H, H6), 5.33-5.23 (m, 2H, H7), 4.64 (d, J=5.74 Hz, 2H, H5), 4.37-4.34 (m, 1H, H2), 
3.14-3.08 (dd, J1=4.8 Hz, J2=18.4 Hz, 2H, H3); 
13
C NMR (101 MHz, D2O)  171.5 (C=O), 171.2 
(C=O), 131.8 (C6), 119.3 (C7), 67.1 (C5), 49.7 (C2), 34.4 (C3); IR (cm
-1
): 3437, 2913, 1742, 1726, 
1505, 1227, 1206. 
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N-Boc-(R)- and (S)--allyl aspartic acid (51) 
 
In a round bottom flask were solved 5.9 g (28.14 mmol) of either (R)- or (S)- allyl aspartic acid 
hydrochloride 50 in 120 mL of THF/water 1:1 solution. The reaction flask was lowered into an ice 
bath and 11.77 mL (84.42 mmol, 3 eq.) of triethylamine were added. Then, 7.37 g (33.77 mmol, 1.2 
eq.) of Boc2O were added and the reaction was stirred at room temperature for 24 h. The reaction 
mixture was then diluted with 200 mL of EtOAc and washed with aqueous KHSO4 1M until pH = 3 
and brine. The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The product was then dried under high vacuum for a few hours affording 7.38 g (96%) of the 
pure expected product as viscous transparent oil. 
Rf=0.1 (EtOAc 100%); []D20=+33.3 (S-, CHCl3, c=1.00); 
1
H NMR (400 MHz, CDCl3)  9,90 (bs, 
1H, OH), 5.94-5.86 (m, 1H, H6), 5.57 (d, J=8.4, 1H, NH), 5.19-5.32 (m, 2H, H7), 4.52- 4.60 (m, 3H, 
H2, H5), 3.07 (dd, J1=4.2 Hz, J2=17.2 Hz, 1H, H3a), 2.89 (dd, J1=4.8Hz, J2=17.1 Hz, 1H, H3b), 1.46 
(s, 9H, tBu); 
13
C NMR (101 MHz, CDCl3)  176.0 (C=O), 171.2 (C=O), 156.0 (C=O), 132.0 (C6), 
119.1 (C7), 80.9 (C(CH3)3), 66.2 (C5), 50.2 (C2), 36.9 (C3), 28.7 (C(CH3)3); IR (cm
-1
): 3331, 2980, 
1732, 1504, 1385, 1163. 
 
(S)- and (R)-serine methyl ester hydrochloride (52) 
 
In a round bottom flask at 0°C were dissolved 6 g (57.09 mmol) of L- or D-serine in 45mL MeOH. 
Acetyl chloride (16.2 mL, 228 mmol, 4 eq.) was added dropwise in the reaction mixture. Once the 
addition was finished, the reaction flask was equipped with a condenser and the mixture was heated to 
reflux. After 2.5 h reflux was then stopped and the flask was cooled to room temperature. 200 mL of 
Et2O were added provoking the precipitation of the resulting salt which was filtered on a glass funnel 
and dried under high vacuum affording 8.79 g (99%) of serine methyl ester hydrochloride as a white 
solid. 
mp: 162-164 °C; []D20=+3.98 (S-,MeOH, c=1.00); 1H NMR (400 MHz, D2O)  4.25 (t, J=3.8 Hz, 
1H, H2 ), 4.08 (dd, J1=4.3 Hz, J2=12.6 Hz, 1H, H3a), 3.98 (dd, J1=3.4 Hz, J2=12.6 Hz, 1H, H3b), 3.83 
(s, 3H, OCH3); 
13
C NMR (101 MHz, D2O)  169.3 (C=O), 59.6 (C3), 55.1 (C2), 54.1 (OCH3); S: IR 
(cm
-1
): 3358, 2928, 1750, 1595, 1510, 1260, 1095, 1040; R: IR (cm
-1
): 3366, 2924, 1748, 1595, 1508, 
1256, 1094, 1036. 
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(S)- and (R)-N-benzyl-serine methyl ester (53) 
 
6 g (38.6 mmol) of S- or R- serine methylester hydrochloride 52 were dissolved in 90 mL MeOH, and 
the mixture was cooled to -10°C. 9.4 mL of iPr2EtN (54.0 mmol, 1.4 eq.) and 0,79 mL (7.71 mmol, 
1eq.) of freshly distilled benzaldehyde were successively added dropwise. The reaction was stirred for 
4 hours at r.t.. The temperature was then lowered again to -10°C and 2.9 g (76.6 mmol, 2eq.) of 
NaBH4 were added portionwise over 30 min. The reaction mixture was again let react for half an hour, 
then, reaction was quenched by adding at low temperature HCl 4 M until no more gas formation was 
observed. The mixture was washed 3 times with Et2O. The organic phases were combined and 
extracted with HCl 4 M twice. The aqueous phases were then combined and neutralized by careful 
addition of saturated NaHCO3 solution until a pH=8 was reached. The aqueous phase was then 
extracted 4 times with Et2O. The organic phase was separated and dried over Na2SO4, filtered, 
concentrated under reduced pressure and dried under vacuum affording 7.35 g (91%) of benzyl serine 
methyl ester as transparent oil. 
Rf=0.2 (EtOAc/ hexane 1:1); []20=+39.4 (R-; CHCl3, c=1.00); 
1
H NMR (400 MHz, CDCl3)  7.38 – 
7.26 (m, 5H, C6H5), 3.91 (d, J = 13.0, 1H, CH2Ph), 3.82 (dd, J = 4.4, 10.9, 1H, H3), 3.77 (m, 4H, 
CH2Ph, OCH3), 3.66 (dd, J = 6.2, 10.8, 1H, H3), 3.46 (dd, J = 4.5, 6.1, 1H, H2), 2.78 (s, 1H, OH); 
13
C 
NMR (101 MHz, CDCl3)  173.6 (C=O), 139.3 (C6H5 quat), 129.0 (C6H5), 128.8 (C6H5), 127.8(C6H5), 
62.8 (C3), 62.2 (C2), 52.6 (OCH3), 52.4 (CH2Ph); S: IR (cm -1): 3320, 2951, 1736, 1454, 1202, 1142, 
1057; R: IR (cm -1): 3320, 2951, 1738, 1202, 1142, 1057. 
 
4-allyl 1-[2-(benzylamino)-3-methoxy-3-oxopropyl] N-(tert-butoxycarbonyl)-aspartate (55 a-c)
 
To a solution of either (R)- or (S)-N-benzylserine methyl ester 53 (734 mg, 3.51 mmol, 1 eq.) and 
EDC·HCl (3.4 g, 17.6 mmol, 5 eq.) in dry CH2Cl2 (20 ml) at 0°C under a N2 atmosphere, β-allyl (2R)- 
or (2S)-N-(tert-butoxycarbonyl) aspartate ester 51 (1.92 g, 7.01 mmol, 2 eq.) was added as a solution 
in CH2Cl2. After 30 min, DMAP (214 mg, 1.76 mmol, 0.5 eq.) was added in one portion. The mixture 
was stirred at 0°C  for 2 h and for additional 4 h at r.t.. The resulting mixture was diluted with EtOAc 
(70 ml) and washed with KHSO4 1M aqueous solution (2x40 ml), aqueous NaHCO3 (2x40 ml) and 
brine (2x40 ml), dried over Na2SO4, and volatiles were removed under reduced pressure. The residue 
was purified by flash chromatography on silica gel (Hexane/EtOAc, 7:3) to afford the desired product 
as a transparent oil (1.54 g, 94%). 
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Rf=0.30 (Hexane/EtOAc 6:4); 
a) []D20=-2.65 (c=1.00, CHCl3); 
1
H NMR (400 MHz, CDCl3)  7.24-7.34 (m, 5H, C6H5), 5.83-5.93 
(m, 1H, H9), 5.48 (d, J = 8.5 Hz, 1H, NHBoc), 5.30 (d, J = 17.2 Hz, 1H, H10a), 5.23 (d, J = 10.4 Hz, 
1H, H10b), 4.51-4.61 (m, 3H, H2, H8), 4.32-4.48 (m, 2H, H7), 3.88 (d, J = 13.1 Hz, 1H, CH2Ph), 3.75 
(s, 3H, OCH3), 3.73 (d, J = 13.1 Hz, 1H, CH2Ph), 3.55 (t, J = 4.7 Hz, 1H, H6), 2.99 (dd, J1 = 17.0 
Hz, J2=4.3 Hz, 1H, H3a), 2.85 (dd, J1=17.0 Hz, J2=4.7 Hz, 1H, H3b), 2.21 (bs, 1H, OH), 1.45 (s, 9H, 
C(CH3)3); 
13
C NMR (101 MHz, CDCl3)  172.8 (C=O), 171.0 (2C=O), 155.7 (COBoc), 139.6 
(C6H5 - quat), 132.1 (C9), 128.9 (C6H5), 128.7 (C6H5), 127.6 (C6H5), 119.1 (C10), 80.6 (C(CH3)3), 
66.2 (C8), 66.1 (C7), 59.5 (C6), 52.7 (C2), 52.2 (CH2Ph), 50.3 (OCH3), 37.1 (C3), 28.7 (C(CH3)3); IR 
(cm
-1
): 3358, 2928, 1738, 1500, 1454, 1385, 1163, 1053. 
b) []D20=+11 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CDCl3)  7.26-7.34 (m, 5H, C6H5), 5.83-5.93 
(m, 1H, H9), 5.47 (d, J = 8.4, 1H, NHBoc), 5.32 (d, J = 17.2, 1H, H10a), 5.25 (d, J = 10.5, 1H, H10b), 
4.66 – 4.52 (m, 3H, H2, H8), 4.46 (dd, J = 4.6, 11.0, 1H, H7a), 4.35 (dd, J = 4.8, 11.0, 1H, H7b), 3.89 
(d, J = 13.1, 1H, CH2Ph), 3.80 – 3.68 (m, 4H, OCH3, CH2Ph ), 3.55 (t, J = 4.7, 1H, H6), 3.01 (dd, J 
= 4.3, 17.0, 1H, H3a), 2.86 (dd, J = 4.7, 17.1, 1H, H3b), 1.96 (s, 1H, OH), 1.45 (s, 9H, C(CH3)3); IR 
(cm
-1
): 3362, 2978, 1740, 1500, 1455, 1368, 1167, 1053. 
c) 
1
H NMR (400 MHz, CD2Cl2) δ 7.37-7.20 (m, 5H), 5.95-5.82 (m, 1H), 5.41 (br d, 1H, J = 7.9 Hz), 
5.34-5.18 (m, 2H), 4.61-4.48 (m, 3H), 4.39 (dd, 1H, J = 10.9, 4.6 Hz), 4.30 (dd, 1H, J = 10.9, 4.9 
Hz), 3.86 (d, 1H, J = 13.1 Hz), 3.71 (s, 3H), 3.70 (d, 1H, J = 13.1 Hz), 3.51 (t, 1H, J = 4.7 Hz), 
2.94 (dd, 1H, J = 17.2, 4.7 Hz), 2.82 (dd, 1H, J = 17.0, 4.8 Hz), 1.42 (s, 9H); 
13
C NMR (101 MHz, 
CD2Cl2) δ 172.4, 170.6, 139.7, 131.9, 128.3, 128.2, 127.1, 118.1, 65.9, 65.6, 59.1, 52.0, 51.8, 50.0, 
36.7, 28.0; HRMS (ESI) m/z calcd for [C23H33N2O8]
+
: 465.22314 [M+H]
+
; found: 465.22267. 
 
OH-DKP1-CO2Allyl (49 a); OH-DKP2-CO2Allyl (49 b); OH-DKP3-CO2Allyl (49 c) 
 
Compound 55 (1.08 g, 1.82 mmol, 1 eq.) was deprotected according to general procedure GP1. The 
corresponding trifluoroacetate salt 57  was dissolved in iPrOH (20 ml) and iPr2EtN (0.9 ml, 5.6 mmol, 
4 eq.) was added at r.t.. The reaction was stirred for 18 h at r.t., monitoring the formation of DKP by 
TLC (EtOAc/Hexane: 8/2). The solution was then concentrated under reduced pressure and the residue 
was purified by flash chromatography on silica gel (Hexane/EtOAc, 75:25) to afford the desired 
product as a white foam (543.8 mg, 90%). 
57: Rf=0.37 (DCM/MeOH 95:5); []D32=8.7 (c=1.50 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) 
7.59-7.37 (m, 5H), 6.01-5.86 (m, 1H), 5.41-5.25 (m, 2H), 4.78-4.59 (m, 4H), 4.48-4.37 (m, 2H), 
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4.29 (d, J=12.98 Hz, 1H), 4.08-4.01 (br, 1H), 3.89-3.81 (s, 3H), 3.17 (dd, J=18.33 , 3.91 Hz, 1H), 
3.10 (dd, J1=18.53 Hz, J2=6.10 Hz, 1H); 
13
C NMR (100 MHz, CD2Cl2)  170.1, 166.3, 165.9, 
131.2, 130.5, 130.0, 129.3, 118.9, 66.5, 62.7, 56.1, 53.9, 53.7, 53.4, 53.2, 52.9, 50.6, 49.4, 33.4; 
IR (film): max 2921, 2850, 1759, 1681, 1539, 1456, 1392, 1202, 1137; HRMS (ESI) m/z calcd for 
[C18H25N2O6]
+
: 365.17071 [M+H]
+
; found: 365.17033. 
49 a) Rf=0.25 (EtOAc/Hexane: 8/2); []D20=-72.1 (c= 1.00 in CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 
7.41 – 7.19 (m, 5H, C6H5), 7.02 (d, J = 2.1 Hz, 1H, NH), 5.96 – 5.78 (m, J = 17.1, 10.4, 5.8 Hz, 
1H, H11), 5.38 – 5.19 (m, 3H, H12, CH2Ph), 4.67 – 4.53 (m, 2H, H10), 4.53 – 4.43 (m, 1H, H6), 
4.06 (d, J = 15.0 Hz, 1H, CH2Ph), 4.00 – 3.91 (m, J = 6.7 Hz, 1H, C9a), 3.91 – 3.80 (m, J = 3.1 
Hz, 2H, C9b, C3), 3.20 (dd, J = 17.6, 3.5 Hz, 1H, C7a), 3.11 (dd, J = 17.6, 10.1 Hz, 1H, C7b); 
13
C 
NMR (101 MHz, CDCl3) δ 171.8 (C=O), 166.8 (C=O), 166.2 (C=O), 135.6 (C6H5 – quat.), 131.9 
(C11), 129.5 (C6H5), 128.6 (C6H5), 128.6 (C6H5), 119.5 (C12), 66.4 (C10), 61.2 (C3), 60.6 (C9), 52.8 
(C6), 47.8 (CH2Ph), 40.7 (C7); IR (cm
-1
): 3427, 2928, 1740, 1653, 1452, 1383, 1339, 1275, 1184, 
1128. 
49 b) Rf=0.10 (EtOAc/Hexane 8:2); [a]D20=-35.3 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.43 - 7.25 (m, 5H), 7.20 (br s, 1H), 6.02 - 5.83 (m, 1H), 5.39 - 5.20 (m, 3H), 4.70 - 4.55 (m, 3H), 
4.12 (d, 1H, J = 15.2 Hz), 4.01 (dd, 1H, J = 11.8, 1.9 Hz), 3.90 (dd, 1H, J = 11.8, 3.1 Hz), 3.81 
(bs, 1H,), 3.21 (dd, 1H, J = 17.4, 4.0 Hz), 2.86 (dd, 1H, J = 17.4, 8.0 Hz); 
13
C NMR (101 MHz, 
CD2Cl2) δ 170.8, 168.2, 166.6, 135.9, 131.8, 128.8, 127.9, 127.9, 127.8, 118.3, 117.9, 65.7, 61.9, 
61.6, 51.1, 47.3, 37.1; IR (neat): νmax 3364, 3032, 2942, 1738, 1651, 1452, 1383, 1329, 1273, 
1183, 1129; HRMS (ESI) m/z calcd for [C17H20N2NaO5]
+
: 355.12644 [M+Na]
+
; found: 
355.12590. 
 
N3-DKP1-CO2Allyl (58 a); N3-DKP2-CO2Allyl (58 b); N3-DKP3-CO2Allyl (58 c) 
 
To a solution of diketopiperazine 49 (559 mg, 1.7 mmol, 1 eq.) in CH2Cl2/toluene (6.6 ml/12.2 ml), 
under a nitrogen atmosphere and at -20 ºC, PPh3 (535 mg, 2.0 mmol, 1.2 eq.) was added and the 
mixture was stirred until a solution was obtained. Addition of hydrazoic acid (0.45 M in toluene, 7.5 
ml, 3.4 mmol, 2 eq.) was followed by dropwise addition of DIAD (0.42 ml, 2.0 mmol, 1.2 eq.) and the 
reaction was stirred at -20ºC during 3.5 h. The reaction mixture was loaded onto a silica gel column 
(Hexane/EtOAc, 6:4) thus removing the hydrazo-derivative. The resulting crude residue was further 
purified by flash chromatography (CH2Cl2/MeOH, 99:1) to afford the desired product as a white foam 
(a: 309 mg, 51%; b-c: 486 mg, 80%). 
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In the case of the cis isomer, an almost unseparable mixture of compounds 58a and 60a was obtained 
in a 2-3:1 ratio. 
a) Rf=0.25 (EtOAc/Hexane: 8/2); []D20=-72.1 (c= 1.00 in CHCl3) 
1
H NMR (400 MHz, CDCl3)   
7.39 – 7.21 (m, 5H, C6H5), 6.77 (s, 1H, NH), 5.84-5.91 (m, 1H, H11), 5.41 – 5.27 (m, 2H, H12), 5.25 
(d, J = 15.0, 1H, CH2Ph), 4.70 – 4.57 (m, 2H, H10), 4.52 (dt, J = 2.7, 10.7, 1H, H6), 4.17 (d, J=15.0 
Hz, 1H, CH2Ph), 4.03 (q, J = 3.5, 1H, H3), 3.92 – 3.85 (m, 2H, H2, H9), 3.24 (dd, J = 2.7, 17.7, 1H, 
H7a), 3.16 (br s, 1H, OH); 3.11 (dd, J = 10.9, 17.7, 1H, H7b); 
13
C NMR (101 MHz, CDCl3)   171.8 
(C=O), 166.8 (C=O), 166.2 (C=O), 135.6 (C6H5 – quat.), 131.9 (C6), 129.5 (C6H5), 128.6 (C6H5), 
128.6 (C6H5), 119.5 (C7), 66.4 (C5), 61.2 (C2), 60.6 (C4), 52.8 (C1), 47.8 (CH2Ph), 40.7 (C3); IR 
(cm
-1
): 3427, 2928, 1740, 1653, 1452, 1383, 1339, 1275, 1184, 1128. 
c) Rf=0.13 (Hexane/EtOAc 6:4); [a]D20=+55.9 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.39 – 7.26 (m, 5H), 7.09 (d, 1H, J = 11.3 Hz), 6.00 – 5.83 (m, 1H), 5.35 (dq, 1H, J = 1.5, 17.2 
Hz), 5.28 (dq, 1H, J = 1.3, 10.4 Hz), 5.16 (d, 1H, J = 15.1 Hz), 4.69 – 4.60 (m, 3H), 4.26 (d, 1H, J 
= 15.1 Hz), 3.95 (t, 1H, J = 2.9 Hz), 3.89 (dd, 1H, J = 2.3, 12.7 Hz), 3.65 (dt, 1H, J = 6.6, 13.2 Hz), 
3.29 (dd, 1H, J = 3.6, 17.5 Hz), 2.84 (dd, 1H, J = 8.9, 17.5 Hz); 
13
C NMR (101 MHz, CD2Cl2) δ 
171.0, 166.8, 166.4, 135.61, 131.9, 129.5, 128.7, 128.5, 119.4, 66.3, 59.5, 52.1, 51.5, 51.4, 48.3, 
37.6; IR (cm
-1
): νmax 3250, 2937, 2118, 1732, 1694, 1447, 1329, 1277, 1184; MS (ESI) m/z calcd 
for [C17H20N5O4]
+
: 380.13 [M+H]
+
; found: 380.2. 
 
N-Boc-DKP1- CO2Allyl (59 a); N-Boc-DKP2- CO2Allyl (59 b); N-Boc-DKP3- CO2Allyl (59 c) 
 
To a solution of azide  58 (268 mg, 0.75 mmol, 1 eq.) in THF (2.5 ml), under a nitrogen atmosphere 
and at -20 ºC, Me3P (0.83 ml of 1 M solution in THF, 0.83 mmol, 1.1 eq.) and 2-(t-
butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 206 mg, 0.83 mmol, 1.1 eq.) were added 
successively. After stirring for 5 h at r.t., the solution was diluted with CH2Cl2 (60 ml) and washed 
with H2O (3x30 ml) and brine. The organic phase was dried over Na2SO4 and volatiles were removed 
under reduced pressure. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 99:1) to afford the desired product as a white foam (a: 308 mg, 95%; b: 246 mg, 
76%). 
a) Rf=0.2 (CH2Cl2/MeOH 97:3); [a]D20=-123.7 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 
7.33 (m, 5H, C6H5), 6.99 (s, 1H, NH), 5.92 (m, 1H, H11), 5.56 (d, J = 15.1, 1H, CH2Ph), 5.35 (dd, J 
= 1.3, 17.2, 1H, H12b), 5.28 (dd, J = 0.9, 10.4, 1H, H12b), 5.20 (t, J = 6.4, 1H, NHBoc), 4.65 (d, J = 
5.7, 2H, H10), 4.50 (dt, J = 2.6, 11.2, 1H, H6), 4.09 (d, J = 15.1, 1H, CH2Ph), 3.90 – 3.76 (m, 2H, 
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H2, H9a), 3.49 (m, 1H, H9b), 3.28 (dd, J = 2.4, 17.6, 1H, H7a), 2.84 (dd, J = 11.2, 17.6, 1H, H7b), 1.46 
(s, 9H, C(CH3)3); 
13
C NMR (101 MHz, CDCl3) δ 171.5 (C=O), 166.7 (C=O), 164.9 (C=O), 156.2 
(C=O), 135.6 (C6H5 – quat.), 131.8 (C11), 129.4 (C6H5), 128.9 (C6H5), 128.5 (C6H5), 119.3 (C12), 
80.8 (C(CH3)3), 66.4 (C10), 59.2 (C3), 52.4 (C6), 47.2 (CH2Ph), 40.8 (C9), 40.6 (C7), 28.7 (C(CH3)3); 
IR (cm
-1
): 3389, 2928, 1663, 1524, 1453, 1339, 1271, 1169. 
b) Rf=0.14 (DCM/MeOH 97:3); [a]D20=+16.9 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 7.41 
– 7.21 (m, 5H), 6.94 (s, 1H), 5.91 (m, 1H), 5.51 (d, 1H, J = 15.1 Hz), 5.39 – 5.23 (m, 2H), 5.05 (br 
s, 1H), 4.64 (d, 2H, J = 5.6 Hz), 4.49 (dd, 1H, J = 2.8, 9.3 Hz), 4.09 (d, 1H, J = 15.1 Hz), 3.83 – 
3.76 (m, 2H), 3.61 – 3.47 (m, 1H), 3.35 (dd, 1H, J = 3.3, 17.6 Hz), 2.79 (dd, 1H, J = 9.4, 17.6 Hz), 
1.45 (s, 9H); 
13
C NMR (101 MHz, CDCl3) δ 171.3, 167.6, 165.3, 156.3, 135.8, 131.8, 129.4, 128.8, 
128.5, 119.4, 80.8, 66.4, 59.7, 51.3, 47.6, 41.1, 38.3, 28.7; IR (cm
-1
): νmax 3328, 2980, 1692, 1524, 
1453, 1329, 1273, 1171; MS (ESI) m/z calcd for [C22H30N3O6]
+
: 432.21 [M+H]
+
; found: 432.3. 
 
N-Boc-DKP-COOH (DKP1-DKP3) 
 
Allyl ester 59 (363 mg, 0.84 mmol, 1 eq.) was dissolved in CH2Cl2 (6.0 ml) under a nitrogen 
atmosphere. After cooling the solution at 0 ºC, pyrrolidine (83 μl, 1.01 mmol, 1.2 eq), PPh3 (40 mg, 
0.15 mmol, 0.18 eq) and [Pd(PPh3)4] (39 mg, 0.034 mmol, 0.04 eq) were added successively. After 
stirring for 1 h at 0°C, the mixture was diluted with EtOAc (25 ml) and extracted with aqueous 
NaHCO3 (4x10 ml). The combined aqueous phases were acidified to pH 2 with a 1 M KHSO4 solution 
and then extracted with CH2Cl2. The resulting organic phase was dried over Na2SO4 and the solvent 
was evaporated to afford the desired product as a fluffy white solid (327 mg, 99%) that was used 
without further purification. 
 
N3-DKP-CO2H (DKP1*-DKP3*) 
11
 
 
Allyl ester 58 (300 mg, 0.84 mmol, 1 eq.) was dissolved in CH2Cl2 (8.0 ml) under a nitrogen 
atmosphere, and the mixture was cooled to 0°C. [Pd(PPh3)4] (290 mg, 0.25 mmol, 0.3 eq) and freshly 
distilled N-methyl aniline (109μl, 1.0 mmol, 1.2 eq.) were added successively. The mixture was then 
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allowed to reach r.t.. After 1 h of stirring, the mixture was diluted with EtOAc (40 ml) and extracted 
with aqueous NaHCO3 (4 x 20 ml). The combined aqueous phases were acidified to pH 2 by adding a 
KHSO4 1M solution and then extracted with CH2Cl2 (4 x 20 ml). The resulting organic phase was 
dried over Na2SO4 and the solvent was evaporated to afford the desired product as a slightly yellow 
solid (241 mg, 90%) which was used without further purification. 
In the case of the cis isomer, a mixture of compounds 58a and 60a could be used as the starting 
material, without affecting reactivity. A mixture of free carboxylic acids DKP1* and 61a was thus 
obtained. Successive precipitations of by-product with small amounts of CH2Cl2 afforded DKP1* in 
good purity. 
DKP1*: 
1
H NMR (300 MHz, CDCl3) δ 8.83 (s, 1H, COOH), 7.42 – 7.19 (m, 5H, C6H5), 5.16 (d, J = 
15.1 Hz, 1H, CH2Ph), 4.56 (dt, J = 11.6, 2.6 Hz, 1H, H6), 4.21 (d, J = 15.1 Hz, 1H, CH2Ph), 3.97 (t, J 
= 2.1 Hz, 1H, H3), 3.86 (dd, J = 12.8, 1.9 Hz, 1H, H9a), 3.66 (dd, J = 12.8, 3.5 Hz, 1H H9b), 3.31 (dd, J 
= 18.0, 2.6 Hz, 1H, H7a), 3.05 (dd, J = 18.0, 11.7 Hz, 1H, H7b). 
DKP3*: 
1
H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H, COOH), 7.42 – 7.31 (m, 3H, C6H5), 7.31 – 7.23 
(m, J = 7.9 Hz, 2H, C6H5), 5.18 (d, J = 15.1 Hz, 1H, CH2Ph), 4.66 (dd, J = 9.8, 2.9 Hz, 1H, H6), 4.27 
(d, J = 15.1 Hz, 1H, CH2Ph), 3.96 (t, J = 2.4 Hz, 1H, H3), 3.89 (dd, J = 12.8, 2.2 Hz, 1H, H9a), 3.69 
(dd, J = 12.8, 3.4 Hz, 1H H9b), 3.38 (dd, J = 17.9, 3.2 Hz, 1H, H7a), 2.80 (dd, J = 17.9, 9.9 Hz, 1H, 
H7b). 
 
2.2 -  DKP4-DKP6 
N-benzyl-dimethyl aspartate (63) 
6,7
 
 
At 0 °C to 50 ml of anhydrous methanol, 3.75 ml (47.5 mmol) of thinly chloride was added dropwise. 
The solution was stirred at 0 °C for 30 min and then 6.332 g (47.5 mmol) of Asp was added. The 
reaction mixture was stirred at r.t. for 24 h and TLC (CH3Cl/CH3OH, 9:1) indicated complete 
disappearance of Asp. The reaction mixture was evaporated under reduced pressure and the residue 
was triturated with petroleum ether repeatedly to provide 7.495 mg (98%) of HCl•Asp-(OCH3)2 as a 
colorless which was directly used for the next reaction. 
To a vigorously stirred solution of 500 mg (2.54 mmol) of dimethyl aspartate hydrochloride and 160 
mg (2.54 mmol) of sodium cyanoborohydride in 12 mL of methanol at rt was added 265 mg (2.54 
mmol) of benzaldehyde in one portion. After being stirred for 4 h, the mixture was cooled in an ice 
bath, and the pH was lowered to ca. 1 with concd HCl. The mixture was then allowed to warm to r.t. 
for 2 h, and the methanol was removed under reduced pressure at r.t.. The white residue was dissolved 
into a minimum volume of water, and the pH was raised to ca. 10 with saturated aqueous Na2CO3. 
After three ethyl acetate extractions, combined organic portions were washed with brine, dried over 
Na2CO3, and evaporated to give a pale yellow oil. 
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methyl 3-azido-2-(tert-butoxycarbonylamino)propanoate (69) 
 
In a round bottom flask were solved (10.0 g, 64.3 mmol, 1 eq.) of serine methyl ester hydrochloride in 
232 mL of THF/water 1:1 solution. The reaction flask was lowered into an ice bath and 27 ml (193 
mmol, 3 eq.) of triethylamine were added. Then, 16.8 g (77.1 mmol, 1.2 eq.) of Boc2O were added and 
the reaction was stirred at room temperature for 24 h. The reaction mixture was then diluted with 200 
mL of EtOAc and washed with aqueous KHSO4 1M until pH = 3 and brine. The organic phase was 
dried over Na2SO4, filtered and concentrated under reduced pressure. The product was then dried 
under high vacuum for a few hours affording 12.3 g (90 %) of pure Boc-Ser-OMe 68  as viscous 
transparent oil which was used in the next step without purification. 
To triphenyl phosphine (1.45 g, 5.54 mmol, 1.2 eq.) in THF (11 mL) at -78 °C was added DIAD (1 ml, 
5.54 mmol, 1.2 eq.) in THF (10 mL) followed by the HN3 solution (1.8 M in toluene, 3.1 ml, 
5.54mmol,  1.2 eq.) and Boc-serine methyl ester 68 (1.00 g, 4.62 mmol) in THF (10 mL). After the 
mixture stirred at -78 °C for 30 min and then allowed to slowly reach 0°C (within 3 h). The solvent 
was evaporated and the residue was chromatographed with hexane/EtOAc 9:1 to provide 839 mg 
(74%) of the azide as a mobile oil which crystallizes upon standing in the refrigerator. 
 
3-azido-2-(tert-butoxycarbonylamino)propanoic acid (70) 
 
Compound 69 (350.0 mg, 1.433 mmol) in THF (6 mL) at 0 °C was treated with LiOH monohydrate 
(84.0 mg, 2.00 mmol) in water (4 mL). After 1 h the mixture was concentrated, diluted with water, 
washed with ether, acidified with 1 M KHSO4, and extracted into DCM which was dried and 
evaporated to provide 329.2 mg (quant.) of a colorless oil. 
 
(R)-dimethyl-2-((S)-3-azido-N-benzyl-2-(tert-butoxycarbonylamino)propanamido)succinate (72 
a);  
(S)-dimethyl-2-((R)-3-azido-N-benzyl-2-(tert-butoxycarbonylamino)propanamido)succinate (72 
b) 
 
DCC (1.77 g, 8.56 mmol, 1 eq.) was added to a solution of N-Boc-Ser(N3)-OH (69) (3.94g, 17.11 
mmol, 2 eq.) 60 ml of CH2Cl2, in one portion. A white precipitate (DCU) formed and stirring 
continued for 1h at r.t.. The mixture was then filtered on a cotton wool to remove DCU. The white 
Chapter 5 Experimental section 139 
DCU residue was washed twice with cold CH2Cl2. The filtrate was concentrated under reduced 
pressure at r.t., and dried under high vacuum to afford symmetric anhydride 70a or 70b as a pale 
yellow foam, which was used without further purification. N-benzyl-aspartic acid dimethylester 63 
(1.51 g, 6.01 mmol, 0.7 eq.) was dissolved in CH2Cl2 (50 ml) and the mixture was cooled to 0°C. A 
solution of symmetric anhydride in 50 ml of CH2Cl2 was then added dropwise, very slowly. The 
reaction mixture was let to reach r.t. and stirred overnight. The solvent was afterwards removed under 
reduced pressure and the residue was purified by flash chromatography on silica gel (Hexane/EtOAc, 
8:2) to afford the desired product as a viscous transparent oil (2.22 g, 80%). 
Rf=0.37 (Hexane/EtOAc, 7:3); [a]D20=-38.6 (72 a, c=1.0 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) 
(rotamers ratio in CD2Cl2 A/B = 4:1) δ 7.51 – 7.11 (m, 5H), 5.61 – 5.50 (m, 1HB), 5.40 – 5.28 (m, 1HB, 
overlapping with solvent signal), 5.17 (t, 1HB, J = 7.1 Hz), 5.07 – 4.99 (m, 1HB), 4.86 – 4.69 (m, 3HA, 
1HB), 4.54 – 4.38 (m, 1HA, 1HB), 3.74 (dd, 1HB, J = 12.3, 5.4 Hz), 3.69 – 3.65 (m, 3HA, 1HB), 3.63 (s, 
3HA), 3.52 (dd, 1HA, J = 12.4, 6.3 Hz), 3.41 (dd, 1HA, J = 12.3, 6.0 Hz), 3.28 (dd, 1HA, J = 16.9, 7.4 
Hz), 3.05 (dd, 1HB, J = 17.1, 7.0 Hz), 2.71 (dd, 1HB, J = 17.2, 7.3 Hz), 2.55 (dd, 1HA, J = 16.1, 6.1 
Hz), 1.45 (s, 9H); 
13
C NMR (101 MHz, CD2Cl2) δ 171.9, 171.3, 170.4, 155.5, 136.3, 129.5, 129.3, 
129.2, 129.1, 129.0, 128.8, 128.2, 128.0, 127.9, 80.9, 58.0, 56.9, 56.6, 53.4, 53.1, 53.0, 52.6, 52.4, 
51.4, 48.1, 35.3, 34.9, 28.6; IR (neat): νmax 3343, 2979, 2953, 2106, 1739, 1712, 1651, 1497, 1438, 
1367, 1289, 1250, 1166; MS (ESI) m/z calcd for [C21H29N5NaO7]
+
: 486.20 [M+Na]
+
; found: 486.3. 
 
N3-DKP4-CO2Me (66 a); N3-DKP6-CO2Me (66 b) 
  
Dipeptide 72 (1.44 g, 3.11 mmol, 1 eq.) was deprotected according to general procedure GP1, with the 
addition of Et3SiH (1.24 ml, 7.78 mmol, 2.5 eq.) as an ion scavenger. The corresponding 
trifluoroacetate salt was dissolved in iPrOH (40 ml) and iPr2EtN (2.13 ml, 12.44 mmol, 4 eq.) was 
added at r.t.. The reaction was stirred for 5 h at r.t., then the solution was concentrated under reduced 
pressure and the residue was purified by flash chromatography on silica gel (EtOAc/Hexane, 8:2) to 
afford the desired product as a white foam (927.4 mg, 90%). 
Rf=0.33 (Hexane/EtOAc 2:8); [a]D20=+32.2 (66 a, c=1 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.45 – 7.24 (m, 5H), 6.83 (s , 1H), 5.13 (d, 1H, J = 15.3 Hz), 4.53 – 4.47 (m, 1H), 4.24 (d, 1H, J = 15.3 
Hz), 4.12 (t, 1H, J = 4.7 Hz), 3.91 (dd, 1H, J = 12.5, 5.8 Hz), 3.85 (dd, 1H, J = 12.5, 3.6 Hz), 3.65 (s, 
3H), 3.07 (dd, 1H, J = 17.5, 3.3 Hz), 2.88 (dd, 1H, J = 17.5, 5.0 Hz); 
13
C NMR (101 MHz, CD2Cl2) δ 
170.4, 167.6, 164.5, 135.6, 128.9, 127.9, 127.8, 56.0, 54.3, 52.0, 47.4, 34.6; IR (neat): νmax 3249, 3066, 
3030, 3007, 2953, 2924, 2852, 2362, 2342, 2117, 1736, 1558, 1496, 1449, 1372, 1332, 1281, 1204, 
1180, 1138; MS (ESI) m/z calcd for [C15H18N5O4]
+
: 332.14 [M+H]
+
; found: 332.3. 
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NH2-DKP4-CO2Me (73 a); NH2-DKP6-CO2Me (73 b) 
 
Compound 66 (737 mg, 2.22 mmol, 1 eq.) was dissolved in THF (45 ml) and Pd/C (237 mg, 0.22 
mmol, 0.1 eq.) was added. The flask was thoroughly purged with H2, and the system was closed. The 
reaction mixture was stirred at r.t. for 4 h, and then filtered through a Celite pad. The cake thus 
obtained was washed thoroughly with THF. The filtrate was concentrated and dried to give the crude 
product as a transparent paste (643.9 mg, 95%) which was used without further purification. 
Rf=0.13 (CH2Cl2/MeOH 95:5); [a]D20=+83.2 (73 a, c=1  in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.30 – 7.09 (m, 5H), 6.75 (br s, 1H), 4.99 (d, 1H, J = 15.3 Hz), 4.15 – 4.04 (m, 2H), 4.00 (br s, 1H), 
3.53 (s, 3H), 3.18 (dd, 1H, J = 13.1, 3.6 Hz), 2.99 – 2.84 (m, 2H), 2.73 (dd, 1H, J = 17.0, 5.1 Hz), 1.33 
(s, 2H);
 13
C NMR (101 MHz, CD2Cl2) δ 170.3, 167.4, 166.2, 136.1, 128.8, 127.7, 56.3, 55.9, 51.9, 
47.2, 44.2, 35.0; IR (neat): νmax 1736, 1685, 1659, 1496, 1449, 1371, 1318, 1254, 1203, 1179, 1109; 
MS (ESI) m/z calcd for [C15H20N3O4]
+
: 306.14 [M+H]
+
; found: 306.3. 
 
NHBoc-DKP4-CO2Me (74 a); NHBoc-DKP6-CO2Me (74 b) 
 
To a solution of 73 (586 mg, 1.92 mmol, 1 eq.) in THF (35 ml) Boc2O (461 mg, 2.11 mmol, 1.1 eq.) 
was added in one portion. After stirring the mixture at r. t. overnight, EtOAc (60 ml) was added. The 
solution was washed with 1 M KHSO4 (4x) and brine (1x). The organic phase was dried over Na2SO4 
and volatiles were removed under reduced pressure, to afford the desired product as a white foam 
(739.5 mg, 95%), which was used without further purification. 
Rf=0.23 (EtOAc/Hex 7:3); [a]D20=+82.2 (74 a, c=1  in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 7.33 – 
7.06 (m, 5H), 6.69 (br s, 1H), 5.12 (br s, 1H), 4.96 (d, 1H, J = 15.2 Hz), 4.26 (s, 1H), 4.14 (d, 1H, J = 
15.3 Hz), 4.00 (s, 1H), 3.68 – 3.57 (m, 3H), 3.56 – 3.45 (m, 4H), 2.86 (d, 1H, J = 16.9 Hz), 2.72 (dd, 
1H, J = 17.1, 4.9 Hz), 1.35 (s, 9H);
 13
C NMR (101 MHz, CD2Cl2) δ 170.3, 167.3, 166.0, 146.7, 135.9, 
128.8, 127.8, 127.6, 79.9, 56.6, 55.9, 51.9, 47.7, 42.2, 35.1, 28.0; IR (neat): νmax 3328, 3004, 2979, 
2953, 2934, 1809, 1737, 1690, 1586, 1508, 1497, 1450, 1393, 1368, 1333, 1250, 1208, 1168, 1119; 
MS (ESI) m/z calcd for [C20H28N3O6]
+
: 406.20 [M+H]
+
; found: 406.3. 
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NHBoc-DKP4-COOH (DKP4); NHBoc-DKP6-COOH (DKP6) 
 
Compound 74 (710 mg, 1.75 mmol, 1 eq.) was dissolved in THF (60 ml) and the mixture was cooled 
to 0 °C. A solution of LiOH·H2O (183.7 mg, 4.38 mmol, 2.5 eq.) in H2O (30 ml) was added dropwise. 
The resulting solution was let reacting for 1 h at 0 °C. Then, maintaining the temperature at 0 °C, the 
mixture was acidified with HCl 1M to pH = 1-2, and extracted with CH2Cl2 (4x). The collected 
organic phases were dried over Na2SO4 and volatiles removed under reduced pressure. Either DKP4 
or DKP6 were afforded as a white foam (685 mg, 100%), which was used in subsequent steps without 
further purification. 
 
2.3 -  DKP5-DKP7 
N3-DKP5-CO2Me (77 a); N3-DKP7-CO2Me (77 b) 
 
A flame-dried flask under N2 was charged with a solution of 66 (640 mg, 1.93 mmol, 1 eq.) in dry 
THF (32 ml). The temperature was lowered to -78°C and KHMDS (4.25 ml of a 0.5 M solution in 
toluene, 2.12 mmol, 1.1 eq.) was added dropwise. After 30 min benzyl bromide (1.18 ml, 9.65 mmol, 
5 eq.) was added, and a final solvent ratio THF/DMF 7:3 was reached by adding DMF (13.6 ml). The 
mixture was allowed to reach -40°C and stirred for 3 h. Then aqueous NH4Cl was slowly added and 
the mixture was extracted with EtOAc (3x). Organic phases were washed with brine and dried over 
Na2SO4. Volatiles were removed under reduced pressure and the residue was purified by flash 
chromatography on silica gel (Hex/EtOAc, 7:3) to afford the desired product as a viscous transparent 
oil (761 mg, 86%). 
Rf=0.20 (Hexane/EtOAc 6:4); [a]D20=+14.8 (77 b, c=1  in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.46 – 7.27 (m, 10H), 5.42 – 5.34 (m, 1H, overlapping with solvent signal), 5.29 (d, 1H, J = 15.5 Hz), 
4.31 – 4.25 (m, 1H), 4.23 – 4.14 (m, 3H), 4.11 (dd, 1H, J = 12.9, 2.0 Hz), 3.82 (dd, 1H, J = 12.8, 3.2 
Hz), 3.61 (s, 3H), 3.26 (dd, 1H, J = 17.5, 2.9 Hz), 2.93 (dd, 1H, J = 17.5, 5.1 Hz);
 13
C NMR (101 
MHz, CD2Cl2) δ  170.9, 166.7, 165.6, 136.0, 129.5, 128.8, 128.4, 127.3, 104.3, 59.0, 55.7, 52.5, 52.1, 
47.8, 47.6, 35.4; IR (neat): νmax 2117, 1735, 1660, 1449, 1439, 1362, 1329, 1267, 1216, 1174; MS 
(ESI) m/z calcd for [C22H24N5O4]
+
: 422.18 [M+H]
+
; found: 422.3. 
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NHBoc-DKP5-CO2Me (78 a); NHBoc-DKP7-CO2Me (78 b) 
 
To a solution of azide 77 (751 mg, 1.78 mmol, 1 eq.) in THF (48 ml), under a nitrogen atmosphere and 
at -20 ºC, 2-(t-butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 964 mg, 3.92 mmol, 2.2 eq.) 
and Me3P (3.57 ml of 1 M solution in toluene, 3.56 mmol, 2 equiv) were added successively. After 
stirring for 6 h at r.t., the solution was diluted with CH2Cl2 and washed with H2O (3x) and brine. The 
organic phase was dried over Na2SO4 and volatiles were removed under reduced pressure. The residue 
was purified by flash chromatography on silica gel (CH2Cl2/EtOAc, 8:2) to afford the desired product 
as a white foam (716 mg, 87%). 
Rf=0.39 (CH2Cl2/EtOAc, 9:1); [a]D20=-103.6 (78 b, c=1.5 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.48 – 7.24 (m, 10H), 5.56 (d, 1H, J = 15.3 Hz), 5.12 (d, 1H, J = 15.1 Hz), 4.98 (br s, 1H), 4.36 – 4.18 
(m, 3H), 4.05 (s, 1H), 3.87 – 3.63 (m, 2H), 3.57 (s, 3H), 3.23 (dd, 1H, J = 17.3, 2.7 Hz), 2.92 (dd, 1H, 
J = 17.3, 4.9 Hz), 1.47 (s, 9H);
 13
C NMR (101 MHz, CD2Cl2) δ 170.8, 166.7, 166.4, 156.5, 136.5, 
136.3, 129.6, 129.4, 129.2, 128.5, 128.4, 80.3, 59.4, 56.0, 52.5, 48.0, 47.1, 41.5, 35.7, 28.8; IR (neat): 
νmax 3323, 2978, 1738, 1714, 1658, 1497, 1450, 1366, 1330, 1252, 1202, 1168; MS (ESI) m/z calcd for 
[C27H34N3O6]
+
: 496.24 [M+H]
+
; found: 496.3. 
 
NHBoc-DKP5-CO2H (DKP5); NHBoc-DKP7-CO2H (DKP7) 
 
Compound 78 (370 mg, 0.75 mmol, 1 eq.) was dissolved in THF (30 ml) and the mixture was cooled 
to 0 °C. A solution of LiOH·H2O (78.3 mg, 1.86 mmol, 2.5 eq.) in H2O (15 ml) was added dropwise. 
The resulting solution was let reacting for 1 h at 0 °C. Then, maintaining the temperature at 0 °C, the 
mixture was acidified with HCl 1M to pH = 1-2, and extracted with CH2Cl2 (4x). The collected 
organic phases were dried over Na2SO4 and volatiles removed under reduced pressure. Either DKP5 
or DKP7 were afforded as a white foam (361 mg, 100%), which was used in subsequent steps without 
further purification. 
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2.4 -  DKP8 
 (R)-N-(tert-butoxycarbonyl)glutamic acid -methyl ester (79) 
 
To a flask containing MeOH (4,6 ml) and cooled to -14 °C was slowly added Acetyl chloride (1.3ml, 
18.4 mmol, 2.7 eq) followed by D-glutamic acid (1g, 6.8 mmol, 1eq). Cooling bath was removed, and 
the solution was stirred for 30 min at r.t. and then poured into Et2O (330 mL). The precipitate was 
filtered off and washed well with Et2O (50 mL) to give (R)- glutamic acid -methyl ester 
hydrochloride (1.25 g, 93%) as a white solid, which was used without further purification. 
In a round bottom flask was solved 1 g (5.06 mmol, 1 eq) of (R)- glutamic acid -methyl ester 
hydrochloride in 20 mL of THF/water 1:1 solution. The reaction flask was lowered into an ice bath, 
and triethylamine  (2.12 ml, 15.2 mmol, 3 eq.) and Boc2O (1.21 g, 5.56 mmol, 1.1 eq)  were added. 
After stirring at r.t. for 24 h. The reaction mixture was diluted with 60 mL of EtOAc and washed with 
aqueous KHSO4 1M until pH = 3 and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure. The product was then dried under high vacuum for a few hours 
affording 1.3 g (98%) of the pure expected product as viscous transparent oil. 
 
(R)-1-((S)-2-(benzylamino)-3-methoxy-3-oxopropyl)5-methyl2-(tert-
butoxycarbonylamino)pentanedioate (80) 
 
(R)-N-(tert-butoxycarbonyl)glutamic acid -methyl ester 79 (1.0 g, 3.8 mmol, 1.3 eq.) was coupled 
with (S)-N-benzylserine methyl ester 53 (607 mg, 2.9 mmol, 1 eq.) according to general procedure 
GP2. The crude product was purified by flash chromatography on silica gel (Hexane/EtOAc, 7:3) to 
afford the desired product as a transparent oil (774 mg, 59%). 
Rf=0.35 (Hexane/EtOAc 7:3); [a]D27=-4 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 7.31 
(m,5H), 5.12 (m, 1H), 4.47 (dd, J = 11.0, 4.9 Hz, 1H), 4.30 (dd, J = 11.0, 4.9 Hz, 1H), 3.90 (d, J = 
13.1 Hz, 1H), 3.79 – 3.74 (m, 4H), 3.71 (d, J = 10.3 Hz, 1H), 3.68 (s, 3H), 3.56 (t, J = 4.9 Hz, 1H), 
2.49 – 2.34 (m, 2H), 2.17 (dt, J = 13.3, 7.4 Hz, 1H), 1.95 (dt, J = 14.8, 7.9 Hz, 1H), 1.45 (s, 9H); 13C 
NMR (101 MHz, CD2Cl2) δ 173.7, 173.1, 172.5, 155.8, 140.3, 129.0, 128.8, 127.7, 80.3, 66.2, 59.8, 
53.5, 52.7, 52.4, 52.2, 30.5, 28.6, 28.2; IR (neat): νmax 3368, 2976, 2953, 1739, 1716, 1509, 1454, 
1367, 1249, 1201, 1166, 1051; MS (ESI) m/z calcd for [C22H33N2O8]
+
: 453,22 [M+H]
+
; found: 453.6. 
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HO-DKP8-CO2Me (81) 
 
Isopeptide 80 (440 mg, 0.97 mmol, 1 eq.) was deprotected according to general procedure GP1. The 
corresponding trifluoroacetate salt  was dissolved in iPrOH (12 ml) and iPr2EtN (0.7 ml, 3.9 mmol, 4 
eq.) was added at r.t. The reaction was stirred for 18 h at r.t., monitoring the formation of DKP by 
TLC (EtOAc). The solution was then concentrated under reduced pressure and the residue was 
purified by flash chromatography on silica gel (EtOAc) to afford the desired product as a white foam 
(289 mg, 93%).  
Rf=0.12 (EtOAc); [a]D28=+29.5 (c=1.00 in CHCl3);
 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.25 (m, 
5H), 5.32 (d, J = 15.1 Hz, 1H), 4.43 (t, J = 4.4 Hz, 1H), 4.13 (d, J = 15.1 Hz, 1H), 3.95 (dd, J = 11.7, 
2.4 Hz, 2H), 3.80 (t, J = 2.1 Hz, 1H), 3.67 (s, 3H), 2.53 – 2.26 (m, 3H), 2.23 – 2.10 (m, 1H); 13C NMR 
(101 MHz, CD3OD) δ 174.35, 169.95, 168.69, 136.75, 129.19, 128.77, 128.25, 128.17, 62.82, 61.46, 
53.77, 51.51, 47.41, 29.05, 27.25; IR (neat): νmax 3420, 2952, 1732, 1682, 1653, 1496, 1449, 1328, 
1259, 1175, 1122, 1070; MS (ESI) m/z calcd for [C16H21N2O5]
+
: 321,14 [M+H]
+
; found: 321.4. 
 
N3-DKP8-CO2Me (82) 
 
To a solution of diketopiperazine 81 (104 mg, 0.32 mmol, 1 eq.) in CH2Cl2/toluene/DMF (3 ml / 2.5 
ml / 1 ml), under nitrogen atmosphere and at -20 ºC, PPh3 (128 mg, 0.49 mmol, 1.5 eq.) was added and 
the mixture was stirred until a solution was obtained. Hydrazoic acid (1.9 M in toluene, 0.51 ml, 0.97 
mmol, 3 eq.) was added followed by dropwise addition of DIAD (0.096 ml, 0.49 mmol, 1.5 eq.) and 
the reaction was stirred at -20ºC overnight. The reaction mixture was loaded onto a silica gel column 
(EtOAc/Hexane 8:2) to afford the desired product as a white foam (72 mg, 65%). 
Rf=0.52 (EtOAc); [a]D28=+57.9 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 7.44 – 7.30 (m, 
3H), 7.30 – 7.23 (m, 2H), 5.15 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 4.7 Hz, 1H), 4.25 (d, J = 15.0 Hz, 1H), 
3.94 (d, J = 2.7 Hz, 1H), 3.88 (dd, J = 12.8, 2.4 Hz, 1H), 3.71 (s, 3H), 3.64 (dd, J = 12.7, 3.4 Hz, 1H), 
2.61 – 2.46 (m, 2H), 2.34 (dd, J = 9.1, 3.7 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 174.58, 167.72, 
167.37, 136.06, 129.82, 128.97, 128.71, 78.02, 77.70, 59.99, 54.39, 52.71, 52.42, 48.51, 30.24, 27.73; 
IR (neat): νmax 2116, 1733, 1686, 1654, 1437, 1327, 1289, 1258, 1174; MS (ESI) m/z calcd for 
[C16H20N5O4]
+
: 346,15 [M+H]
+
; found: 346.3. 
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NHBoc-DKP8-CO2Me (84) 
 
Azide 82 (192 mg, 0.55 mmol, 1 eq.) was dissolved in 12 ml of THF. After addition of 59 mg of Pd/C 
10% (0.05 mmol, 0.1 eq.), the mixture was hydrogenated under vigorous stirring over 3 h. Pd/C was 
then filtered off on a celite pad, which was thoroughly washed with THF. The filtrate was 
concentrated to dryness, obtaining amine 83 as a white solid, which was dissolved in THF. The 
mixture was cooled to 0°C before adding Boc anhydride (132 mg, 0.6 mmol, 1.1 eq.) and iPr2EtN 
(0.19 ml, 1.1 mmol, 2 eq.). The mixture was afterwards let to reach r.t. and stirred for 18 h. Volatiles 
were then removed under reduced pressure, and the residue was purified by flash chromatography on 
silica gel (EtOAc/Hexane, 1:1) to afford the desired product as a white foam (201 mg, 87%). 
Rf=0.34 (EtOAc); [a]D20=-4.4 (c=1.00 in CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 9.9 Hz, 
1H), 7.39 – 7.14 (m, 5H), 5.48 (d, J = 15.1 Hz, 1H), 5.29 (s, 1H), 4.25 (t, J = 4.4 Hz, 1H), 4.06 (d, J = 
15.0 Hz, 1H), 3.80 (s, 1H), 3.77 – 3.57 (m, 4H), 3.57 – 3.43 (m, 1H), 2.60 – 2.42 (m, 2H), 2.38 – 2.19 
(m, J = 6.1 Hz, 2H), 1.43 (s, 9H); 
13
C NMR (101 MHz, CDCl3) δ 174.56, 168.93, 166.59, 156.62, 
136.35, 129.64, 128.92, 128.66, 80.80, 60.21, 53.98, 52.59, 47.78, 41.22, 29.96, 28.96, 28.28; IR 
(neat): νmax 3298, 2978, 2952, 1689, 1523, 1448, 1393, 1366, 1329, 1253, 1169, 1059; MS (ESI) m/z 
calcd for [C21H30N3O6]
+
: 420.21 [M+H]
+
; found: 420.3. 
 
NHBoc-DKP8-CO2H (DKP8) 
 
Compound 84 (117 mg, 0.28 mmol, 1 eq.) was dissolved in THF (7 ml). The mixture was cooled to 
0°C and a 2.7M solution of LiOOH in H2O2 (453 mg of LiOH in 7 ml of H2O2 35%) was added  
dropwise. The mixture was stirred for additional 30 min at 0°C, then warmed up to r.t. and stirred for 
7h. After the addition of Na2SO3 (30.6 mg, 0.24 mmol, 6 eq.) the reaction mixture was diluted with 8 
ml of THF/H2O 1:1. KHSO4 1M was added to reach pH = 1-2, and the mixture was extracted with 
DCM (4x). The collected organic phases were dried over Na2SO4 and volatiles removed under reduced 
pressure, to afford crude DKP8 as a yellowish solid. Crude product was dissolved in EtOAc and 
extracted with NaHCO3 sat.; collected aqueous layers were acidified with KHSO4 1M to reach pH 1-2, 
and extracted with DCM (4x). Collected organic phases were dried over Na2SO4 and volatiles 
removed under reduced pressure, to afford DKP-8 as a white foam (100 mg, 90%) which was used 
without further purification. 
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3 -  Synthesis of cyclic[DKP-RGD] compounds 102-107 
Boc-Arg(Mtr)-Gly-OBn (112) 
 
N-Boc glycine benzylester 111 (1.6 mg, 6 mmol, 1.2 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with Boc-Arg(Mtr)-OH 
(2.5g, 5.14 mmol, 1 eq.) according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH; 97:3) to afford the desired product as white foam (2.9 g, 
90%). 
Rf=0.21 (CH2Cl2/MeOH 97:3); [a]D20=-6.0 (c=0.5 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 7.40 - 
7.31 (m, 5H), 7.27 (br, 1H), 6.58 (s, 1H), 6.19 (s, 2H), 6.00 (br, 1H), 5.50 (d, 1H, J = 6.6), 5.15 (s, 
2H), 4.24 (m, 1H), 4.09 (dd, 1H, J = 17.5, 6.4), 3.99 (dd, 1H, J = 17.9, 5.7), 3.84 (s, 3H), 3.25 (m, 2H), 
2.67 (s, 3H), 2.60 (s, 3H), 2.14 (s, 3H), 1.84 (m, 2H), 1.61 (m, 2H), 1.43 (s, 9H); 
13
C NMR (101 MHz, 
CD2Cl2) δ 172.9, 170.0, 158.5, 156.5, 156.0, 138.4, 136.5, 135.4, 133.4, 128.5, 128.4, 128.2, 124.8, 
111.7, 80.1, 67.1, 55.4, 50.5, 41.2, 40.4, 30.0, 28.0, 25.1, 23.8, 18.1, 11.6; IR (neat): νmax 3343, 2937, 
1669, 1621, 1555, 1455, 1366, 1307, 1251, 1171, 1120; MS (ESI) m/z calcd for [C30H44N5O8S]
+
: 
634.29 [M+H]
+
; found: 634.3. 
 
N-Boc-DKP-Arg(Mtr)-Gly-OBn (113) 
 
a) N-Boc-DKP3-Arg(Mtr)-Gly-OBn 
 Compound 112 (973.5 mg, 1.54 mmol, 1.2 eq.) was deprotected according to general procedure 
GP1. The corresponding trifluoroacetate salt was then coupled with DKP3 (500 mg, 1.28 mmol, 1 
eq.) according to general procedure GP2. The residue was purified by flash chromatography on 
silica gel (CH2Cl2/MeOH, 93:7) to afford the desired product as white foam (811 mg, 70%). 
 Rf=0.34 (CH2Cl2/MeOH 9:1); [a]D20=-1.8 (c=0.2 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 7.85 
(br, 1H), 7.69 (br, 1H), 7.53 – 7.28 (m, 11H), 6.56 (s, 1H), 6.35 – 6.03 (br, 3H), 5.64 (br, 1H), 5.35 
(m, 1H), 5.12 (d, 2H, J = 8.3), 4.60 (m, 1H), 4.50 (m, 1H), 4.09 – 4.97 (m, 3H), 3.84 – 3.80 (m, 
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4H), 3.66 – 3.45 (m, 2H), 3.30 – 2.79 (m, 4H), 2.65 (s, 3H), 2.59 (s, 3H), 2.12 (s, 3H), 1.95 – 1.50 
(m, 4H), 1.39 (s, 9H); 
13
C NMR (101 MHz, CD2Cl2) δ 172.5, 170.6, 170.4, 169.9, 167.7, 166.4, 
158.5, 156.6, 156.1, 138.4, 136.5, 135.8, 135.4, 133.3, 128.8, 128.5, 128.4, 128.2, 127.9, 124.8, 
111.7, 79.8, 67.2, 67.1, 60.0, 55.4, 52.7, 51.5, 47.4, 41.2, 40.8, 39.7, 38.1, 31.6, 29.7, 28.0, 25.1, 
23.8, 22.6, 18.1, 13.8, 11.7; IR (neat): νmax 3335, 2937, 1651, 1557, 1455, 1307, 1251; MS (ESI) 
m/z calcd for [C44H59N8O11S]
+
: 907.40 [M+H]
+
; found: 907.6. 
b) N-Boc-DKP4-Arg(Mtr)-Gly-OBn 
 Compound 112 (973.5 mg, 1.54 mmol, 1.2 eq.) was deprotected according to general procedure 
GP1. The corresponding trifluoroacetate salt was then coupled with DKP4 (500 mg, 1.28 mmol, 1 
eq.) according to general procedure GP2. The residue was purified by flash chromatography on 
silica gel (CH2Cl2/MeOH, 93:7) to afford the desired product as white foam (811 mg, 70%). 
 Rf=0.36 (CH2Cl2/MeOH 9:1); [a]D20=+21.7 (c=1 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.85 (t, 1H, J = 5.8 Hz), 7.61 (d, 1H, J = 7.7 Hz), 7.44 – 7.23 (m, 10H), 6.69 (s, 1H), 6.54 (br s, 
2H), 6.19 (br s, 1H), 5.24 (d, 1H, J = 15.2 Hz), 5.17 (s, 2H), 4.56 – 4.47 (m, 1H, J = 8.1 Hz), 4.35 
(t, 1H, J = 4.8 Hz), 4.17 (d, 1H, J = 15.2 Hz), 4.10 (t, 1H, J = 5.4 Hz,), 4.00 (d, 2H, J = 5.9 Hz), 
3.85 (s, 3H), 3.77 – 3.68 (m, 1H), 3.62 – 3.50 (m, 1H), 3.34 – 3.11 (m, 2H), 2.92 (d, 2H, J = 5.4 
Hz), 2.69 (s, 3H), 2.64 (s, 3H), 2.12 (s, 3H), 1.97 – 1.79 (m, 1H), 1.69 – 1.49 (m, 3H), 1.43 (s, 9H); 
13
C NMR (101 MHz, Acetone-d6) δ 138.9, 137.4, 136.9, 135.6, 129.3, 129.1, 128.7, 128.5, 128.2, 
124.6, 112.3, 79.3, 66.8, 57.6, 55.9, 55.6, 53.1, 47.4, 42.9, 41.5, 40.8, 37.3, 28.4, 26.1, 24.0, 18.5, 
11.9; IR (neat): νmax 3331, 2936, 1681, 1555, 1454, 1392, 1366, 1333, 1306, 1249, 1172, 1120; MS 
(ESI) m/z calcd for [C44H59N8O11S]
+
: 907.40 [M+H]
+
; found: 907.5. 
c) N-Boc-DKP5-Arg(Mtr)-Gly-OBn 
 Compound 112 (410 mg, 0.65 mmol, 1.2 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with DKP5 (260 mg, 0.54 mmol, 1 eq.) 
according to general procedure GP2. The residue was purified by flash chromatography on silica 
gel (CH2Cl2/MeOH, 97:3) to afford the desired product as white foam (323 mg, 60% yield). 
 Rf=0.44 (CH2Cl2/MeOH, 9:1); [a]D20=-51.2 (c=0.6 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 
7.69 (br s, 1H), 7.41 (br s, 1H), 7.38 – 7.22 (m, 15H), 6.57 (s, 1H), 6.26 (br s, 2H), 5.33 (d, 1H, J = 
15.6 Hz), 5.24 (d, 1H, J = 15.3 Hz), 5.12 (s, 2H), 4.77 (br s, 1H), 4.51 – 4.41 (m, 1H), 4.36 (br s, 
1H), 4.28 (d, 1H, J = 15.5 Hz), 4.17 (d, 1H, J = 15.4 Hz), 4.08 – 3.95 (m, 3H), 3.84 (s, 3H), 3.76 – 
3.65 (m, 1H), 3.64 – 3.53 (m, 1H), 3.34 – 3.13 (m, 2H), 3.07 (d, 1H, J = 13.3 Hz), 2.93 (dd, 1H, J = 
15.8, 6.6 Hz), 2.66 (s, 3H), 2.58 (s, 3H), 2.11 (s, 3H), 2.01 – 1.88 (m, 1H), 1.75 – 1.48 (m, 3H), 
1.42 (s, 9H); 
13
C NMR (101 MHz, CD2Cl2) δ 172.9, 170.6, 170.3, 167.8, 166.7, 159.1, 157.1, 
139.1, 137.1, 136.5, 136.1, 134.0, 129.6, 129.5, 129.2, 128.9, 128.9, 128.6, 128.5, 128.4, 125.4, 
112.4, 67.7, 59.8, 56.3, 56.1, 47.6, 41.9, 41.6, 41.1, 37.2, 30.3, 29.5, 28.7, 26.2, 24.5, 18.8, 12.3; IR 
(neat): νmax 3329, 2938, 2357, 2341, 1750, 1719, 1660, 1652, 1557, 1455, 1369, 1301, 1257, 1176, 
1121; MS (ESI) m/z calcd for [C51H65N8O11S]
+
: 997.45 [M+H]
+
; found: 997.5. 
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d) N-Boc-DKP-6-Arg(Mtr)-Gly-OBn 
 Compound 112 (973 mg, 1.54 mmol, 1.2 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with DKP6 (500 mg, 1.28 mmol, 1 eq.) 
according to general procedure GP2. The residue was purified by flash chromatography on silica 
gel (CH2Cl2/MeOH, 93:7) to afford the desired product as white foam (811 mg, 70%). 
 Rf=0.38 (CH2Cl2/MeOH 9:1); [a]D20=+23.4 (c=1 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.93 (t, 1H, J = 5.8 Hz), 7.73 (d, 1H, J = 8.1 Hz,), 7.45 – 7.24 (m, 10H), 6.69 (s, 1H), 6.59 (br s, 
2H), 6.24 (br s, 1H), 5.34 (d, 1H, J = 15.2 Hz,), 5.16 (s, 2H), 4.68 – 4.58 (m, 1H), 4.34 (t, 1H, J = 
4.6 Hz), 4.17 (d, 1H, J = 15.1 Hz), 4.11 – 3.93 (m, 3H), 3.85 (s, 3H), 3.75 – 3.65 (m, 1H), 3.65 – 
3.54 (m, 1H), 3.32 – 3.11 (m, 2H), 3.07 (dd, 1H, J = 15.2, 5.8 Hz), 2.97 – 2.85 (m, 1H, overlapping 
with water signal), 2.70 (s, 3H), 2.65 (s, 3H), 2.11 (s, 3H), 1.92 – 1.80 (m, 1H), 1.67 – 1.47 (m, 
3H), 1.42 (s, 9H); 
13
C NMR (101 MHz, Acetone-d6) δ 172.5, 170.2, 169.7, 168.7, 167.2, 158.7, 
157.4, 157.3, 138.9, 137.1, 136.9, 136.8, 135.6, 129.4, 129.1, 128.8, 128.6, 128.2, 124.6, 112.3, 
79.3, 66.9, 57.3, 56.1, 55.7, 52.7, 47.0, 43.1, 41.5, 40.8, 37.1, 30.5, 28.4, 25.7, 24.1, 18.5, 11.9; ; IR 
(neat): νmax 3329, 2932, 1687, 1560, 1451, 1387, 1361, 1338, 1310, 1243, 1177, 1121; MS (ESI) 
m/z calcd for [C44H59N8O11S]
+
: 907.40 [M+H]
+
; found: 907.5. 
e) N-Boc-DKP7-Arg(Mtr)-Gly-OBn 
 Compound 112 (327 mg, 0.52 mmol, 1.1 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with DKP-7 (227 mg, 0.47 mmol, 1 eq.) 
according to general procedure GP2. The residue was purified by flash chromatography on silica 
gel (CH2Cl2/MeOH, 95:5) to afford the desired product as white foam (286 mg, 61%). 
 Rf=0.45 (CH2Cl2/MeOH 9:1); [a]D20=-55.6 (c=0.7 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.85 (t, 1H, J = 5.7 Hz), 7.55 (d, 1H, J = 8.2 Hz), 7.51 – 7.22 (m, 15H), 6.68 (s, 1H), 6.54 (br s, 
2H), 6.26 (br s, 1H), 5.92 (br s, 1H), 5.50 (d, 1H, J = 15.6 Hz), 5.29 (d, 1H, J = 15.3 Hz), 5.16 (s, 
2H), 4.68 – 4.56 (m, 1H), 4.32 (d, 2H, J = 15.2 Hz), 4.26 – 4.20 (m, 1H), 4.06 (t, 1H, J = 3.3 Hz), 
4.03 – 3.92 (m, 2H), 3.84 (s, 3H), 3.79 – 3.65 (m, 2H), 3.40 – 3.22 (m, 1H), 3.22 – 2.99 (m, 3H), 
2.69 (s, 3H), 2.64 (s, 3H), 2.10 (s, 3H), 1.96 – 1.79 (m, 1H), 1.68 – 1.48 (m, 3H), 1.43 (s, 9H); 13C 
NMR (101 MHz, Acetone-d6) δ 171.7, 169.4, 169.1, 166.8, 166.4, 158.0, 156.7, 155.9, 138.3, 
136.3, 128.7, 128.5, 128.3, 128.1, 127.6, 127.3, 123.9, 111.6, 78.5, 66.1, 58.9, 55.5, 54.9, 51.8, 
46.5, 46.2, 40.8, 40.5, 39.9, 36.1, 27.7, 25.1, 23.4, 17.8, 11.2; IR (neat): νmax 3326, 2936, 2361, 
2343, 1748, 1714, 1659, 1650, 1555, 1453, 1366, 1306, 1253, 1172, 1120; MS (ESI) m/z calcd for 
[C51H65N8O11S]
+
: 997.45 [M+H]
+
; found: 997.6. 
f) N-Boc-DKP8-Arg(Mtr)-Gly-OBn 
 Compound 112 (200 mg, 0.31 mmol, 1.1 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with DKP-8 (116 mg, 0.29 mmol, 1 eq.) 
according to general procedure GP2. The residue was purified by flash chromatography on silica 
gel (CH2Cl2/MeOH, 95:5) to afford the desired product as white foam (163 mg, 61%). 
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 Rf=0.4 (CH2Cl2/MeOH 9:1); [a]D29=-2.0 (c=0.2 in CHCl3); 
1
H NMR (400 MHz, CD3OD) δ 7.42 – 
7.26 (m, 10H), 6.67 (s, 1H), 5.39 (d, 1H, J = 15.3 Hz), 5.16 (s, 2H), 4.43 – 4.36 (m, 1H), 4.30 (t, 
1H, J = 3.7 Hz), 4.09 – 4.00 (m, 2H), 3.93 (d, 1H, J = 17.6 Hz), 3.84 (s, 3H), 3.82 – 3.73 (m, 2H), 
3.45 (d, 1H, J = 13.2 Hz), 3.25 – 3.09 (m, 2H), 2.69 (s, 3H), 2.63 (s, 3H), 2.46 – 2.22 (m, 3H), 2.22 
– 2.16 (m, 1H), 2.14 (s, 3H), 1.87 – 1.76 (m, 1H), 1.68 – 1.52 (m, 3H), 1.44 (s, 9H); 13C NMR (101 
MHz, CD2Cl2) δ   173.7, 173.1, 170.3, 168.8, 167.0, 158.8, 157.0, 156.5, 138.8, 136.8, 136.5, 
135.8, 133.9, 129.2, 128.9, 128.7, 128.5, 128.3, 125.1, 112.1, 80.0, 67.4, 60.6, 55.8, 53.9, 53.0, 
48.0, 41.6, 41.1, 40.8, 31.6, 30.3, 28.4, 28.0, 25.6, 24.2, 18.5, 12.1; IR (neat): νmax 3328, 3066, 
3007, 2974, 2937, 1747, 1660, 1550, 1455, 1392, 1366, 1306, 1254, 1173, 1120; MS (ESI) m/z 
calcd for [C45H61N8O11S]
+
: 921.42 [M+H]
+
; found: 921.7. 
 
Cbz-Asp(OtBu)-DKP-Arg(Mtr)-Gly-OBn (114) 
 
a) Cbz-Asp(OtBu)-DKP3-Arg(Mtr)-Gly-OBn 
 Compound 113 a (290 mg, 0.32 mmol, 1 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with Cbz-L-Asp(OtBu)-OH (155 mg, 0.48 
mmol, 1.5 eq.)  according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 9:1) to afford the desired product as white foam (320 
mg, 90%). 
 Rf=0.25 (CH2Cl2/MeOH 9:1); [a]D20=-7.0 (c=1 in CHCl3); 
1
H NMR (400 MHz, CD2Cl2) δ 7.85 – 
7.55 (m, 3H), 7.41 – 7.16 (m, 16H), 6.55 (s, 1H), 6.36 – 6.00 (br, 3H), 5.24 (d, 1H, J = 13.9 Hz), 
5.17 – 5.03 (m, 3H), 4.92 (d, 1H, J = 12.3 Hz), 4.70 – 4.39 (m, 3H), 4.17 (d, 1H, J = 14.7 Hz), 4.01 
– 3.71 (m, 7H), 3.68 – 3.53 (m, 1H), 3.31 – 2.48 (m, 12H), 2.11 (s, 3H), 2.02 – 1.48 (m, 4H), 1.42 
(s, 9H); 
13
C NMR (101 MHz, CD2Cl2) δ 172.5, 172.0, 171.4, 170.6, 170.4, 170.0, 167.5, 166.6, 
165.9, 165.7, 158.5, 156.6, 138.4, 136.5, 136.2, 135.8, 135.4, 133.5, 128.8, 128.5, 128.3, 127.9, 
127.8, 124.8, 111.7, 81.6, 67.1, 59.5, 55.4, 52.4, 51.7, 51.2, 47.5, 41.2, 40.5, 39.6, 38.6, 37.3, 31.6, 
29.7, 27.7, 25.1, 23.8, 22.6, 18.1, 13.8, 11.7; IR (neat): νmax 3327, 2938, 1730, 1651, 1549, 1455, 
1367, 1306, 1254, 1158, 1120; MS (ESI) m/z calcd for [C55H70N9O14S]
+
: 1112.48 [M+H]
+
; found: 
1112.6. 
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b) Cbz-Asp(OtBu)-DKP4-Arg(Mtr)-Gly-OBn 
 Compound 113 b (290 mg, 0.32 mmol, 1 eq.) was deprotected according to general procedure 
GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-L-Asp(OtBu)-OH (124 
mg, 0.38 mmol, 1.2 eq.)  according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 9:1) to afford the desired product as white foam (327 
mg, 92%).  
 Rf=0.45 (CH2Cl2/MeOH 9:1); [a]D20=+22.1 (c=1 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.84 (t, 1H, J = 5.8 Hz), 7.77 (t, 1H, J = 5.9 Hz), 7.60 (d, 1H, J = 8.0 Hz), 7.46 – 7.21 (m, 16H), 
6.77 (d, 1H, J = 8.2 Hz), 6.69 (s, 1H), 6.54 (br s, 2H), 6.43 – 6.17 (br, 1H), 5.23 (d, 1H, J = 15.2 
Hz), 5.19 – 5.10 (m, 3H), 5.06 (d, 1H, J = 12.5 Hz), 4.58 (td, 1H, J = 7.8, 5.6 Hz), 4.53 – 4.46 (m, 
1H), 4.43 (t, 1H, J = 5.3 Hz), 4.18 (d, 1H, J = 15.2 Hz), 4.12 (t, 1H, J = 5.3 Hz), 4.06 – 3.93 (m, 
2H), 3.93 – 3.81 (m, 4H), 3.70 – 3.59 (m, 1H), 3.31 – 3.11 (m, 2H), 2.97 – 2.89 (m, 2H), 2.87 – 
2.77 (m, 1H, overlapping with water signal), 2.76 – 2.58 (m, 7H), 2.12 (s, 3H), 1.97 – 1.77 (m, 1H), 
1.70 – 1.48 (m, 3H), 1.42 (s, 9H).; 13C NMR (101 MHz, Acetone-d6) δ 172.3, 172.0, 170.2, 169.8, 
169.4, 168.5, 166.4, 158.4, 157.1, 156.5, 138.7, 137.4, 137.1, 136.6, 135.4, 129.1, 128.8, 128.7, 
128.4, 128.2, 127.9, 124.3, 112.0, 80.9, 66.7, 66.6, 57.4, 55.4, 54.7, 47.1, 41.7, 41.3, 40.6, 37.9, 
36.9, 29.9, 29.7, 29.6, 29.4, 29.2, 29.0, 28.8, 27.7, 25.8, 23.8, 18.2, 11.6; IR (neat): νmax 3317, 2937, 
1726, 1667, 1548, 1454, 1367, 1306, 1254, 1190, 1156, 1120; MS (ESI) m/z calcd for 
[C55H70N9O14S]
+
: 1112.48 [M+H]
+
; found: 1112.5. 
c) Cbz-Asp(OtBu)-DKP5-Arg(Mtr)-Gly-OBn 
 Compound 113 c (147 mg, 0.15 mmol, 1 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with Cbz-L-Asp(OtBu)-OH (58 mg, 0.18 
mmol, 1.2 eq.) according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford the desired product as white foam 
(172 mg, 96%). 
 Rf=0.43 (CH2Cl2/MeOH 95:5); [a]D20=-23.6 (c=0.7 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.89 (t, 1H, J = 5.9 Hz), 7.51 – 7.19 (m, 20H), 6.75 – 6.65 (m, 2H), 6.55 (br s, 2H), 6.33 (br s, 1H), 
5.39 (d, 1H, J = 15.4 Hz), 5.16 (s, 2H), 5.10 (d, 1H, J = 13.8 Hz), 5.04 (d, 1H, J = 15.5 Hz), 4.59 – 
4.49 (m, 3H), 4.46 (d, 1H, J = 15.6 Hz), 4.28 (d, 1H, J = 15.5 Hz), 4.20 – 4.15 (m, 1H), 4.08 – 3.91 
(m, 3H), 3.84 (s, 3H), 3.81 – 3.73 (m, 1H), 3.39 – 3.24 (m, 1H), 3.22 – 3.11 (m, 1H), 3.08 (dd, 1H, 
J = 15.9, 3.5 Hz), 2.92 (dd, 1H, J = 15.9, 6.4 Hz), 2.87 – 2.77 (m, 4H), 2.73 – 2.60 (m, 4H), 2.08 (s, 
3H, overlapping with solvent signal), 1.95 – 1.81 (m, 1H), 1.69 – 1.50 (m, 3H), 1.42 (s, 9H); 13C 
NMR (101 MHz, Acetone-d6) δ 171.7, 171.2, 169.8, 169.4, 166.1, 162.8, 158.0, 156.7, 147.4, 
136.9, 136.5, 128.7, 128.6, 128.3, 128.1, 128.0, 127.8, 127.6, 127.3, 111.6, 80.4, 66.3, 66.1, 58.5, 
55.9, 54.9, 52.2, 52.0, 46.8, 46.6, 40.9, 40.1, 39.3, 37.2, 35.9, 27.3, 25.6, 23.4, 17.8, 11.2; IR (neat): 
νmax 3324, 2938, 1731, 1660, 1654, 1546, 1451, 1368, 1310, 1253, 1160, 1122; MS (ESI) m/z calcd 
for [C62H76N9O14S]
+
: 1202.52 [M+H]
+
; found: 1202.5. 
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d) Cbz-Asp(OtBu)-DKP6-Arg(Mtr)-Gly-OBn 
 Compound 113 d (400 mg, 0.44 mmol, 1 eq.) was deprotected according to general procedure 
GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-L-Asp(OtBu)-OH (171 
mg, 0.52 mmol, 1.2 eq.) according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 9:1) to afford the desired product as white foam (451 
mg, 92%). 
 Rf=0.46 (CH2Cl2/MeOH 9:1); [a]D20=+25.1 (c=1 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.92 (br s, 1H), 7.82 (br s, 1H), 7.70 (br s, 1H), 7.43 – 7.22 (m, 15H), 6.81 (d, 1H, J = 8.1 Hz), 6.68 
(s, 1H), 6.58 (br s, 2H), 5.31 (d, 1H, J = 15.1 Hz), 5.19 – 5.10 (m, 3H), 5.05 (d, 1H, J = 12.6 Hz), 
4.60 (m, 2H), 4.41 (t, 1H, J = 5.1 Hz), 4.17 (d, 1H, J = 15.1 Hz), 4.10 – 3.91 (m, 3H), 3.89 – 3.80 
(m, 4H), 3.80 – 3.68 (m, 1H), 3.31 – 3.11 (m, 2H), 3.04 (dd, 1H, J = 15.3, 5.7 Hz), 2.98 – 2.86 (m, 
1H, overlapping with water signal), 2.82 (dd, 1H, J = 16.2, 5.4 Hz), 2.70 (s, 3H), 2.65 (s, 3H), 2.11 
(s, 3H), 1.92 – 1.79 (m, 1H), 1.70 – 1.46 (m, 3H), 1.41 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 
172.7, 172.5, 170.4, 170.2, 169.7, 168.7, 167.0, 158.7, 157.4, 156.9, 138.9, 137.7, 137.1, 136.9, 
136.8, 135.6, 129.4, 129.3, 129.1, 129.0, 128.8, 128.7, 128.5, 128.2, 124.6, 112.3, 81.1, 66.9, 57.3, 
55.7, 55.3, 52.8, 52.7, 47.1, 44.0, 43.7, 41.9, 41.5, 40.8, 38.6, 38.3, 37.0, 30.5, 28.0, 25.8, 24.1, 
18.5, 11.9; IR (neat): νmax 3312, 2943, 1729, 1672, 1553, 1453, 1369, 1309, 1259, 1186, 1161, 
1124; MS (ESI) m/z calcd for [C55H70N9O14S]
+
: 1112.48 [M+H]
+
; found: 1112.5. 
e) Cbz-Asp(OtBu)-DKP7-Arg(Mtr)-Gly-OBn 
 Compound 113 e (210 mg, 0.21 mmol, 1 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with Cbz-L-Asp(OtBu)-OH (82 mg, 0.25 
mmol, 1.2 eq.)   according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 97:3) to afford the desired product as white foam 
(226 mg, 90%). 
 Rf=0.45 (CH2Cl2/MeOH 95:5); [a]D20=-28.9 (c=0.8 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
7.85 (t, 1H, J = 5.8 Hz), 7.53 (d, 1H, J = 8.1 Hz), 7.50 – 7.21 (m, 21H), 6.71 (d, 1H, J = 8.3 Hz), 
6.67 (s, 1H), 6.53 (br s, 2H), 6.24 (br s, 1H), 5.44 (d, 1H, J = 15.5 Hz), 5.24 (d, 1H, J = 15.2 Hz), 
5.18 – 5.10 (m, 3H), 5.07 (d, 1H, J = 12.6 Hz), 4.64 – 4.50 (m, 2H), 4.39 – 4.30 (m, 2H), 4.27 (s, 
1H), 4.14 (t, 1H, J = 3.5 Hz), 4.06 – 3.94 (m, 2H), 3.94 – 3.77 (m, 5H), 3.38 – 3.22 (m, 1H), 3.20 – 
3.01 (m, 3H), 2.84 – 2.78 (m, 1H, overlapping with water signal), 2.69 (s, 3H), 2.66 – 2.56 (m, 4H), 
2.09 (s, 3H), 1.94 – 1.78 (m, 1H), 1.66 – 1.45 (m, 3H), 1.41 (s, 9H); 13C NMR (101 MHz, Acetone-
d6) δ 172.1, 171.5, 170.0, 169.8, 169.5, 167.5, 166.7, 158.4, 157.1, 138.6, 136.7, 136.6, 129.2, 
128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.2, 127.9, 127.6, 124.3, 111.9, 80.7, 66.6, 66.5, 58.7, 
55.9, 55.4, 52.3, 52.2, 47.0, 46.6, 41.2, 40.3, 39.5, 37.7, 36.4, 30.2, 27.7, 25.6, 23.8, 18.2, 11.6; IR 
(neat): νmax 3322, 2936, 1729, 1659, 1651, 1549, 1454, 1367, 1306, 1256, 1161, 1120; MS (ESI) 
m/z calcd for [C62H76N9O14S]
+
: 1202.52 [M+H]
+
; found: 1202.5. 
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f) Cbz-Asp(OtBu)-DKP8-Arg(Mtr)-Gly-OBn 
 Compound 113 f (143 mg, 0.16 mmol, 1 eq.) was deprotected according to general procedure GP1. 
The corresponding trifluoroacetate salt was then coupled with Cbz-L-Asp(OtBu)-OH (62 mg, 0.19 
mmol, 1.2 eq.) according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/EtOH, 95:5) to afford the desired product as white foam 
(155 mg, 86%). 
 Rf=0.5 (CH2Cl2/MeOH 9:1); [a]D20=-3.0 (c=0.35 in CHCl3); 
1
H NMR (400 MHz, Acetone-d6) δ 
8.02 (s, 1H), 7.97 – 7.89 (m, 2H), 7.58 (d, 1H, J = 7.9 Hz), 7.39 – 7.21 (m, 15H), 6.87 (d, 1H, J = 
8.6 Hz), 6.66 (s, 1H), 6.54 (br s, 2H), 5.31 (d, 1H, J = 15.2 Hz), 5.16 – 5.09 (m, 3H), 5.01 (d, 1H, J 
= 12.5 Hz), 4.61 – 4.52 (m, 2H), 4.41 (br s, 1H), 4.14 (d, 1H, J = 15.2 Hz), 4.04 (dd, 1H, J = 17.6, 
6.0 Hz), 3.95 (dd, 1H, J = 17.6, 5.8 Hz), 3.90 – 3.86 (m, 1H), 3.85 – 3.76 (m, 4H), 3.76 – 3.66 (m, 
1H), 3.28 – 3.10 (m, 2H), 2.81 (dd, 1H, J = 16.3, 5.3 Hz), 2.70 – 2.59 (m, 7H), 2.56 – 2.40 (m, 2H), 
2.36 – 2.24 (m, 1H), 2.23 – 2.11 (m, 1H), 2.08 (s, 3H), 1.89 – 1.78 (m, 1H), 1.70 – 1.49 (m, 3H), 
1.38 (s, 9H); 
13
C NMR (101 MHz, Acetone-d6) δ 174.0, 173.2, 172.7, 170.7, 170.5, 168.5, 167.6, 
158.9, 157.6, 157.2, 139.1, 137.8, 137.1, 137.0, 135.8, 129.6, 129.3, 129.2, 129.0, 128.8, 128.7, 
128.4, 124.9, 112.5, 81.3, 67.3, 67.2, 60.6, 55.9, 54.2, 53.3, 53.0, 48.0, 41.8, 41.1, 40.4, 38.3, 31.9, 
30.5, 28.2, 28.0, 26.3, 24.3, 18.7, 12.1; IR (neat): νmax 3309, 2932, 2359, 1731, 1652, 1541, 1455, 
1258, 1120; MS (ESI) m/z calcd for [C56H72N9O14S]
+
: 1126.49 [M+H]
+
; found: 1126.7. 
 
H-Asp(OtBu)-DKP-Arg(Mtr)-Gly-OH (115) 
 
a) H-Asp(OtBu)-DKP3-Arg(Mtr)-Gly-OH 
 Compound 114 a (307 mg, 0.28 mmol, 1 eq.) was treated with Pd/C 10%  (29.3 mg, 0.03 mmol, 
0.1 eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (248 mg, 100%) that was used without further purification. 
b) H-Asp(OtBu)-DKP4-Arg(Mtr)-Gly-OH 
 Compound 114 b (307 mg, 0.28 mmol, 1 eq.) was treated with Pd/C 10%  (29.3 mg, 0.03 mmol, 
0.1 eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (248 mg, 100%) that was used without further purification. 
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c) H-Asp(OtBu)-DKP5-Arg(Mtr)-Gly-OH 
 Compound 114 c (170 mg, 0.14 mmol, 1 eq.) was treated with Pd/C 10%  (14.9 mg, 0.014 mmol, 
0.1 eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (137 mg, 100%) that was used without further purification. 
d) H-Asp(OtBu)-DKP6-Arg(Mtr)-Gly-OH 
 Compound 114 d (400 mg, 0.36 mmol, 1 eq.) was treated with Pd/C 10%  (38.1 mg, 0.04 mmol, 
0.1 eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (322 mg, 100%) that was used without further purification. 
e) H-Asp(OtBu)-DKP7-Arg(Mtr)-Gly-OH 
 Compound 114 e (218 mg, 0.18 mmol, 1 eq.) was treated with Pd/C 10%  (19.3 mg, 0.018 mmol, 
0.1 eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (176 mg, 100%) that was used without further purification. 
f) H-Asp(OtBu)-DKP8-Arg(Mtr)-Gly-OH 
 Compound 114 f (148 mg, 0.13 mmol, 1 eq.) was treated with Pd/C 10%  (13.8 mg, 0.013 mmol, 
0.1 eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (124 mg, 100%) that was used without further purification. 
 
Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP] (116) 
 
a) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP3] 
 To a solution of 115 a (80 mg, 0.09 mmol, 1 eq.) in DMF (64 ml), under nitrogen atmosphere and 
at 0 ºC, DIPEA (92 μl, 0.54 mmol, 6 eq.) and DPPA (58 μl, 0.27 mmol, 3 eq.) were added 
successively. After stirring the reaction mixture at 0 ºC for 5 h, it was allowed to reach r.t., and 
stirred for 2 days. DMF was then removed under reduced pressure and the residue was purified by 
flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford the desired product as white 
foam (58.7 mg, 75%). 
 Rf=0.34 (CH2Cl2/MeOH, 9:1); 
1
H NMR (400 MHz, CD3OD) δ 7.33 – 7.14 (m, 5H), 6.57 (s, 1H), 
5.06 (d, 1H, J = 15.1 Hz), 4.87 – 4.79 (m, 1H), 4.49 – 4.40 (m, 1H), 4.33 (d, 1H, J = 17.2 Hz), 3.92 
– 3.80 (m, 3H), 3.74 (s, 3H), 3.69 (dd, 1H, J = 10.2, 4.6 Hz), 3.45 – 3.34 (m, 2H), 3.10 (t, 2H, J = 
6.6 Hz), 2.78 (dd, 1H, J = 16.4, 8.5 Hz), 2.64 (dd, 1H, J = 13.4, 10.1 Hz), 2.58 (s, 3H), 2.51 (s, 3H), 
2.46 – 2.33 (m, 2H), 2.03 (s, 3H), 2.01 – 1.76 (m, 2H), 1.58 – 1.37 (m, 2H), 1.32 (s, 9H); 13C NMR 
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(101 MHz, CD3OD) δ 173.8, 173.3, 172.3, 171.7, 171.2, 159.8, 158.2, 139.5, 137.9, 136.9, 134.9, 
130.1, 129.1, 125.7, 114.2, 112.9, 82.4, 60.3, 56.0, 53.2, 50.4, 48.4, 43.6, 39.6, 38.5, 37.1, 28.3, 
27.5, 27.0, 24.2, 18.8, 12.1; MS (ESI) m/z calcd for [C40H56N9O11S]
+
: 870.38 [M+H]
+
; found: 
870.8. 
b) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP4] 
 Compound 115 b (224 mg, 0.25 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (380.2 mg, 1 mmol, 4 eq.), HOAt (136.1 mg, 1 mmol, 4 eq.) 
and DIPEA (0.26 ml, 1.5 mmol, 6 eq). The crude product was purified by flash chromatography on 
silica gel (CH2Cl2/MeOH, 95:5) to afford yellowish solid that was further purified by Biotage 
(gradient: 95% H2O / 5% acetonitrile to 5% H2O / 95% acetonitrile), to obtain the product as white 
foam (133 mg, 61%). 
 Rf=0.45 (CH2Cl2/MeOH 9:1); 
1
H NMR (400 MHz, CD3OD) δ 7.41 – 7.21 (m, 5H), 6.68 (s, 1H), 
5.36 (br s, 1H), 4.53 – 4.41 (m, 1H), 4.39 – 4.28 (m, 1H), 4.24 – 3.89 (m, 3H), 3.85 (s, 1H), 3.78 
(d, 1H, J = 10.6 Hz,), 3.68 – 3.48 (m, 1H), 3.31 – 3.26 (m, 1H) 3.20 (t, 2H, J = 5.7 Hz), 2.98 – 2.86 
(m, 1H), 2.83 – 2.72 (m, 2H), 2.72 – 2.56 (m, 7H), 2.14 (s, 3H), 1.89 – 1.75 (m, 1H), 1.74 – 1.52 
(m, 3H), 1.49 (s, 9H); 
13
C NMR (101 MHz, CD3OD) δ 172.3, 172.1, 169.9, 169.4, 168.4, 166.9, 
158.5, 138.1, 136.5, 128.6, 127.5, 124.3, 111.4, 81.3, 56.8, 54.6, 53.2, 41.9, 40.7, 40.1, 35.8, 30.7, 
27.8, 26.9, 22.8, 17.3, 10.7; MS (ESI) m/z calcd for [C40H56N9O11S]
+
: 870.38 [M+H]
+
; found: 
870.4. 
c) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP5] 
 Compound 115 c (224 mg, 0.25 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (103.4 mg, 0.27 mmol, 4 eq.), HOAt (37.3 mg, 0.27 mmol, 4 
eq.) and DIPEA (54 μl, 0.41 mmol, 6 eq). The crude product was purified by flash chromatography 
on silica gel (CH2Cl2/MeOH, 95:5) to afford yellowish solid that was further purified by Biotage 
(gradient: 95% H2O / 5% acetonitrile to 5% H2O / 95% acetonitrile), to obtain the product as white 
foam (20 mg, 31%). 
 Rf=0.33 (CH2Cl2/MeOH 9:1); 
1
H NMR (400 MHz, Acetone-d6) δ 8.00 (d, 1H, J = 6.9 Hz), 7.84 (d, 
1H, J = 6.7 Hz), 7.79 – 7.70 (m, 1H), 7.58 (d, 1H, J = 7.7 Hz), 7.48 – 7.17 (m, 10H), 6.69 – 6.62 
(m, 2H), 6.52 (br s, 2H), 6.38 (br s, 2H), 5.30 (d, 1H, J = 15.4 Hz), 5.24 (d, 1H, J = 16.0 Hz), 5.02 
(d, 1H, J = 8.2 Hz), 4.65 – 4.38 (m, 2H), 4.38 – 3.89 (m, 5H), 3.82 (s, 3H), 3.52 (dd, 1H, J = 15.6, 
2.3 Hz), 3.42 (dd, 1H, J = 13.9, 4.4 Hz), 3.28 – 3.13 (m, 2H), 2.87 (dd, 1H, J = 16.2, 8.2 Hz), 2.72 
– 2.54 (m, 9H), 2.08 (s, 3H), 1.91 – 1.78 (m, 1H), 1.73 – 1.48 (m, 3H), 1.40 (s, 9H); 13C NMR (101 
MHz, Acetone-d6) δ 172.1, 171.7, 171.6, 169.4, 169.1, 166.9, 158.0, 156.6, 138.5, 138.2, 136.3, 
136.1, 128.9, 128.5, 127.9, 127.7, 127.0, 123.9, 111.6, 80.4, 58.9, 58.7, 54.9, 50.8, 49.3, 46.7, 41.9, 
40.3, 39.4, 39.2, 36.8, 27.7, 27.3, 26.2, 23.3, 17.7, 11.2; MS (ESI) m/z calcd for [C47H62N9O11S]
+
: 
960.43 [M+H]
+
; found: 960.7. 
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d) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP6] 
 Compound 115 d (322 mg, 0.36 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (547.2 mg, 1.44 mmol, 4 eq.), HOAt (195.8 mg, 1.44 mmol, 
4 eq.) and DIPEA (0.37 ml, 2.2 mmol, 6 eq). The crude product was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford yellowish solid that was further 
purified by Biotage (gradient: 95% H2O / 5% acetonitrile to 5% H2O / 95% acetonitrile), to obtain 
the product as white foam (180 mg, 58%). 
 Rf=0.47 (CH2Cl2/MeOH 9:1); 
1
H NMR (400 MHz, DMSO-d6) δ 9.08 – 8.95 (m, 1H), 8.37 (d, 1H, J 
= 8.2 Hz), 7.95 (br s, 1H), 7.71 – 7.61 (m, 1H), 7.46 (br s, 1H, J = 7.6 Hz), 7.39 – 7.22 (m, 5H), 
6.88 – 6.64 (m, 2H), 6.55 – 6.25 (m, 1H), 5.14 (d, 1H, J = 14.9 Hz), 4.21 (br s, 2H), 4.05 (d, 1H, J 
= 16.0 Hz), 3.99 – 3.92 (m, 1H), 3.90 – 3.75 (m, 5H), 3.63 – 3.43 (m, 3H), 3.01 (m, 2H), 2.88 (dd, 
1H, J = 16.2, 7.4 Hz), 2.78 – 2.48 (m, 8H, overlapping with solvent signal), 2.44 (dd, 1H, J = 16.3, 
7.0 Hz), 2.06 (s, 3H), 1.74 – 1.58 (m, 1H), 1.56 – 1.26 (m, 12H); 13C NMR (101 MHz, DMSO-d6) δ 
172.3, 171.6, 170.9, 169.8, 167.4, 166.7, 158.6, 157.2, 138.8, 137.8, 136.7, 135.7, 129.8, 128.8, 
128.5, 124.7, 112.9, 81.2, 58.5, 56.6, 55.6, 53.4, 51.5, 47.2, 43.6, 42.1, 36.6, 35.5, 32.4, 29.9, 28.8, 
26.8, 24.7, 19.1, 12.9; MS (ESI) m/z calcd for [C40H56N9O11S]
+
: 870.38 [M+H]
+
; found: 870.4. 
e) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP7] 
 Compound 115 e (167 mg, 0.17 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (259.7 mg, 0.68 mmol, 4 eq.), HOAt (93 mg, 0.68 mmol, 4 
eq.) and DIPEA (0.17 ml, 1.02 mmol, 6 eq). The crude product was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford yellowish solid that was further 
purified by Biotage (gradient: 95% H2O / 5% acetonitrile to 5% H2O / 95% acetonitrile), to obtain 
the product (75 mg, 46%) as a 2:1 mixture of two inseparable diastereomers. 
 Rf=0.32 (CH2Cl2/MeOH 9:1);
 1
H NMR (400 MHz, CD3OD) δ (two diastereomers A and B; A/B = 
2:1) 7.47 – 7.19 (m, 10HA+ 10HB), 6.70 – 6.65 (m, 1HA + 1HB), 5.40 (d, 1HB, J = 15.2 Hz), 5.35 (d, 
1HB, J = 16.6 Hz), 5.19 (d, 1HA, J = 14.9 Hz), 5.05 – 4.94 (m, 2HA), 4.78 (dd, 1HA, J = 11.5, 2.1 
Hz), 4.57 (t, 1HB, J = 6.7 Hz), 4.52 (d, 1HB, J = 16.7 Hz), 4.46 (d, 1HA, J = 17.4 Hz), 4.43 – 4.39 
(m, 1HB), 4.34 (d, 1HB, J = 16.5 Hz), 4.29 – 4.19 (m, 1HA + 2HB), 4.13 (d, 1HA, J = 15.1 Hz), 4.08 
– 3.96 (m, 2HA), 3.91 (d, 1HB, J = 15.3 Hz), 3.88 – 3.78 (m, 3HA + 4HB), 3.70 (dd, 1HA, J = 10.4, 
4.1 Hz), 3.66 – 3.56 (m, 1HA + 1HB), 3.53 – 3.42 (m, 1HA + 1HB), 3.28 – 3.09 (m, 2HA + 2HB), 
3.03 – 2.80 (m, 2HA + 1HB), 2.78 – 2.65 (m, 4HA + 4HB), 2.63 (s, 3HB), 2.60 (s, 3HA), 2.58 – 2.43 
(m, 1HA + 2HB), 2.15 (s, 3HB), 2.13 (s, 3HA), 2.11 – 2.00 (m, 1HA), 1.94 – 1.81 (m, 1HA + 1HB), 
1.80 – 1.70 (m, 1HB), 1.66 – 1.52 (m, 2HA + 2HB), 1.49 – 1.44 (m, 9HA + 9HB); 
13
C NMR (101 
MHz, CD3OD) δ (two rotamers) 173.2, 172.2, 171.7, 171.1, 170.7, 170.4, 169.8, 168.5, 167.5, 
158.5, 156.7, 138.1, 136.9, 136.5, 135.8, 135.5, 133.5, 128.7, 128.6, 128.5, 128.3, 127.9, 127.8, 
127.0, 126.9, 126.1, 124.3, 111.4, 80.9, 59.7, 58.4, 56.9, 56.8, 54.6, 53.8, 50.2, 48.7, 43.2, 42.2, 
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39.7, 38.2, 35.9, 35.6, 35.1, 28.3, 26.9, 26.0, 25.5, 22.9, 17.4, 13.0, 10.7; MS (ESI) m/z calcd for 
[C47H62N9O11S]
+
: 960.43 [M+H]
+
; found: 960.5. 
f) Cyclo[DKP-8-Arg(Mtr)-Gly-Asp(OtBu)] 
 Compound 115 f (124 mg, 0.13 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (197 mg, 0.52 mmol, 4 eq.), HOAt (70 mg, 0.52 mmol, 4 
eq.), and DIPEA (137 μl, 0.8 mmol, 6 eq.). The crude product was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 93:7) to afford the desired product as white foam (85 
mg, 74%). 
 Rf=0.4 (CH2Cl2/MeOH, 9:1); 
1
H NMR (400 MHz, CD3OD) δ 7.41 – 7.22 (m, 5H), 6.66 (s, 1H), 
5.31 (d, 1H, J = 15.3 Hz), 4.47 (dd, 1H, J = 8.4, 4.9 Hz), 4.27 (dd, 1H, J = 8.7, 5.8 Hz), 4.18 – 4.08 
(m, 2H), 4.05 (d, 1H, J = 15.3 Hz), 3.97 (d, 1H, J = 16.8 Hz), 3.88 – 3.79 (m, 4H), 3.67 (d, 1H, J = 
16.8 Hz), 3.55 (d, 1H, J = 13.7 Hz), 3.26 – 3.14 (m, 2H), 2.91 (dd, 1H, J = 16.6, 4.9 Hz), 2.76 (dd, 
1H, J = 16.6, 8.4 Hz), 2.71 – 2.56 (m, 7H), 2.56 – 2.42 (m, 2H), 2.12 (s, 3H), 1.86 – 1.52 (m, 5H), 
1.44 (s, 9H); 
13
C NMR (101 MHz, CD3OD) δ 176.4, 175.9, 175.0, 173.9, 171.6, 171.6, 169.6, 
169.5, 159.9, 158.2, 139.5, 138.0, 137.4, 134.8, 130.0, 129.0, 125.7, 112.8, 82.4, 60.4, 56.0, 54.9, 
53.0, 52.4, 48.2, 44.0, 41.1, 40.2, 37.5, 31.8, 30.7, 29.0, 28.3, 27.4, 24.4, 18.9, 12.1; MS (ESI) m/z 
calcd for [C41H58N9O11S]
+
: 884.40 [M+H]
+
; found: 884.46. 
 
Cyclo[Arg-Gly-Asp-DKP] 
 
(102) Cyclo[Arg-Gly-Asp-DKP3] 
 Compound 116 a (50 mg, 0.06 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC (Water's Atlantis 21 mm x 10 
cm column, gradient: 90% H2O / 10% acetonitrile to 70% H2O / 30% acetonitrile) to give the 
desired compound (as trifluoroacetate salt) as white solid (34 mg, 80%). 
 1
H NMR (600 MHz, H2O/D2O 9:1, T= 298K) δ 8.76 (d, 1H, J = 8.2 Hz, Arg-NH), 8.28 (t, 1H, J = 
6.7 Hz, DKP-NH10), 8.06 (s, 1H, DKP-NH1), 8.02 – 7.95 (m, 1H, Gly-NH), 7.85 (d, 1H, J = 8.6 
Hz, Asp-NH), 7.37 – 7.18 (m, 5H, H-Ar), 7.10 (t, 1H, J = 5.9 Hz, NH-guan), 5.01 (m, 1H, CH2-
Ph), 4.76 (m, 1H, αH-Asp), 4.48 (m, 1H, DKP-H6), 4.21 (dd, 1H, J = 17.7, 8.2 Hz, αH-Gly), 4.16 
– 4.00 (m, 3H, DKP-H3 + CH2-Ph + αH-Arg), 3.90 (dd, 1H, J = 15.8, 7.1 Hz, DKP-H9), 3.63 – 
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3.47 (m, 2H, DKP-H9 + αH-Gly), 3.13 (dd, 2H, J = 13.2, 6.8 Hz, δH-Arg), 2.86 – 2.76 (m, 2H, 
DKP-H7, βH-Asp), 2.68 (dd, 1H, J = 17.1, 7.0 Hz, DKP-H7), 2.56 (dd, 1H, J = 14.4, 5.3 Hz, βH-
Asp), 1.95 – 1.84 (m, 1H, βH-Arg), 1.77 – 1.66 (m, 1H, βH-Arg), 1.63 – 1.46 (m, 2H, γH-Arg); 
13
C NMR (151 MHz, H2O/D2O 9:1, T= 298K) (obtained by HSQC experiment) δ 128.7, 127.6, 
127.5, 59.3, 53.8, 51.9, 49.3, 47.7, 42.4, 40.5, 39.1, 37.8, 34.7, 25.5, 24.4; MS (ESI) m/z calcd for 
[C26H36N9O8]
+
: 602.27 [M+H]
+
; found: 602.3. 
(103) Cyclo[Arg-Gly-Asp-DKP4] 
 Compound 116 b (93.7 mg, 0.11 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC (Water's Atlantis 21 mm x 10 
cm column, gradient: 90% H2O / 10% acetonitrile to 70% H2O / 30% acetonitrile) to give the 
desired compound as white solid (62 mg, 80%). 
 1
H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ  8.88 (br s, 1H, Asp-NH), 8.37 – 8.23 (m, 2H, 
Arg-NH + Gly-NH), 8.20 (m, 1H, DKP-NH4), 7.59 (m, 1H, DKP-NH10), 7.35 – 7.19 (m, 5H, H-
Ar), 7.11 (t, 1H, J = 6.1 Hz, NH-guan), 5.08 (m, 1H, CH2-Ph), 4.35 (m, 1H, αH-Asp), 4.29 – 4.14 
(m, 2H, αH-Arg + DKP-H6), 4.01 – 3.82 (m, 2H, αH-Gly + DKP-H3), 3.77 – 3.58 (m, 2H, αH-
Gly + DKP-H9), 3.34 (m, 1H, DKP-H9), 3.12 (m, 2H, δH-Arg), 3.01 – 2.67 (m, 4H, DKP-H7 + 
βH-Asp), 1.85 – 1.43 (m, 4H, βH-Arg + γH-Arg); 13C NMR (151 MHz, H2O/D2O 9:1, T= 298K) 
(obtained by HSQC experiment) δ 128.7, 127.6, 57.5, 53.5, 53.3, 52.0, 47.3, 42.3, 40.7, 40.6, 
35.7, 34.3, 28.0, 24.4; HRMS (ESI) m/z calcd for [C26H35N9O8Na]
+
: 624.25008 [M+Na]
+
; found: 
624.24942. 
(104) Cyclo[Arg-Gly-Asp-DKP5] 
 Compound 116 c (20 mg, 0.02 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC (Water's Atlantis 21 mm x 10 
cm column, gradient: 90% H2O / 10% acetonitrile to 30% H2O / 70% acetonitrile) to give the 
desired compound (as trifluoroacetate salt) as white solid (9.5 mg, 60%). 
 1
H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.61 – 8.53 (m, 1H, DKP-NH10), 8.48 (d, 1H, J = 
6.6 Hz, Arg-NH), 8.42 (d, 1H, J = 8.3 Hz, Asp-NH), 8.23 (d, 1H, J = 9.6 Hz, Gly-NH), 7.44 – 
7.19 (m, 10H, H-Ar), 7.11 – 7.03 (m, 1H, NH-guan), 5.10 (m, 1H, CH2-Ph), 5.00 (m, 1H, CH2-
Ph), 4.62 (m, 1H, αH-Asp), 4.41 (m, 1H, DKP-H6), 4.37 (m, 1H, CH2-Ph), 4.33 (m, 1H, DKP-
H3), 4.32 (m, 1H, DKP-H9), 4.23 (m, 1H, αH-Gly), 4.15 (d, 1H, J = 15.4 Hz, CH2-Ph), 4.11 (m, 
1H, αH-Arg), 3.42 (d, 1H, J = 17.3 Hz, αH-Gly), 3.34 (m, 1H, DKP-H9), 3.10 (dd, 2H, J = 12.6, 
6.6 Hz, δH-Arg), 2.86 (dd, 1H, J = 16.8, 7.8 Hz, βH-Asp), 2.70 (dd, 1H, J = 17.0, 7.2 Hz, βH-
Asp), 2.55 (m, 2H, DKP-H7), 1.82 – 1.50 (m, 4H, βH-Arg + γH-Arg);13C NMR (151 MHz, 
H2O/D2O 9:1, T= 298K) (obtained by HSQC experiment) δ 128.7, 128.5, 126.2, 59.5, 55.1, 51.5, 
50.1, 48.3, 48.1, 41.9, 40.3, 39.7, 39.4, 38.6, 26.8, 24.3; HRMS (ESI) m/z calcd for 
[C33H41N9O8Na]
+
: 714.29703 [M+Na]
+
; found: 714.29588. 
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(105) Cyclo[Arg-Gly-Asp-DKP6] 
 Compound 116 d (80.2 mg, 0.09 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by (Water's Atlantis 21 mm x 10 cm 
column, gradient: 90% H2O / 10% acetonitrile to 70% H2O / 30% acetonitrile) to give the desired 
compound (as trifluoroacetate salt) as white solid (54 mg, 82%). 
 1
H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.80 (d, 1H, J = 6.4 Hz, Asp-NH), 8.40 – 8.26 (m, 
2H, Gly-NH + Arg-NH), 8.07 (s, 1H, DKP-NH4), 7.89 (t, 1H, J = 6.1 Hz, DKP-NH10), 7.40 – 
7.22 (m, 5H, H-Ar), 7.10 (t, 1H, J = 5.7 Hz, NH-guan), 5.06 (d, 1H, J = 17.9 Hz, CH2-Ph), 4.35 
(m, 1H, αH-Asp), 4.29 (m, 1H, αH-Arg), 4.26 – 4.19 (m, 2H, DKP-H6 + CH2-Ph), 3.96 – 3.89 
(m, 1H, DKP-H3), 3.90 – 3.75 (m, 2H, αH-Gly + DKP-H9), 3.67 (dd, 1H, J = 15.6, 6.1 Hz, αH-
Gly), 3.58 – 3.43 (m, 1H, DKP-H9), 3.13 (dd, 2H, J = 12.9, 6.9 Hz, δH-Arg), 2.81 – 2.67 (m, 3H, 
DKP-H7 + βH-Asp), 2.56 (dd, 1H, J = 16.1, 8.3 Hz, βH-Asp), 1.84 – 1.48 (m, 4H, βH-Arg + γH-
Arg);
13
C NMR (151 MHz, H2O/D2O 9:1, T= 298K) (obtained by HSQC experiment) δ 128.6, 
127.6, 57.6, 54.9, 53.1, 51.3, 47.7, 47.1, 42.8, 40.4, 35.4, 35.0, 27.8, 24.2; HRMS (ESI) m/z calcd 
for [C26H35N9O8Na]
+
: 624.25008 [M+Na]
+
; found: 624.24929. 
(106) Cyclo[Arg-Gly-Asp-DKP7] 
 Compound 116 e (65 mg, 0.068 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC (Water's Atlantis 21 mm x 10 
cm column, gradient: 90% H2O / 10% acetonitrile to 40% H2O / 60% acetonitrile) to give 31A (as 
trifluoroacetate salt) (21.3 mg) and 31B (as trifluoroacetate salt) (10.6 mg) as white solids (60% 
overall). 
 106 A: 
1
H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.66 (d, 1H, J = 7.7 Hz, Arg-NH), 8.04 (t, 
1H, J = 6.6 Hz, DKP-NH10), 7.95 – 7.89 (m, 1H, Gly-NH), 7.77 – 7.70 (m, 1H, Asp-NH), 7.44 – 
7.16 (m, 10H, H-Ar), 7.10 – 7.04 (m, 1H, NH-guan), 5.06 – 4.99 (m, 1H, CH2-Ph), 4.89 (m, 1H, 
αH-Asp), 4.80 (m, 1H, CH2-Ph), 4.69 (m, 1H, DKP-H6), 4.57 (m, 1H, CH2-Ph), 4.39 – 4.33 (m, 
2H, αH-Gly, DKP-H3), 4.14 – 4.07 (m, 1H, αH-Arg), 4.04 (d, 1H, J = 14.8 Hz, CH2-Ph), 3.91 
(dd, 1H, J = 15.4, 7.1 Hz, DKP-H9), 3.71 – 3.61 (m, 1H, DKP-H9), 3.60 – 3.52 (m, 1H, αH-Gly), 
3.10 (dd, 2H, J = 12.9, 6.9 Hz, δH-Arg), 2.90 – 2.76 (m, 2H, DKP-H7, βH-Asp), 2.62 (dd, 1H, J 
= 17.1, 6.3 Hz, βH-Asp), 2.58 – 2.49 (m, 1H, DKP-H7), 2.01 – 1.87 (m, 1H, βH-Arg), 1.73 – 1.58 
(m, 1H, βH-Arg), 1.55 – 1.42 (m, 2H, γH-Arg); 13C NMR (151 MHz, H2O/D2O 9:1, T= 298K) 
(obtained by HSQC experiment) δ 128.1, 48.0, 43.2, 40.9, 39.7, 37.7, 36.9, 25.4, 24.4; MS (ESI) 
m/z calcd for [C33H42N9O8]
+
: 692,31 [M+H]
+
; found: 692.4. 
 106 B: 
1
H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.55 (d, 1H, J = 8.1 Hz, Asp-NH), 8.45 (t, 
1H, J = 5.8 Hz, Gly-NH), 8.34 (d, 1H, J = 5.9 Hz, Arg-NH), 7.73 (d, 1H, J = 8.4 Hz, DKP-
NH10), 7.46 – 7.16 (m, 10H, H-Ar), 7.16 – 7.10 (m, 1H, NH-guan), 5.27 – 5.15 (m, 2H, CH2-Ph), 
4.52 (m, 1H, αH-Asp), 4.44 (m, 1H, DKP-H6), 4.36 – 4.29 (m, 1H, CH2-Ph), 4.20 (d, 1H, J = 
14.8 Hz, CH2-Ph), 4.16 – 4.07 (m, 2H, αH-Arg, DKP-H3), 3.80 (dd, 1H, J = 15.2, 4.1 Hz, αH-
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Gly), 3.76 – 3.63 (m, 2H, αH-Gly, DKP-H9), 3.38 – 3.28 (m, 1H, DKP-H9), 3.16 (dd, 2H, J = 
13.6, 7.1 Hz, δH-Arg), 2.94 (dd, 1H, J = 14.9, 6.1 Hz, DKP-H7), 2.87 – 2.72 (m, 2H, DKP-H7, 
βH-Asp), 2.60 (dd, 1H, J = 16.6, 7.2 Hz, βH-Asp), 1.77 (dd, 2H, J = 15.6, 8.3 Hz, βH-Arg), 1.69 
– 1.52 (m, 2H, γH-Arg);13C NMR (151 MHz, H2O/D2O 9:1, T= 298K) (obtained by HSQC 
experiment) δ 128.4, 60.7, 56.8, 53.6, 51.4, 49.6, 47.5, 43.5, 40.6, 39.3, 36.7, 35.6, 27.8; MS 
(ESI) m/z calcd for [C33H42N9O8]
+
: 692,31 [M+H]
+
; found: 692.3. 
(107) Cyclo[Arg-Gly-Asp-DKP8] 
 Compound 116 f (50 mg, 0.06 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC HPLC (Water's Atlantis 21 
mm x 10 cm column, gradient: 95% H2O / 5% acetonitrile to 80% H2O / 20% acetonitrile) to give 
the desired compound (as trifluoroacetate salt) as white solid (34 mg, 80%). 
 1
H NMR (400 MHz, D2O, 291 K) δ 8.21 – 8.14 (m, 1H), 7.35 – 7.12 (m, 5H), 5.07 (d, J = 15.7 
Hz, 1H), 4.45 (t, J = 6.3 Hz, 1H), 4.24 – 4.16 (m, 1H), 4.10 – 3.94 (m, 3H), 3.90 – 3.72 (m, 4H), 
3.61 (d, J = 14.8 Hz, 1H), 3.08 (t, J = 6.6 Hz, 2H), 2.76 (t, J = 5.4 Hz, 2H), 2.47 (m, 4H), 1.78 – 
1.42 (m, 6H). MS (ESI) m/z calcd for [C27H38N9O8]
+
: 616,28 [M+H]
+
; found: 616.3. 
 
4 -  Synthesis of cyclic[DKP-isoDGR] compounds 
4.1 -  Solid phase peptide synthesis 
GENERAL REMARKS: The syntheses of compounds 120 were carried out by manual coupling using 
Fmoc/tBu strategy on SASRIN
TM
 resin (200-400 mesh, 1.02 mmol/g) on a 0.1 mmol scale. Swelling 
of the resin was achieved suspending it in either DCM or DMF for 15 min. 
SASRIN
TM
 RESIN LOADING: The first Fmoc protected amino acid (Fmoc-GlyOH, 119 mg, 0.4 
mmol, 4 eq.) residue was dissolved in the minimum amount of DMF, and the solution was cooled to 
0° C. DIC (62 l, 0.4 mmol, 4 eq.) was added dropwise. The mixture was stirred for 20 min at the 
same temperature before adding it to the resin (98 mg, 0.1 mmol, 1 eq.). DMAP (1.2 mg, 0.01 mmol, 
0.1 eq.) was then added in one portion. The reaction vessel was gently shaken for 1 h at r.t.. Resin was 
thoroughly washed  in the order with DMF (4x), DCM (4x), iPrOH (3x). Capping was performed (see 
general procedure GP10). 
COUPLING REACTIONS: A sample vial equipped with a magnetic stirrer was charged with the 
appropriate N-protected-amino acid (2.5 - 4 eq.), which was dissolved in a 1:1 mixture of DCM/DMF. 
After cooling the mixture to 0 °C DIC (2.5 – 4 eq.) and HOAt (2.5 – 4 eq.) were added successively. 
The mixture was stirred for 20 min at the same temperature. The solution was then added to the N-
deblocked swelled peptidylresin (0.1 mmol, 1 eq.). The resin was gently agitated for 2-18 h and, after 
sucking off the solution, it was washed in the order with DMF (4x), DCM (4x), iPrOH (3x) and/or 
Et2O (2x). If a Fmoc-amino acid was coupled, Kaiser test was performed. If resin gives a positive 
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colour test, coupling procedure was repeated with fresh reagents. After a maximum of 3 coupling 
cycles, capping was performed (see general procedure GP10). 
Exact amounts of the used amino acids and coupling reagents for SPPS are reported in Table 5.1. 
 
Table 5.1 - Exact amounts of the used amino acids and coupling reagents for SPPS 
REAGENTS eq. n (mmol) AMOUNTS 
Fmoc-L-Asp(OH)-OtBu 3 0.3 123 mg 
DIC 3 0.3 47 l 
HOAt 3 0.3 41 mg 
DKP2*or DKP3* 2.5 0.25 79 mg 
DIC 2.5 0.25 38 l 
HOAt 2.5 0.25 34 mg 
Cbz-L-Arg(Mtr)-OH · CHA 4 0.4 248 mg 
DIC 4 0.4 62 l 
HOAt 4 0.4 27 mg 
 
Fmoc DEPROTECTION: After successful coupling, washing and  Fmoc deprotecting steps were 
carried out as described in general procedure GP7. This deprotection/coupling strategy was applied for 
each synthetic step involving N-Fmoc protected -amino acids. 
AZIDE REDUCTION: After successful coupling of DKP* building blocks, washing and  azide 
reduction steps were carried out as described in general procedure GP8. 
 
Cbz-Arg(Mtr)-DKP-isoAsp(OtBu)-Gly-OH (120) 
 
CLEAVAGE FROM SASRIN
TM
 RESIN: The resin was thoroughly washed with DCM (5 to 10 times) 
and then treated with 1% TFA in DCM (2ml) for 2-5 min. The mixture was filtered off with a N2 
pressure into a vial containing at least 2 eq. of pyridine in MeOH (0.2 ml 2M). The filtrate was 
checked for the peptide by TLC (DCM:MeOH=9:1). Treatment with 1% TFA in DCM was repeated 
as long as peptide was cleaving from the resin (5-8 times). Peptide containing fractions were combined 
and half of the DCM volume was removed at reduced pressure. The mixture was then diluted with 
aboundant EtOAc and washed with 1M KHSO4 aq. (4x) to remove pyridinium trifluoroacetate and free 
the carboxylic acid. The organic layer was dried over Na2SO4, filtered and evapourated to afford a 
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white solid which was purified by flash chromatography (DCM:MeOH=9:1) (a: 89 mg, 88%; b: 90 
mg, 88%).  
a) 
1
H NMR (400 MHz, MeOD) δ 8.35 (d, J = 6.2 Hz, 1H), 8.30 – 8.14 (m, 1H), 7.47 – 7.24 (m, 9H), 
7.19 (d, J = 7.6 Hz, 1H), 6.65 (s, 1H), 5.38 (d, J = 15.4 Hz, 1H), 5.09 (q, J = 12.4 Hz, 2H), 4.75 – 
4.56 (m, 2H), 4.13 (dd, J = 17.2, 9.3 Hz, 2H), 3.90 (dd, J = 12.5, 5.7 Hz, 4H), 3.82 (s, 1H), 3.60 
(dd, J = 15.6, 4.8 Hz, 3H), 3.16 (s, 2H), 3.05 (dd, J = 16.3, 4.0 Hz, 1H), 2.83 (dd, J = 16.4, 6.8 Hz, 
1H), 2.77 (d, J = 6.2 Hz, 2H), 2.68 (s, 3H), 2.62 (s, 3H), 2.12 (s, 3H), 1.73 (d, J = 5.6 Hz, 1H), 1.65 
– 1.49 (m, 3H), 1.47 (s, 9H); 13C NMR (101 MHz, MeOD) δ 175.0, 172.5, 171.8, 170.9, 170.8, 
168.2, 167.6, 159.1, 157.7, 138.8, 137.4, 137.1, 136.5, 134.1, 129.2, 128.8, 128.4, 128.3, 128.1, 
125.0, 112.1, 82.6, 67.2, 59.8, 55.5, 55.3, 51.4, 50.7, 41.2, 39.5, 37.5, 29.5, 27.5, 23.7, 18.1, 11.4; 
MS (ESI) m/z calcd for [C48H64N9O14S]
+
: 1022.43 [M+H]
+
; found: 1022.8. 
b) 
1
H NMR (400 MHz, MeOD) δ 7.43 – 7.22 (m, 9H), 6.67 (s, 1H), 5.38 (d, J = 15.3 Hz, 1H), 5.19 – 
5.01 (m, 2H), 4.71 (t, J = 5.9 Hz, 1H), 4.62 (s, 1H), 4.18 – 4.06 (m, 2H), 4.02 – 3.92 (m, 1H), 3.90 
(dd, J = 6.7, 3.7 Hz, 1H), 3.87 – 3.79 (m, 2H), 3.67 – 3.55 (m, 4H), 3.16 (dd, J = 13.2, 6.5 Hz, 1H), 
3.05 – 2.91 (m, 1H), 2.88 – 2.74 (m, 3H), 2.69 (s, 3H), 2.62 (s, 3H), 2.13 (s, 3H), 1.75 (bs, 1H), 
1.67 – 1.51 (m, 4H), 1.47 (s, 9H); 13C NMR (101 MHz, MeOD) δ 172.5, 171.7, 170.9, 170.9, 
168.2, 167.7, 159.2, 157.7, 157.4, 138.8, 137.4, 137.2, 136.3, 129.6, 129.2, 129.0, 128.8, 128.4, 
128.3, 128.2, 125.0, 112.08, 82.71, 67.09, 59.76, 55.32, 55.26, 51.69, 50.63, 41.09, 39.41, 38.02, 
37.52, 34.20, 32.33, 32.0, 30.0, 29.9, 29.7, 29.7, 29.5, 27.4, 25.3, 23.6, 23.0, 18.1, 13.7, 11.4; MS 
(ESI) m/z calcd for [C48H64N9O14S]
+
: 1022.43 [M+H]
+
; found: 1022.9. 
 
4.2 -  In solution 
H-Arg-DKP-isoAsp(OtBu)-Gly-OH (121) 
 
a) H-Arg-DKP2-isoAsp(OtBu)-Gly-OH 
 Compound 120 a (89 mg, 0.09 mmol, 1 eq.) was treated with Pd/C 10%  (9.2 mg, 0.009 mmol, 0.1 
eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (77 mg, 100%) that was used without further purification. 
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b) H-Arg-DKP3-isoAsp(OtBu)-Gly-OH 
 Compound 120 a (90 mg, 0.09 mmol, 1 eq.) was treated with Pd/C 10%  (9.3 mg, 0.009 mmol, 0.1 
eq.) in the conditions described in general procedure GP3. The crude product was obtained  as 
white solid (78 mg, 100%) that was used without further purification. 
 
Cyclo [isoAsp(OtBu)-Gly-Arg(Mtr)-DKP] (122) 
 
a) Cyclo [isoAsp(OtBu)-Gly-Arg(Mtr)-DKP2] 
 Compound 121 a (77 mg, 0.09 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (136 mg, 0.36 mmol, 4 eq.), HOAt (49 mg, 0.36 mmol, 4 
eq.) and DIPEA (93 l, 0.54 mmol, 6 eq). The crude product was purified by flash chromatography 
on silica gel (CH2Cl2/MeOH, 95:5) to afford the desired product as white foam (41 mg, 55%). 
 
1
H NMR (400 MHz, MeOD) δ 7.49 – 7.16 (m, 5H), 6.68 (s, 1H), 5.37 (d, J = 15.3 Hz, 1H), 5.03 (t, 
J = 6.9 Hz, 1H), 4.80 – 4.67 (m, 1H), 4.31 – 4.01 (m, 4H), 3.85 (s, 5H), 3.39 (d, J = 1.6 Hz, 1H), 
3.26 – 3.13 (m, 2H), 2.79 (dd, J = 14.0, 4.5 Hz, 1H), 2.75 – 2.71 (m, 1H), 2.69 (s, 3H), 2.62 (s, 
3H), 2.15 (s, 3H), 1.82 – 1.56 (m, 4H), 1.51 (s, 9H); 13C NMR (101 MHz, MeOD) δ 174.2, 171.5, 
170.7, 170.1, 169.7, 167.1, 166.7, 158.5, 156.8, 138.1, 136.5, 135.6, 133.5, 128.6, 127.8, 127.6, 
124.3, 111.4, 82.0, 59.1, 54.6, 53.9, 50.7, 48.5, 48.2, 48.0, 47.8, 47.6, 47.4, 47.2, 47.0, 46.4, 41.4, 
41.4, 40.0, 38.3, 37.3, 29.3, 27. 6, 26.8, 25.6, 22.8, 17.4, 10.7; MS (ESI) m/z calcd for 
[C40H56N9O11S]
+
: 870.38 [M+H]
+
; found: 870.8. 
b) Cyclo [isoAsp(OtBu)-Gly-Arg(Mtr)-DKP3] 
 Compound 121 b (78 mg, 0.09 mmol, 1 eq.) was cyclized in the conditions described in general 
procedure GP4, in presence of HATU (137 mg, 0.36 mmol, 4 eq.), HOAt (49 mg, 0.36 mmol, 4 
eq.) and DIPEA (93 l, 0.54 mmol, 6 eq). The crude product was purified by flash chromatography 
on silica gel (CH2Cl2/MeOH, 95:5) to afford the desired product as white foam (31 mg, 35%). 
 1
H NMR (400 MHz, MeOD) δ 7.62 – 7.01 (m, 4H), 6.68 (s, 1H), 5.44 (d, J = 15.3 Hz, 1H), 5.06 
(dd, J = 11.8, 3.2 Hz, 1H), 4.65 – 4.55 (m, 1H), 4.32 – 4.19 (m, 2H), 4.07 (d, J = 15.3 Hz, 1H), 
3.84 (s, 4H), 3.72 (dd, J = 33.2, 14.8 Hz, 3H), 3.30 – 3.12 (m, 3H), 2.91 (dd, J = 14.7, 3.3 Hz, 2H), 
2.69 (s, 3H), 2.63 (s, 3H), 2.40 – 2.22 (m, 1H), 2.14 (s, 3H), 1.91 – 1.74 (m, 2H), 1.73 – 1.56 (m, 
5H), 1.50 (s, 9H); 
13
C NMR (101 MHz, MeOD) δ 175.8, 172.5, 171.8, 170.9, 170.5, 168.4, 167.1, 
162.7, 162.4, 159.2, 157.5, 138.7, 137.1, 136.4, 134.0, 129.3, 129.2, 128. 8, 128.7, 128.34, 128.3, 
125.0, 112.1, 112.09, 82.9, 59.7, 55.3, 54.3, 51.3, 50.1, 47.2, 41.9, 39.2, 38.5, 37.8, 30.0, 29.0, 
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27.4, 26.5, 23.6, 18.1, 11.4; MS (ESI) m/z calcd for [C40H56N9O11S]
+
: 870.38 [M+H]
+
; found: 
870.8. 
 
Cyclo [isoAsp-Gly-Arg-DKP] (118) (119) 
 
(118) Cyclo [isoAsp-Gly-Arg-DKP2] 
 Compound 122 a (41 mg, 0.05 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC (Water's Atlantis 21 mm x 10 
cm column, gradient: 90% H2O / 10% acetonitrile to 40% H2O / 60% acetonitrile) to give the 
desired compound (as trifluoroacetate salt) as white solid (7 mg, 24%) 
MS (ESI) m/z calcd for [C26H36N9O8]
+
: 602,27 [M+H]
+
; found: 602,3. 
(119) Cyclo [isoAsp-Gly-Arg-DKP3] 
 Compound 122 b (31 mg, 0.035 mmol) was fully deprotected in the conditions described in  
general procedure GP5. The crude product was purified by HPLC (Water's Atlantis 21 mm x 10 
cm column, gradient: 90% H2O / 10% acetonitrile to 60% H2O / 40% acetonitrile) to give the 
desired compound (as trifluoroacetate salt) as white solid (6 mg, 29%). 
 MS (ESI) m/z calcd for [C26H36N9O8]
+
: 602,27 [M+H]
+
; found: 602,2. 
 
5 -  Synthesis of -peptide foldamer [DKP1-Ala-Ala]2-DKP1-NH2 (127) 
(S)-N-(((2S,5S)-5-(2-amino-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-yl)methyl)-2-((S)-2-(2-
((2S,5S)-5-(((S)-2-((S)-2-(2-((2S,5S)-5-(aminomethyl)-4-benzyl-3,6-dioxopiperazin-2-yl) 
acetamido)propanamido)propanamido)methyl)-4-benzyl-3,6-dioxopiperazin-2-yl) 
acetamido)propanamido)propanamide (127) 
 
 
GENERAL REMARKS: The synthesis was carried out by manual coupling using Fmoc/tBu strategy 
on the acid labile Rink amide MBHA resin (loading 0.6 mmol/g) pre-modified with an Fmoc 
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protecting group on a 0.1 mmol scale. Swelling of the resin was achieved suspending it in either DCM 
or DMF for 15 min. 
Resin Fmoc deprotection was aceived  following general procedure GP6. 
 
COUPLING REACTIONS: 
Fmoc--amino acid residues: A 1M solution (in either a 1:1 mixture of DCM/DMF or dioxane) of the 
appropriate N-Fmoc-protected succinimidyl ester (0.4 mmol, 4 eq.) was added to the resin, which was 
gently shaken for 2-18 h. The resin was washed in the order with DMF (4x), DCM (4x), iPrOH (3x) 
and/or Et2O (2x). Kaiser test was performed. If resin gives a positive colour test, coupling procedure 
was repeated with fresh reagents (half of the amounts). After a maximum of 3 coupling cycles, 
capping was performed (see general procedure GP9). Preparation of amino acid succinimidyl esters: 
DCC (1.1 eq) was added to a stirring solution of the appropriate Fmoc-amino acid and N-hydroxy 
succinimide in dry THF, at 0 °C. The reaction mixture was stirred at 0° C for 4 h, and then allowed to 
stand in a refrigerator at 0° C for 16 h. The separated solid was removed by filtration and washed with 
THF (2x). The filtrate and washings were combined, and volatiles were removed at reduced pressure. 
The residue was dissolved in a small amount of DCM, and solution was filtered to remove insoluble 
material. Removal of volatiles at reduced pressure gave a foamy solid, which might be crystallized 
from a 1:1 mixture of DCM:PE. The isolated solid could be stored at -20 °C. 
DKP1*: A sample vial equipped with a magnetic stirrer was charged DKP1* (80 mg, 0.25 mmol, 2.5 
eq.) and HOBt (42 mg, 0.275 mmol,  2.75 eq.). A minimum amount of DMF to dissolve was added. 
After cooling the mixture to 0 °C DCC (57 mg, 0.275 mmol, 2.75 eq.) was added as a solution in 
DCM (1M), dropwise. The mixture was stirred for 20 min at the same temperature. DCU, which 
formed as a white solid, was let to settle and then filtered off. The solution was then added to the N-
deblocked swelled peptidylresin (0.1 mmol, 1 eq.). The resin was gently agitated for 18 h and, after 
sucking off the solution, it was washed in the order with DMF (4x), DCM (4x), iPrOH (3x) and/or 
Et2O (2x). 
 
Exact amounts of the used amino acids for SPPS are reported in Table 5.2. 
 
Table 5.2 - Exact amounts of the used amino acids for SPPS 
REAGENTS eq. n (mmol) AMOUNTS 
Fmoc-L-Ala-L-Ala-OSu (130) 4 0.4 191 mg 
Fmoc-L-Ala-OSu (128) 4 0.4 163 mg 
 
Synthesis of Fmoc-L-Ala-L-Ala-OH (129): A solution of Fmoc-L-Ala-OSu (686 mg, 1.68 mmol, 1 eq.) 
in a mixture of EtOH/Acetone 4:1 was added under stirring to 2 ml of a water solution containing 150 
mg of L-Ala-OH (1.68 mmol, 1 eq.) and 283 mg of NaHCO3 (3.37 mmol, 2 eq.). After stirring the 
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mixture for 20 h, the organic solvent was evapourated and additional 15 ml of water were added. 
Insoluble impurities were removed by filtration. The filtrate was then acidified adding HClconc., and the 
precipitate was collected and washed several times with water to obtain pure product in 76% yield 
(490 mg). 
1
H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.4 Hz, 2H), 7.39 (t, J = 7.3 Hz, 
2H), 7.35 – 7.22 (m, 3H), 6.87 (d, J = 6.6 Hz, 1H), 5.57 (dd, J = 6.4, 2.9 Hz, 1H), 4.93 (p, J = 7.3 Hz, 
1H), 4.45 – 4.25 (m, J = 7.0 Hz, 3H), 4.24 – 4.06 (m, J = 6.9 Hz, 1H), 3.73 (s, 1H), 2.81 (d, J = 9.5 
Hz, 2H), 1.56 (d, J = 7.2 Hz, 1H), 1.42 – 1.36 (m, 2H). 
 
Fmoc DEPROTECTION: After successful coupling, washing and Fmoc deprotecting steps were 
carried out as described in general procedure GP7. This deprotection/coupling strategy was applied for 
each synthetic step involving N-Fmoc protected -amino acids. 
AZIDE REDUCTION: After successful coupling of DKP1* building blocks, washing and  azide 
reduction steps were carried out as described in general procedure GP8. 
CLEAVAGE FROM RINK AMIDE RESIN: 
Small cleavage: 0.5 ml of a solution of TFA, TIS and water (90:5:5) was added to a few beads of the 
resin in a sample vial. The mixture was gently agitated for 2 h. Cold Et2O was added and volatiles 
were removed with a N2 flux. Addition of more cold ether resulted in the precipitation of the product. 
Et2O was removed with a pipette. The process was repeated twice, in order to purify the peptide. 
MeOH was then added, dissolving the peptide. The resin beads were separated and washed with more 
MeOH. Volatiles were then removed under a N2 flux, affording the peptide. 
Final cleavage: 1.5 ml of a solution of TFA, TIS and water (90:5:5) was added to the resin. The 
mixture was gently agitated for 2.5 h. After removal of the TFA under reduced pressure the peptides 
were precipitated from ice-cold diethyl ether. After filtering off the solution the peptides were 
acidified with conc. acetic acid and dissolved in a solution of 10 % acetic acid in water. The solvent 
was removed via lyophilization overnight and the crude peptides purified by preparative RP-HPLC. 
60 mg of 127 were obtained (0.053 mmol, 53%). 
Preparative reversed-phase HPLC of compound 127 was performed on Phenomenex Luna C18 100 Ǻ 
3 μm column (150mm  x 2 mm). 97% (5.9‰ TFA in water) /  3% acetonitrile to 2% (5.9‰ TFA in 
water) /  98 % acetonitrile; linear gradient has been used during 30 min, at a flow rate of 0.3 mL/min, 
with detection at 206 nm. 
1
H NMR (600 MHz, DMSO, 310 k) δ 8.57, 8.57, 8.32, 8.31, 8.28, 8.27, 8.21, 8.20, 8.18, 8.17, 8.09, 
8.09, 8.08, 8.05, 8.04, 8.00, 7.84, 7.51, 7.35, 7.35, 7.34, 7.33, 7.33, 7.32, 7.32, 7.31, 7.29, 7.29, 7.28, 
7.27, 7.27, 7.26, 7.25, 7.05, 7.05, 5.10, 5.08, 5.08, 5.06, 4.90, 4.87, 4.37, 4.37, 4.37, 4.36, 4.35, 4.35, 
4.34, 4.33, 4.33, 4.32, 4.31, 4.30, 4.28, 4.28, 4.27, 4.27, 4.26, 4.26, 4.15, 4.13, 4.13, 4.11, 4.09, 4.08, 
4.07, 4.07, 3.79, 3.79, 3.78, 3.77, 3.62, 3.60, 3.60, 3.59, 3.59, 3.59, 3.59, 3.59, 3.58, 3.58, 3.57, 2.84, 
2.83, 2.81, 2.80, 2.76, 2.76, 2.75, 2.74, 2.74, 2.74, 2.73, 2.72, 2.72, 2.70, 2.70, 2.69, 2.68, 2.68, 2.67, 
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2.66, 2.64, 2.64, 2.62, 2.62, 2.61, 2.61, 1.26, 1.25, 1.24, 1.23, 1.21, 1.20, 1.20, 1.19; MS (ESI) m/z 
calcd for [C54H69N14O13]
+
: 1121.52 [M+H]
+
; found: 1121.7. 
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168  Appendix of NMR Data 
50: -allyl aspartic acid hydrochloride 
1
H NMR (400 MHz, D2O): 
 
51: N-Boc--allyl aspartic acid  
1
H NMR (300 MHz, CDCl3): 
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52: serine methylester hydrochloride 
1
H NMR (300 MHz, D2O): 
 
53: N-Bn-Ser-OMe 
 
1
H NMR (300 MHz, CDCl3): 
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55 a + b: N-Bn-Ser(O-(S)-N-Boc-Asp(OAll))-OMe 
1
H NMR (300 MHz, CDCl3): 
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55 c: (S)-N-Bn-Ser(O-(R)-N-Boc-Asp(OAll))-OMe 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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57 c: (S)-N-Bn-Ser(O-(R)-Asp(OAll))-OMe bis-trifluoroacetate 
 
49 a: OH-DKP1-OAll 
1
H NMR (300 MHz, CDCl3): 
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49 c: OH-DKP3-OAll 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2) 
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58 a: N3-DKP1-CO2Allyl + 60 a: H2C=DKP-CO2Allyl 
1
H NMR (300 MHz, CDCl3): 
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58 c: N3-DKP3-CO2Allyl 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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59 c: N-Boc-DKP3- CO2Allyl 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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DKP1* - 
1
H NMR (300 MHz, CDCl3): 
 
DKP3* - 
1
H NMR (400 MHz, CDCl3): 
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72 a: N-Boc-(R)-Ser(N3)-N-Bn-(S)-Asp(OMe)-OMe 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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66 a: N3-DKP4-CO2Me 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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73 a: NH2-DKP4-CO2Me 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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74 a: NHBoc-DKP4-CO2Me 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
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77 b: N3-DKP7-CO2Me 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
 
  
Appendix of NMR Data  183 
78 b: NHBoc-DKP7-CO2Me 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
 
  
184  Appendix of NMR Data 
80: (S)-N-Bn-Ser(O-(R)-N-Boc-Glu(OMe))-OMe 
1
H-NMR (400 MHz, CDCl3): 
 
13
C-NMR (101 MHz, CD2Cl2): 
 
 
  
Appendix of NMR Data  185 
81: HO-DKP8-CO2Me  
1
H-NMR (400 MHz, CD2Cl2): 
 
13
C-NMR (101 MHz, CD3OD): 
 
  
186  Appendix of NMR Data 
82: N3-DKP8-CO2Me 
1
H-NMR (400 MHz, CDCl3): 
 
13
C-NMR (101 MHz, CDCl3): 
 
  
Appendix of NMR Data  187 
84: NHBoc-DKP8-CO2Me 
1
H-NMR (400 MHz, CDCl3): 
 
13
C-NMR (101 MHz, CDCl3): 
 
  
188  Appendix of NMR Data 
112: (N-Boc-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
 
 
  
Appendix of NMR Data  189 
113 a: (Boc-DKP3-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
 
 
190  Appendix of NMR Data 
114 a: (Cbz-Asp(OtBu)-DKP3-Arg(Mtr)-Gly-OBn 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
 
 
Appendix of NMR Data  191 
116 a: (Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP3]) 
1
H NMR (400 MHz, CD3OD): 
 
13
C NMR (101 MHz, CD3OD): 
 
 
192  Appendix of NMR Data 
102: (Cyclo[Arg-Gly-Asp-DKP-3]) 
 
1
H NMR (600 MHz, H2O/D2O 9:1): 
  
Appendix of NMR Data  193 
113 b: (N-Boc-DKP4-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
194  Appendix of NMR Data 
114 b: (Cbz-Asp(OtBu)-DKP4-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
Appendix of NMR Data  195 
116 b: (Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP4])  
1
H NMR (400 MHz, CD3OD): 
 
13
C NMR (101 MHz, CD3OD): 
 
  
196  Appendix of NMR Data 
103: (Cyclo[Arg-Gly-Asp-DKP4]) 
 
 
1
H NMR (400 MHz, H2O/D2O 9:1): 
 
 
  
Appendix of NMR Data  197 
113 c: (N-Boc-DKP5-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, CD2Cl2): 
 
13
C NMR (101 MHz, CD2Cl2): 
 
  
198  Appendix of NMR Data 
114 c: (Cbz-Asp(OtBu)-DKP5-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
Appendix of NMR Data  199 
116 c: (Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP5]): 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
200  Appendix of NMR Data 
104: (Cyclo[Arg-Gly-Asp-DKP5]) 
 
1
H NMR (400 MHz, H2O/D2O 9:1): 
 
 
  
Appendix of NMR Data  201 
113 d: (Boc-DKP6-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
202  Appendix of NMR Data 
114 d: (Cbz-Asp(OtBu)-DKP6-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
Appendix of NMR Data  203 
116 d: (Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP6]) 
1
H NMR (400 MHz, DMSO-d6): 
 
13
C NMR (101 MHz, DMSO-d6): 
 
 
 
204  Appendix of NMR Data 
105: (Cyclo[Arg-Gly-Asp-DKP6]) 
 
 
1
H NMR (400 MHz, H2O/D2O 9:1): 
 
  
Appendix of NMR Data  205 
113 e: (N-Boc-DKP7-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
206  Appendix of NMR Data 
114 e: (Cbz-Asp(OtBu)-DKP7-Arg(Mtr)-Gly-OBn) 
1
H NMR (400 MHz, Acetone-d6): 
 
13
C NMR (101 MHz, Acetone-d6): 
 
  
Appendix of NMR Data  207 
116 e: (Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP7]) 
1
H NMR (400 MHz, CD3OD): 
 
13
C NMR (101 MHz, CD3OD): 
 
  
208  Appendix of NMR Data 
106 A (Cyclo[Arg-Gly-Asp-DKP7-A]) 
1
H NMR (400 MHz, H2O/D2O 9:1): 
 
106 B (Cyclo[Arg-Gly-Asp-DKP7-B]) 
1
H NMR (400 MHz, H2O/D2O 9:1) 
 
  
Appendix of NMR Data  209 
113 f: (N-Boc-DKP8-Arg(Mtr)-Gly-OBn) 
1
H-NMR (400 MHz, CD3OD): 
 
13
C-NMR (101 MHz, CD2Cl2): 
 
  
210  Appendix of NMR Data 
114 f: (N-Cbz-Asp(OtBu)-DKP8-Arg(Mtr)-Gly-OBn) 
1
H-NMR (400 MHz, Acetone-d6): 
 
13
C-NMR (101 MHz, Acetone-d6): 
 
  
Appendix of NMR Data  211 
116 f: Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP8] 
1
H-NMR (400 MHz, CD3OD): 
 
13
C-NMR (101 MHz, CD3OD): 
 
  
212  Appendix of NMR Data 
107: Cyclo[Arg-Gly-Asp-DKP8] 
1
H NMR (400 MHz, D2O): 
 
 
 
 
 
  
Appendix of NMR Data  213 
120 a: Cbz-Arg(Mtr)-DKP2-isoAsp(OtBu)-Gly-OH 
1
H NMR (400 MHz, MeOD): 
 
13
C NMR (101 MHz, MeOD): 
 
  
214  Appendix of NMR Data 
120 b: Cbz-Arg(Mtr)-DKP3-isoAsp(OtBu)-Gly-OH 
1
H NMR (400 MHz, MeOD): 
 
13
C NMR (101 MHz, MeOD): 
 
  
Appendix of NMR Data  215 
122 a: Cyclo [isoAsp(OtBu)-Gly-Arg(Mtr)-DKP2] 
1
H NMR (400 MHz, MeOD): 
 
13
C NMR (101 MHz, MeOD): 
 
  
216  Appendix of NMR Data 
122 b: Cyclo [isoAsp(OtBu)-Gly-Arg(Mtr)-DKP3] 
1
H NMR (400 MHz, MeOD): 
 
13
C NMR (101 MHz, MeOD): 
 
  
Appendix of NMR Data  217 
Fmoc-L-Ala-L-Ala-OSu 
1
H NMR (300 MHz, CDCl3): 
 
 
127 
1
H NMR (600 MHz, DMSO, 310 K) 
 
 
